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Summary
In the ovary, follicular development and oocyte maturation are followed by
ovulation. Cells comprising the follicle then luteinise and form the corpus luteum.
Progesterone production by the corpus luteum peaks during the mid luteal phase. In
primates, in the absence of pregnancy, progesterone production declines 2-3 weeks
after ovulation, and the corpus luteum regresses. This thesis examines cellular and
biochemical changes which occur in the corpus luteum during luteal regression in the
primate, using the marmoset monkey, Callithrix jacchus as a model. The hypotheses
that PGF2a, apoptosis and changes in the vasculature are involved in luteolysis are
explored.
Ovaries were studied on luteal days 10,18 and 22 (corresponding to the mid luteal
phase, functional luteal regression and structural luteal regression respectively), and
also 12 and 24 hours after administration of either PGF2a or GnRH antagonist.
Decreased progesterone concentrations indicative of functional luteal regression
were apparent 12 hours later.
Analysis of haematoxylin and eosin stained sections of corpora lutea indicated that
the administration of PGF2a or GnRH antagonist resulted in apoptosis, and also in
the formation of cytoplasmic vacuoles in steroidogenic cells. Apoptosis in corpora
lutea was further investigated by 3' end labelling DNA extracted from corpora lutea,
and by in situ 3' end labelling of sections of ovarian tissue. Apoptosis was found to
occur after induced luteolysis and in naturally regressing corpora lutea but only after
progesterone had decreased to follicular phase values. Therefore the decline in
progesterone characteristic of functional luteal regression was not caused by the
apoptotic cell death of steroidogenic cells. However, apoptosis played a role in
structural luteal regression.
Ubiquitin is expressed only by live cells undergoing a process of non-apoptotic cell
death. Ubiquitin expression was only found in PGF2a, but not in GnRH antagonist
9
treated luteal tissue, suggesting three possible explanations: that the cells in GnRH
antagonist treated animals were dead prior to the collection point of 12 hours, or that
the cells were not in a cell death pathway, or that cell death was occurring via
different mechanisms in PGF2a and GnRH antagonist treated animals.
The importance of the vasculature in luteal regression was investigated by labelling
endothelial cells with an antibody against von Willebrand Factor VIII Antigen.
Endothelial cell numbers remained constant after administration of luteolytic agents,
indicating that induced luteal regression was not effected by vascular changes.
Similarly, the vascualture did not change during functional regression in untreated
animals. Vascular remodelling, however, occurred during structural luteal regression,
when the vasculature changed from an extensive network of small capillaries to a
system comprised of a lower number of larger blood vessels.
Three different techniques were used to assess cell proliferation during luteal
regression; immunocytochemistry with antibodies directed against the cell cycle
markers Proliferating Cell Nuclear Antigen and Ki67, and also by measurement of in
vivo incorporation of bromoxydeuridine. Luteal cell proliferation decreased during
functional luteal regression, but rose again during structural luteal regression.
Although the instigating mechanism for functional luteal regression in the primate
remains unknown, it is possible that the endogenous production of PGF2a causes
functional luteal regression in primates. These studies have demonstrated that
structural luteal regression is effected by decreased luteal cell proliferation
concomitant with increased apoptosis. The extensive vascular network conducive for
steroidogenesis in the functioning corpus luteum is replaced by a less extensive
vascular network of larger vessels during structural luteal regression. This probably
facilitates the transportation of the cellular debris of regression away from the ovary,
and allows the process of structural luteal regression to proceed.
10
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In primates, two ovoid ovaries lie on either side of the uterus. The mean (± S.D) size
of preovulatory marmoset ovaries is 5.3 (±0.7) x 4.3(±0.6) x 3.6 (±0.9)mm (Cui and
Mathews, 1994). Each ovary consists of an outer cortex, an inner medulla and the
hilus which is the anterior margin where the ovary is attached to a double fold of the
peritoneum (Clement, 1987). Primordial follicles, consisting of an oocyte
surrounded by a layer of granolosa cells, are located in the cortex of the ovary
(Guedes and Miraglia, 1977). In mature female primates, primordial follicles
increase in size until gonadotrophins bring about the process of ovulation (Macklon
and Fauser 1998; Kholkute and Nandedkar 1983), whereby the oocyte is released
from the follicle into the oviduct. Cells comprising the follicle differentiate into the
cells of the corpus luteum and commence progesterone production (Wehrenberg et
al., 1997; Einspanier et al., 1997). Progesterone produced by the corpus luteum
prevents the ovulation of additional follicles (Soules et al., 1984, Baird et al., 1975).
If the ovulated oocyte is not fertilised it is crucial that progesterone production by the
corpus luteum cease in order to allow the ovulation of another, potentially fertilisable
oocyte, and hence ensure survival of the species (Behrman et al., 1993). It is also
necessary to remove luteal tissue to make room for subsequent follicular
development. The mid-luteal phase human corpus luteum occupies 50% of the total
ovarian volume and weighs approximately 3g (Clement 1987). The reproductive
lifespan of a woman is in the order of 500 ovulations, which would result in a 1.5kg
gain in luteal weight if there were not some mechanism to remove luteal tissue.
Tuteal regression is the cessation of steroid hormone production by the corpus
luteum, and the removal of luteal tissue.
1.1.1 Aims of Project
The mechanisms which confer a species-specific life-span upon primate corpora
(Fairchild Benyo et al., 1993) or which initiate primate luteal regression (Michael et
al., 1994) or which control the time taken to complete luteal regression (Behrman et
al., 1993) are not known. The ability to understand and modify these mechanisms
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would benefit the treatment of early pregnancy losses caused by luteal phase defects
(Fairchild Benyo et al., 1993).
The aim of this project is to examine luteal regression for the first time in a
commonly used primate model, the marmoset monkey (Callithrixjacchus).
Endocrinological and cellular changes that occur during luteal regression will be
described, and candidate mechanisms for the initiation and regulation of luteal
regression will be examined.
1.1.2 Hypotheses
Marmoset luteal regression is initiated in vivo by one of the following:
a) PGF2a.
b) Apoptotic cell death.
c) Changes in the vasculature.
1.1.3 Choice of Animal Model
The following strategies were adopted in order to investigate these hypotheses:
• To induce luteal regression by in vivo administration of a PGF2a analogue.
PGF2a-treated corpora lutea to be compared with corpora lutea collected from
(a) animals treated in vivo with a GnRH antagonist to block LH-stimulated
steroidogenesis and (b) untreated, spontaneously regressing corpora lutea. This
strategy assumes that pharmacological induction of luteolysis with a mechanism
that mimics the natural, in vivo luteolytic signal will result in corpora lutea with
morphological and functional characteristics similar to those seen in
spontaneously regressing corpora lutea.
• To collect ovarian tissue from different stages of the luteal phase and after
induced luteal regression, and to quantify apoptotic cell death in these corpora
lutea.
• To identify and quantify vascular endothelial cells in corpora lutea from different
stages of the luteal phase and after induced luteal regression.
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The use of human corpora lutea for these studies was considered, but it was not
ethically permissible to administer luteolytic agents to women, and also the numbers
of willing donors were insufficient for these studies. In addition, tracking human
reproductive cycles and collecting tissue was time-consuming and costly in terms of
expertise and administration. Of the non-human primates, the marmoset, Callithrix
jacchus, was selected for these studies because:
• Protocols for inducing luteal regression with GnRH antagonist and PGF2a were
well characterised and permitted for use in marmosets. In addition, PGF2a does
not reliably induce luteal regression when administered intravenously to other
primates, therefore the proposed hypothesis would be more difficult to
investigate in macaques or humans.
• Procedures for tracking the reproductive cycle were well established,
inexpensive, and relatively stress-free for the animals and handlers.
• Sufficient numbers of animals from a successful, captive-bred colony were
available for use.
• Marmosets were less expensive and easier to house than other non-human
primates.
1.1.3.1 Marmosets as a Primate Model.
Species differences exist between primates, therefore no one primate can be said to
be completely representative of all primates. A brief comparison of corpora lutea of









14 days Theca-lutein surround
granulosa-lutein,
occasionally penetrating





17 days Theca-lutein surround
granulosa-lutein,
occasionally penetrating











2. Retamales et al., 1994
3. Fraser et al., 1997
4. Zelinski-Wooten et al., 1991
5. Webley GE et al 1990
6. Torii R et al 1996
The major difference between primate and non-primate luteal regression is that
PGF2a derived from the uterus does not cause luteolysis in humans (Beling et al.,
1970) or rhesus macaques (Neill et al., 1969), whereas it does in non-primates
(Poyser, 1981; Knickerbocker et al., 1988). Although uterine-derived PGF2a does
not induce regression in primates, endogenous luteal production of PGF2a may play
a role. In humans, systemically administered PGF2a resulted in a transient decrease
in circulating progesterone concentrations (Karim and Hillier, 1979). PGF2a
injected into the corpus luteum of rhesus macaques caused luteolysis (Auletta et al.,
1984) and systemically administered PGF2a caused luteolysis in marmosets when
applied after day 8 of the luteal phase (Summers et al., 1985).
Although marmoset and human luteal morphology is dissimilar (Webley et al.,
1990), corpora lutea are functionally similar with regards to types, although not
levels, of steroid hormone production (Ohara A et al., 1987; Steinetz et al., 1995).
Fluman and marmoset corpora lutea have similar patterns of inhibin (Smith et al.,
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1990; Groome et al., 1996) and oxytocin production (Einspanier et al., 1994; Khan-
Dawood 1987) while melatonin stimulates luteal cell progesterone production in
both human (Webley et al., 1988) and marmoset corpora lutea (Webley and Hearn
1987). Human chorionic gonadotropin prevents luteal regression in both humans
(Zeleznik) and marmosets (Hearn and Webley 1987), and there is a high degree of
conservation between marmoset and human chorionic gonadotrophins (Simula et al.,
1995).
The factors, or order of events, which initiate and regulate luteolysis in marmosets
and humans are likely to be similar, if not identical. However, it is also likely that
species differences would manifest as variations in the concentration, threshold of
effectiveness and time of action of these factors. Despite species differences, the
examination of luteolytic mechanisms in marmosets is more likely to provide data
relevant to human luteolysis, than would an equivalent investigation using a non-
primate model.
In the UK, marmosets comprise 37% of the primates used by contract research
laboratories and pharmaceutical companies (Owen et al., 1997). Marmosets have
been used as model primates in other studies (Puri et al., 1989). It is therefore
important to identify the differences and similarities between marmosets and
humans accurately, in order to determine the extent to which data derived from
studies conducted in marmosets may be extrapolated to humans. This project will
therefore add to current information regarding marmoset reproductive
endocrinology, thus promoting the usefulness of the marmoset as a primate model.
1.2 Background Information about Marmosets
Marmoset are platyrrhine primates with approximately 15 taxa (Tagliaro et al., 1997)









Marmosets are common in the eastern and coastal rain forests of Brazil (In Biology,
Rearing and Care ofYoung Primates, 1977), where they are arboreal and diurnal.
They are omnivorous, eating fruit, tree sap, seeds, insects, rodents and occasionally
small birds (Hearn 1987). They occur in groups of up to 30 animals consisting
primarily of a mating pair and their mature, subadult, juvenile and infant offspring,
and also some unrelated individuals (Hearn 1983). Mates are monogamous and pair
for life, and there appears to be no breeding season in the wild with births occurring
at all times of the year (Hearn 1983; Harter and Erkert 1993). Female reproductive
cycles are independent of male presence, since isolated female marmosets had a
cycle length of 28.8±4.9 days, which was similar to the cycle-length of female adults
housed with vasectomized or castrated males (Harter and Erkert 1993: Harding et al.,
1982).
Intrasex dominance hierarchies are established in family groups (Abbot et al., 1988)
and marmoset populations appear to be regulated by the suppression of subordinate
female reproductive cyclicity by the dominant female. Most subordinate females do
not secrete LH, and are therefore anovulatory (Abbot et al., 1988). Secretion of LH
after administration of an exogenous GnRH challenge is proportional to social status.
The LH response in subordinate females is significantly lower than in females who
are higher in the dominance hierarchy. Isolation of subordinate females restores
serum LH concentrations and ovulation. GnRH secretion is similar in dominant and
subordinate females, therefore inhibition of LH production seems to occur at the
level of the pituitary (Abbot et al., 1997). Suppression of ovulation is not absolute;
breeding females are more effective at suppressing subordinate ovulation than non-
breeding dominant females, however even subordinates that ovulate do not become
pregnant (Saltzman et al., 1997). The dominant female can also cause a decrease in
circulating testosterone concentrations in subordinate males (Hearn, 1983), so
effectively ensuring that there is only one breeding pair in each family group.
In captivity, singletons, twins or triplets are born at 5-6 month intervals (Hearn,
1987) after a gestation of 144 ± 2 days (Hearn, 1983). Ovulation can occur 10.5±0.7
days after parturition (Hearn, 1983); lactation therefore does not inhibit
folliculogenesis in the marmoset.
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Marmosets display little sexual dimorphism, and there is no difference in growth rate
or adult weight (350-450g) between males and females (Abbot and Hearn 1978).
Adult size is reached by one year of age, and puberty occurs at about 15 months of
age (Hearn, 1983). Females may continue breeding up to 16 years of age, and may
live as long as twenty years.
1.2.1 Female Marmoset Reproductive Cycle
The female marmoset does not menstruate (Abbot and Hearn 1978) but the
concentration of peripheral plasma progesterone increases after ovulation, therefore
elevated progesterone levels are indicative of the luteal phase (Hillier et al., 1988).
Harding et al (1982) found that the total cycle length in female marmosets was 30.1
±3.8 days (mean ± SD, n=30, range 24-41 days, median 29.5 days) and during this
time progesterone levels were below lOng/ml for 8.8 ± 3.7 days, but higher than 10
ng/ml, therefore assumed to be post-ovulatory and indicative of the luteal phase, for
21.5 ± 2.2 days (mean ± SD, n=30, range 14-29 days, median 21.5) (Harding et al.,
1982). Marmosets in another colony were found to have a cycle length of 28.6 ± 1
days (mean ± s.e.m) with a luteal phase of 19.2 ± 0.6 days (Summers et al., 1985,
Harlow et al., 1984) which is slightly lower than that found in Hardings' study.
Combining these studies suggests that in the captive marmoset the preovulatory or
follicular phase lasts approximately 9 days, during which peripheral concentrations
of estrogen are elevated (0.1-3 ng/ml, Abbot, 1992) and progesterone concentrations
are less than lOng/ml. The luteal phase lasts approximately 19 days and is
characterised by peripheral progesterone concentrations higher than lOng/ml.
1.3 Development and Structure of the Follicle
1.3.1 Development of the Oocyte.
Mammalian somatic cells contain two copies of each chromosome, and are therefore
diploid (2n). Sexual reproduction requires the fusion of two haploid (In) gametes,
the spermatazoa and the oocyte, each of which contains only one copy of each
chromosome. The production of haploid gametes occurs by meiosis, which consists
of two sequential cell division processes (Cell cycle and replication 1993 In:
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Wheater's Functional Histology 3rd Edition Editors: PR Wheater, HG Burkitt, VG
Daniels pp 31-40). In females, the first cell division results in the formation of two
genetically distinct diploid daughter cells, one of which progresses to the second
meiotic division, the other degenerates and forms a polar body. The second division
produces one haploid daughter cell, and another polar body (In: Wheater's
Functional Histology 1993; Eppig, 1991). Cell divisions consists of prophase,
metaphase, anaphase and teleophase, which are analogous to the stages found in
somatic cell mitotic division.
During embryonic development, primordial germ cells migrate to the genital ridge
and form a primitive ovary (Eppig, 1991). The primordial germ cells initially
undergo mitosis to produce large numbers of diploid oogonia. In humans, oogonia
begin meiosis in the fifth month of fetal life, but this process is arrested in the
prophase of the first meiotic division. Meiotic arrest occurs before birth, but after the
formation of primordial follicles; structures 15 - 20pm in diameter consisting of an
oocyte surrounded by a layer of flattened granulosa cells (In: Wheater's Functional
Histology 1993; Eppig, 1991). Meiosis is reinitiated by a preovulatory surge of LH, a
situation that only occurs post-puberty. The gonadotrophin surge stimulates
completion of the first meiotic division and production of the first polar body.
Ovulated oocytes are therefore diploid, and are arrested in metaphase II.
Spermatazoan penetration stimulates completion of metaphase II and the second
meiotic division, resulting in the production of a haploid oocyte and a second polar
body. Fertilisation could be said to occur when the male and female gamete nuclei
coalesce to produce a new diploid genetic combination (Eppig, 1991).
1.3.2 Folliculogenesis
Reports regarding the number of primordial follicles present in human ovaries at
birth vary from 400 000 (Clement, 1987) to two million (Macklon and Fauser 1998).
Follicular development to the early antral stage occurs throughout childhood, but
further follicular development does not occur in the absence of ovulatory
concentrations of gonadotrophins, and these follicles become atretic. Consequently,
approximately 500 000 primordial follicles are present when menstruation begins
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(Macklon and Fauser 1998). A small study of only three prepubertal marmosets
found that oocytes in the outer ovarian cortex were not surrounded by granulosa
cells, but that 2 or more rows of follicular cells surrounded oocytes of the inner
cortex. This study also concluded that granulosa cells originated in the stroma of the
ovarian medulla, and migrated along 'cords' to surround the oocytes in the outer
cortex in order to form primordial follicles (Guedes and Miraglia 1977). The process
of maturation from primordial follicle to ovulation is known as folliculogenesis. This
takes approximately six months in women (Gougeon, 1982), with the last 14 days of
folliculogenesis occurring during the first half of the menstrual cycle.
Follicular development begins when granulosa cells in a primordial follicle begin to
proliferate. It is not known what initiates granulosa cell proliferation (Robker and
Richards, 1998) but the relatively slow increase in cell numbers results in the
formation of a primary follicle. Vascularisation of the surrounding stroma occurs,
and when the follicle diameter is about 0.15mm in humans (Gougeon, 1998) the
surrounding stroma differentiates into the theca interna and theca externa layers to
form a multi-layered secondary follicle (Macklon and Fauser 1998). Baboon
primordial follicles developed into secondary follicles in vitro in defined
gonadotrophin-free media (Wandjii et al., 1997), indicating that gonadotrophins are
not required for primordial to secondary follicle development in primates. Secondary
follicle theca interna cells acquire LH receptors, followed by granulosa cell
acquisition of FSH receptors in the late secondary/early antral stage of development
(Macklon and Fauser 1998). Theca interna cells of secondary follicles secrete
androstenedione and testosterone in response to LH, (Gougeon, 1998). Granulosa
cells convert androstenedione and testosterone into estrone and estradiol in response
to FSH (Macklon and Fauser 1998). In marmosets, granulosa cells of late
secondary/early antral follicles expressed nuclear androgen receptors (Hillier et al.,
1997) and androgen stimulated the growth of pre- and early antral follicles in rhesus
macaques (Vendola et al., 1998). Late secondary to early antral primate follicle
development, during which human follicles only grow from approximately 0.18 to
0.2 mm in diameter, may therefore proceed according to the following sequence of
events:
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• Theca cell LH expression
• Theca cell production of androgens
• Granulosa cell expression of nuclear androgen receptors
• Granulosa cell expression of FSH receptors
• Granulosa cell conversion of androgens into estrogens.
Subsequent follicular development results in granulosa cell expression of LH
receptors. Acquisition of gonadotrophin receptors is concurrent with increased
proliferation and the rapid formation of large preovulatory follicles (Robker and
Richards 1998). As already mentioned, human preantral follicular diameter is
approximately 0.18mm and the early antral follicle 0.2mm (Gougeon 1998). The
smallest antral follicles measured in marmoset ovaries were 0.6mm in diameter
(Gilchrist et al., 1999). In cycling marmoset ovaries 90% of antral follicles were 0.5-
1,0mm in diameter, and the remaining 10% of antral follicles were 1-1,9mm in
diameter (Hillier et al., 1987). The one to three follicles destined to ovulate were
2±0.2mm 4 days before ovulation, and ovulating follicles had diameters 2.3±0.2mm
2 days before ovulation (Oerke et al., 1996; Nubbemeyer et al., 1997). Marmoset
follicles grow to a maximum of 4mm in diameter before ovulating (Oerke et al.,
1996; Hillier et al., 1987) whereas human ovulatory follicles increase from 2mm to
over 20mm in diameter during the 14 day follicular phase (Hillier 1991).
1.3.3 Endocrinology of folliculogenesis.
In humans, it takes approximately 90 days for a follicle to develop from the early
antral to the preovulatory size. Estradiol production is proportional to size in follicles
which have a diameter larger than 8mm (Macklon and Fauser 1998). Estradiol,
however, inhibits hypothalamic production of FSH. The length of time that a follicle
is capable of responding to elevated FSH levels prior to the initiation of negative
feedback mechanisms is thought to result in the selection of a dominant follicle
(Macklon and Fauser 1998). The majority of antral follicles respond to falling FSH
levels by undergoing atresia, but the dominant follicle is apparently more sensitive to
FSH than follicles destined for atresia, and can therefore continue to function despite
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falling FSH levels. Increased FSH sensitivity is not via increased FSH receptor
expression (Gougeon 1998), but may be attributable to synergistic enhancement of
receptor action by growth factors; as well as dominant follicle suppression of
subordinate follicles by production of inhibin B. FSH upregulates steroidogenic
enzyme activity in marmoset granulosa cells in vitro and also stimulates granulosa
cell LH receptor expression (Hillier et al., 1988). Optimal exposure to FSH may
result in sufficient LH receptors to allow gonadotrophin stimulated steroidogenesis to
occur in the face of falling FSH levels.
Marmosets ovulate 1-4 oocytes, and follicle selection appears to occur around day 8
of the follicular phase, when follicles with a diameter >2mm will eventually ovulate,
but smaller follicles undergo atresia (Tardif et al., 1993). In 64% of cycles examined,
all the follicles which later ovulated were of the same size and had similar rates of
growth. Ovulatory follicles were found on both ovaries in the same cycle, and
analysis of the distribution of ovulation points suggested the existence of interovarian
mechanisms to control the number of ovulatory follicles (Tardif et al., 1993).
1.3.4 Ovulation
Follicular oestradiol stimulates LH production by causing the gonadotrophs of the
anterior pituitary to become progressively more sensitive to GnRH. As the follicular
phase proceeds, the gonadotrophs therefore produce increasing amounts of LH in
response to the same amount of GnRH (Yen, 1972). In normal cycles in women the
amplitude and frequency of GnRH pulses increases throughout the follicular phase,
and these result in corresponding amplitude and frequency increases in LH
pulsitility, culminating in a huge surge of LH immediately before ovulation (March
et al., 1979).
In marmosets, follicles destined to ovulate protruded from the surface of the ovary
one or two days prior to ovulation. They were highly vascularised around the base
and the prospective ovulation point (Torii et al., 1996). Increased blood flow and
increased vascular permeability in the thecal layers are part of the ovulatory process
(Brannstrom and Janson 1991). Careful observation of granulosa cells collected from
women who had received an IYF regime of follicle stimulation and ovulation
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induction, revealed the presence of 'multiple, balloon-like structures tethered to the
cells surface' (Antczak et al., 1997). Immunohistochemical techniques identified the
'balloons' contents' as being VEGF, leptin and transforming growth factor P
(TGFP). 'Balloon' formation seemed to be related to plasma levels of
gonadotrophins, suggesting that the ovulatory LH surge might stimulate granulosa
cell secretion of VEGF, which might be a mechanism through which vascular
permeability is increased in the theca layer. TGFp receptor expression has been
demonstrated in luteinising theca and granulosa cells in marmosets (Wehrenberg et
al., 1998) and the nuclear receptor, steroidogenic factor-1, is also expressed by
luteinising theca cells in the marmoset (Wehrenberg et al., 1997). The LEI surge
causes granulosa cells to cease cycling and begin differentiating into luteal cells
(Robker and Richards 1998) by inhibiting cell cycle activators, cyclin D2 and cyclin
E, and inducing cell cycle inhibitors such as p27kipl (Robker and Richards 1998). The
granulosa cells of p27kipl null mice do not luteinise, and the mice are unable to
maintain pregnancy (Robker and Richards 1998). Granulosa cell luteinisation is also
associated with loss of the cyclic AMP response element binding protein (Somers et
al., 1995), the upregulation of progesterone receptors (Chandrasekher et al., 1991) in
marmoset preovulatory follicles (Einspanier et al., 1997), and the upregulation of
oxytocin and its receptor in preovulatory follicles (Einspanier et al., 1997) The
periovulatory rise in progesterone that has been described in women (March et al.,
1979), pigs (Einspanier et al., 1991) and rhesus monkeys (Stouffer et al., 1993)
probably occurs in response to increasing LH-stimulation of luteinised theca and
granulosa cells (McNatty et al., 1979).
Increasing levels of LH cause desensitisation of LH receptors on theca cells with a
subsequent decrease in production of androgens and consequent decrease in
oestradiol production (Brannstrom and Janson 1991). The LH surge also stimulates
hyaluronic acid accumulation between granulosa cells, resulting in the disruption of
gap junctions and granulosa cell dissociation. Granulosa cells become detached from
the basement membrane in the apical regions, but in other parts of the follicle appear
to migrate towards the thecal layer (Brannstrom and Janson 1991). Extrusion of the
cumulus-oocyte complex onto the surface of the ovary is not caused by increased
27
follicular pressure, but by weakening of the follicle wall at the point of ovulation.
The combination of follicle wall, collogen layers and overlying ovarian epithelium
comprises the morpho-functional unit of ovulation (Brannstrom and Janson 1991).
The surface epithelial cells contain lysosomes which probably contribute to the
breakdown of the follicular wall during ovulation (Brannstrom and Janson 1991).
The surface epithelium is separated from the follicle by collogen-rich tissue. During
ovulation collogen fibres at the ovulatory point become dissociated and fragmented,
smooth muscle cells in the theca externa become elongated, and rupture of thecal
vasculature occurs (Brannstrom and Janson 1991). Dissociation of collogen fibres
and the breakdown of the follicle wall may be mediated by progesterone, which
inhibits collagen formation in human follicle cultures in vitro (Brannstrom and
Janson 1991). Progesterone stimulates the production of prostaglandins and the
activation of collagenases (Brannstrom and Janson 1991). LH may also stimulate
prostaglandin production directly, with multiple consequences. Prostaglandins act on
the vasculature, and may interact with VEGF to increase blood flow and vascular
permeability. Prostaglandins also have chemotactic effects on leukocytes, which
secrete proteases, and stimulate the production of plasminogen activator, thus
enhancing proteolysis and tissue remodelling (Brannstrom and Norman 1993).
Increased blood flow and vascular permeability are thought to maintain
intrafollicular pressure during the process of oocyte-cumulus extrusion through the
ruptured follicle wall (Brannstrom and Janson 1991).
In marmosets, serum levels of progesterone during the follicular phase are less than
20nmol/L, but rise to a mean value of 50nmol/L within 48 hours of the LH surge
(Harlow et al., 1984). Marmosets commonly ovulate 1-4 oocytes, but ovulation is not
synchronous, and time lags of 12-20 hours were found between ovulations in the
same animal (Torii et al., 1996; Oerke et al., 1996).
1.3.5 Formation of the Corpus Luteum
During ovulation the basement membrane separating the theca from the granulosa
cell layer is disrupted and blood vessels invade the luteinising granulosa layer
(Niswender et al., 1994). Luteinising theca cells also migrate into the granulosa-
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lutein, resulting in a wheel-like organisation in which the blood vessels and
associated thecal cells are the spokes of the wheel, the theca-lutein the rim, and
luteinised granulosa cells fill the spaces between the spokes (Baird 1991; Corner
1956). The granulosa layer folds inwards, so reducing the size of the antrum (Van
Blerkom and Motta 1978), and both theca-lutein and granulosa lutein undergo
hypertrophy (Niswender et al., 1994). In five human corpora lutea collected on the
day of ovulation, or day 1 of the luteal phase, Corner (1956) noted that numerous
erythrocytes were caught in a fine fibrin network filling the central cavity, as well as
being lodged between granulosa cells. The vasculature was also dilated and
engorged. Theca cells were vacuolated, and were beginning to luteinise. By luteal
day 2 the thecal layer was completely luteinised and many theca cells were
vacuolated. Granulosa cells in the vicinity were also luteinised, but did not contain
vacuoles. Capillaries were beginning to invade the granulosa layer, which also had
the appearence of streaming towards the central, fibrin-filled cavity. By luteal day 4
angiogenesis was completed and capillaries vascularised the entire granulosa layer
and protruded into the central cavity. Granulosa cell luteinisation continued on luteal
day 5, and this gave the histological appearence of reducing the space between
granulosa-lutein cells as their cytoplasmic volume increased. Fibroblasts started to
appear in the central cavity, and theca and granulosa lutein could be distinguished by
different nuclei:cytoplasm volumes, in theca-lutein the ratio was greater than 1:3, but
in granulosa-lutein the ratio was lower. On luteal day 6 granulosa cell luteinisation
was nearly completed, the granulosa lutein cells were densely packed together and
their cytoplasm contained lipid droplets. In theca-lutein cells, however, the nucleus
occupied most of the cell and the small amount of cytoplasm was vacuolated. Corner
(1956) notes that the corpus luteum was probably fully functional by luteal day 7,
and that luteinisation of the granulosa layer was completed. Generally the two
steroidogenic cell types are easily distinguished and are confined to clearly defined
areas (Sawyer et al., 1991). In new world monkeys, however, the steroidogenic luteal
cells are of uniform morphological appearance, and it is not clear whether they
derive from both theca and granulosa cells, or from just one of these cell types
(Webley et al., 1990). The steroidogenic cells in marmoset corpora lutea have
diameters larger than 10pm and show a size distribution consistent with one
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population of cells. There is a significant increase in mean cell diameter from luteal
day 6 to luteal day 14, but no increase thereafter (Webley et al., 1990).
1.3.6 Accessory corpora lutea
Accessory corpora lutea are thought to be formed when non-ovulated follicles
become luteinised (Behrman et al., 1993). In marmosets, corpora lutea accessoria
(Cla) formation occurs in the periovulatory phase, when large antral follicles with the
morphological features of atresia: wide intercellular spaces between granulosa cells,
disrupted granulosa layer architecture and cell death around the periphery of the
antrum, undergo luteinisation in the outer theca cell layer and in the granulosa cell
layer closest to the basement membrane. The outer, luteinising cells of otherwise
atretic follicles express nuclear SF-l/Ad4BP. Mature Cla consist of layers of
luteinised cells which express SF-l/Ad4BP, whereas true CL do not express SF-
l/Ad4BP (Wehrenberg et al., 1997). It is possible that steroidogenic cells in Cla may
also be larger in diameter than the steroidogenic cells of true corpora lutea (Wulff et
al., 1996)
1.4 The Functioning Corpus Luteum
1.4.1 Luteal Phase Steroid Hormone Production.
Steroid hormones are derived from cholesterol, and the major source of cholesterol in
human corpora lutea is plasma low density lipoprotein (LDL) which is taken up by
steroidogenic luteal cells via specific LDL receptors (Brannian et al., 1991;
Fairchild-Benyo et al., 1993: Strauss and Miller 1991). Cholesterol can either be
stored, or transferred across mitochondrial membranes where it is converted to
pregnenolone by cholesterol side-chain cleavage cytochrome P450 enzyme (P450scc,
Niswender et al., 1994). Pregnenelone is in turn converted to progesterone by the
enzyme 3 beta hydroxysteroid dehydrogenase isomerase (3p FISD, Savard, 1973), or
is converted into androgens by 17a hydroxylase cytochrome P450 (P450na).
Androgens can be converted into oestrogens by aromatase cytochrome P450
(P450arom). The enzyme 17 beta hydroxysteroid dehydrogenase (17p FISD)
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converts androstenedione or oestrone to testosterone or oestradiol respectively
(Savard, 1973; Strauss and Miller 1991). In human corpora lutea, the pattern of
steroidogenesis is similar to that found in the follicle (Ohara et al., 1987). Theca¬
lutein cells, or small luteal cells, contain the enzymes P450na and P450scc and
produce both progesterone and androgen in response to stimulation by LH,
Granulosa-lutein, or large luteal cells, contain the enzymes P450arom and P450scc
and produce oestrogen and high basal levels of progesterone (Behrman et al., 1993;
Sasanoeta/., 1989).
The human corpus luteum produces the steroid hormones progesterone, 17-hydroxy-
progesterone, 4-androstenedione, estrone, 17p-estradiol, pregnenolone and 20a-
hydroxy-4-pregnen-3-one and possesses all the biosynthetic enzymes of the
steroidogenic pathway (Savard, 1973; Sasano et al., 1989).
The primate luteal phase can be separated into three periods based on the amount of
progesterone produced. In marmosets, the first period is characterised by increasing
progesterone concentrations, which rise from 40ng/ml to 87.4ng/ml by the mid luteal
phase (Harding et al., 1982). Progesterone concentrations remain at this level during
the second period, then decrease during the third period to <10ng/ml over the course
of three to five days (Harding et al., 1982). The same pattern occurs in women.
During the follicular phase in normally menstruating women between 24 and 34
years old, progesterone concentrations are 0.3±0.03 ng/ml (n=5) (Soules et al.,
1984). After ovulation progesterone levels increase during the early luteal phase,
then are maximal at 7.5±1.7 ng/ml (n=5) (Soules et al., 1984) from day 8-12 of the
mid luteal phase, then decrease gradually in the late luteal phase until menstruation
occurs (Zeleznik 1991). Similar patterns of secretion and progesterone
concentrations have also been observed in baboons (Stevens et al., 1970) and rhesus
macaques (Monroe et al., 1970).
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1.4.2 The Regulation of Luteal Cells
In ruminents, theca-lutein, or small luteal cells, responded to LH with a 20-fold
increase in progesterone production, but granulosa-lutein, or large luteal cell
progesterone production was not stimulated by LH (Niswender et al., 1994). Both
cell types expressed LH receptors (Harrison et al., 1987), but LH-binding only
stimulated formation of the secondary messenger cAMP in small luteal cells, and the
effect of LH-binding on large luteal cells was unclear. Large luteal cells also had
receptors for the prostaglandins E and F2a, whereas these were not apparent on
small luteal cells (Knickerbocker et al., 1988; Sawyer et al., 1991). Human theca
lutein cells responded to hCG with an increase in progesterone and androgen
production, whereas granulosa lutein did not respond to hCG (Ohara et al., 1987;
Behrman et al., 1993). Small and large luteal cells isolated from macaque corpora
lutea responded to hCG or the secondary messenger analogue dbcAMP with
increased progesterone production (Hild-Petito et al., 1989), so apparently both cell
types have the ability to respond to LH in at least one non-human primate.
Marmosets have only one population of steroidogenic cells (Webley et al., 1990)
which may be derived from both granulosa and theca cells, or from only one of these
populations. Marmoset steroidogenic cells from any stage of the luteal phase
responded to hCG with a two-fold increase in progesterone production (Michael and
Webley, 1993). The in vivo plasma progesterone concentrations were the same on
luteal day 3 and luteal day 14 (Michael and Webley, 1993), but the in vitro
gonadotrophin-free basal production of progesterone by pieces of luteal tissue
decreased with increasing age of the source corpus luteum. Corpora lutea obtained on
luteal days 3, 6 and 14 secreted 700, 21 and 8.2 pmol/mg tissue respectively
(Michael and Webley, 1993). Cloprostenol did not reduce plasma progesterone
concentrations in vivo on luteal day 3, but did inhibit hCG-stimulated cAMP
accumulation in 3 out of 5 day 3 corpora lutea in vitro. These results suggest that
PGF2a receptors were present and functional on luteal day 3, but that basal
progesterone production was more important than gonadotrophin-stimulated
progesterone production in the early luteal phase, and that the gonadotrophin-
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stimulated component of progesterone production became increasingly prevalent as
the corpus luteum aged.
1.5.0 Regression ofthe Corpus Luteum
1.5.1 LH in Luteal Regression.
Withdrawal of LH causes a rapid decrease in luteal steroidogenesis. LH withdrawal
and inhibition of steroidogenesis were effected by hypophysectomy in rats (Smith,
1930) or by immunoneutralisation of LH in sheep (Fuller and Hansel, 1970) or by
administration of a GnRH antagonist in women (Mais et al., 1986) and macaques
(Fraser et al., 1986; Hutchinson et al., 1986). Reduction in levels of circulating
gonadotrophins by administration of GnRH antagonists also caused decreased
progesterone production in marmosets (Hodges et al., 1988) suggesting that
decreased plasma LH concentrations, and/or pulsitility, might precede the luteal
decrease in steroidogenesis in vivo. However gonadotrophin secretion did not
decrease in vivo at the time of luteolysis in macaques or women (Salamonsen et al
1973; Hutchison et al., 1986; Sotrel et al., 1981) and in marmosets a PGF2a
analogue caused luteolysis without a corresponding decrease in plasma LH
concentrations (Webley et al., 1991) suggesting that decreased serum gonadotrophin
levels were either unnecessary for luteolysis in marmosets, or that the administered
PGF2a superseded the effects of LH.
The frequency of LH pulsitility in vivo decreased from one pulse per hour in the mid-
luteal phase to one pulse every eight hours in the late luteal phase in macaques
(Zeleznik, 1991) but maintenance of LH pulsitility at one pulse per hour did not
delay luteolysis nor extend the luteal phase (Zeleznik 1991; Hutchinson et al., 1986).
Therefore, although LH is luteotrophic and steroidogenesis can not proceed in the
absence of LH, in vivo luteal regression is not caused by decreased LH pulsitility nor
decreased serum concentrations. However, it is possible that the endogenous
production of PGF2a might disconnect the LH receptor from its secondary
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messenger pathway, so reducing the ability of luteal cells to respond to LH (see
subsequent section).
Administration of GnRH antagonist results in decreased steroidogenesis, but
induction of luteal regression depends upon the duration of administration, and is
also affected by the stage of the luteal phase. This was shown in macaques in which
the hypothalamus was surgically disconnected from the pituitary. This prevented
GnRH stimulation of the pituitary and resulted in decreased endogenous
gonadotrophin production. Pulsatile infusion of exogenous GnRH to induce a normal
menstrual cycle provided a model in which GnRH could be withdrawn at any stage
of the cycle and its effects examined. Complete withdrawal of LH in the early or mid
luteal phase resulted in a cessation of steroidogenesis, but when GnRH infusion was
resumed three days later steroidogenesis also resumed, and luteolysis occured 14-16
days after ovulation as though there had been no interruption in progesterone
production. Withdrawing LH from days 8 to 11 of the luteal phase also resulted in
decreased steroidogenesis, and menses began on day 11. If GnRH infusion was
resumed on day 11, however, progesterone production was similar to that seen in
control untreated cycles and onset of menses occurred at the same time in both
groups. LH withdrawal during luteal regression on day 14 did not, however, result in
restoration of progesterone production when GnRH infusion was resumed 3 days
later (Hutchison and Zeleznik, 1985). Therefore it was argued that although LH is
obligatory for maintenance of luteal progesterone secretion, it appears that there is a
separate mechanism for regulating luteal lifespan. LH can also be withdrawn by
using GnRH antagonists instead of surgery (Mais et al., 1986) but administration of
GnRH antagonist in women from days 7-9 of the luteal phase caused early onset of
menses and normal progesterone production was resumed in only one of the four
subjects. The latter may be attributed to only partial suppression of LH production to
48% of normal. It was therefore assumed that steroidogenesis still continued during
the period of antagonist treatment, and in addition, the luteal phase of women is
slightly shorter than that of macaques, so administration of the GnRH antagonist may
have occurred at the beginning of luteal regression. Administration of a single dose
of GnRH antagonist to stumptailed macaques at different stages of the luteal phase
also resulted in a suppression of serum progesterone at all stages followed by a
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subsequent resumption of steroidogenesis and luteal phases of the normal length
(Fraser et al., 1986). Administration of GnRH antagonist to macaques for three
consecutive days at different stages of the luteal phase, however, suppressed LH
secretion for 4 days, prevented subsequent resumption of steroidogenesis and caused
early onset of menses (Fraser et al., 1987). Therefore it appears that the duration of
LH inhibition determines whether luteolysis occurs early or not. If inhibition of LH
is 1 -3 days, length of the primate luteal phase remains unchanged, and under these
circumstances it appears that there are separate mechanisms for regulating
steroidogenesis and luteal lifespan.
In marmosets, peak progesterone production occurs during the mid-luteal phase,
which can conservatively be designated as being from luteal day 8 to luteal day 12. A
single dose of GnRH antagonist on luteal day 10 should therefore inhibit
steroidogenesis, but not cause luteal regression. The studies described above suggest
that LH secretion and steroidogenesis in marmosets should resume after clearance of
administered GnRH antagonist. It is not known, however, whether LH-withdrawal
during the mid-luteal phase causes any morphological changes to primate corpora
lutea, and this will be examined in the marmoset corpora lutea collected in the course
of these studies. Secondly, administration of PGF2a to marmosets also resulted in
decreased steroidogenesis (Summers et al., 1985). If the sole action of PGF2a was to
decrease steroidogenesis by inhibiting LH receptor secondary messenger pathways
(see subsequent section), it is reasonable to expect PGF2a-treated corpora lutea to be
similar to GnRH antagonist treated corpora lutea. Alternatively, and more probably,
PGF2a inhibited steroidogenesis by alternative mechanisms (see subsequent
section). And affected other aspects of luteal function. If PGF2a does have multiple
effects upon corpora lutea, it can be hypothesised that PGF2a-treated corpora lutea
will be functionally and morphologically different from GnRH antagonist treated
corpora lutea.
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1.5.2 PGF2a in Luteal Regression
Goding (1974) showed that in the ewe PGF2a produced by the uterus was
transported to the ovary by the uterine vein and a countercurrent system allowed
PGF2a to pass from the vein into the ovarian artery and hence into the ovary to
instigate functional luteolysis. Removal of the uterus prevented production of a
luteolytic dose of PGF2a and delayed the onset of luteolysis (Horton and Poyser,
1976). Interestingly, in rats, although luteolysis was delayed after hysterectomy, it
still occurred after an extended luteal phase (Wang et al., 1993), indicating that
although uterine PGF2a is the usual luteolytic mechanism in rats, there may also be
additional intraovarian luteolytic mechanisms. Hysterectomy did not delay luteolysis
in humans (Beling et al., 1970) or macaques (Neill et al., 1969), therefore primate
luteolysis is not a consequence of uterine prostaglandin production.
Intramuscular administration of PGF2a to baboons in vivo did not cause luteolysis
(Eley et al., 1987) but this was probably due to rapid clearance of PGF2a before it
was able act on the ovary. Intraluteal administration of PGF2a caused decreased
steroidogenesis in marmosets (Summers et al., 1985; Hearn and Webley 1987)
macaques (Auletta et al., 1984; Zelenski-Wooten and Stouffer, 1990) and humans
(Bennegard et al., 1991) which suggests that a luteolytic pathway utilising PGF2a
may also occur in primates although the source of PGF2a may differ from other
eutherian mammals. The in vivo administration of PGF2a caused an immediate
decrease in progesterone production without a corresponding decrease in plasma LH
concentration in marmosets (Webley et al., 1991) and humans (Bennegard et al.,
1991) indicating that PGF2a did not exert a luteolytic effect by inhibiting LH
production, but probably acted locally within the corpus luteum.
Human corpora lutea produce PGF2a, PGE2, PGL (prostacyclin), PGD2 and
thromboxanes (Challis et al., 1976; Swanston et al., 1977; Valenzuela et al., 1983).
The intraluteal concentrations of PGE2 and PGF2a in women were highest during the
early luteal phase and decreased as the corpus luteum aged (Challis et al., 1976;
Swanston et ah, 1977; Patwardhan and Lanthier 1985). PGF2a concentrations
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decreased proportionally more than PGE2, therefore the ratio of PGE2:PGF2a
increased with increasing luteal age (Challis et ah, 1976, Table 1). During the mid
luteal phase there was approximately 4 times more PGE2 than PGF2a, and this
increased to a ratio of 8:1 PGE2 to PGF2a in the late luteal phase (Challis et al,
1976). Later work confirmed this increase in the ratio of PGE2:PGF2a (Vijayakumar
and Walters, 1983). Conversely, in another study utilising 16 human corpora lutea,
PGE2 decreased more markedly than did PGF2a (Patwardhan and Lanthier 1985). In
rhesus macaques, PGE2 concentrations were highest during the early luteal phase and
decreased with increasing luteal age (Houmard and Ottobre 1989) whereas PGF2a
concentrations were high during the early luteal phase, decreased to a nadir during
the mid luteal phase, and increased again during the late luteal phase.
Table 1: Endogenous Prostaglandin and Steroid Concentrations in Human
Corpora Lutea.
PGE PGF2a Prog. Oestradiol Author
ng/g ng/g ng/g 17p ng/g
Early-Mid 34 10 7500 750 Challis et al 1976
Luteal n=21
Phase
- 3 2000 200 Swanston et al
1977 n=40
Late 22 3 6000 200 Challis et al 1976
Luteal n=21
Phase
3.5 500 100 Swanston et al
1977 n=40
- 13-46 Shutt et al., 1975
n=4
PGE2, PGI2 and PGD2 stimulate progesterone production in vitro in human corpora
lutea (Bennegard et al., 1990). PGE2 and PGF2a are also luteotrophic during the mid
luteal phase, and stimulate in vitro progesterone production by macaque (Stouffer et
al., 1979) and marmoset () luteal cells. However, prostaglandin-stimulated
steroidogenesis is lower than that caused by hCG stimulation (Stouffer et al., 1979).
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The trophic effect of prostaglandins during the mid luteal phase was confirmed by
the in vitro treatment of macaque mid luteal phase cells with prostaglandin synthase
inhibitors. Basal progesterone production was halved, and hCG-stimulated
progesterone production completely abolished (Zelinski-Wooten et al., 1990).
Progesterone production was also decreased after the in vivo administration of
prostaglandin synthesis inhibitor to women (Fulghesu et al., 1993).
The in vivo administration of PGF2a from the mid to late luteal phase inhibits
progesterone production in marmosets (Summers et al., 1985, Michael and Webley,
1993) and macaques (Auletta and Kelm, 1994). Administration of a prostaglandin
synthesis inhibitor to women during functional luteal regression (Gibson and Auletta
1986) slowed the endogenous decline in progesterone production. This suggests that
intraluteal prostaglandins inhibit steroidogenesis in vivo, and reducing prostaglandin
synthesis by the in vivo administration of ibuprofen decreased this inhibition and
functional luteolysis was therefore slower than in controls. The in vivo administration
of PGF2a did not abolish hCG-stimulated steroidogenesis in macaques (Auletta and
Kelm, 1994) or marmosets (Hearn and Webley 1987), in marked contrast to its
effects in vitro. PGF2a inhibited hCG-stimulated steroidogenesis in human
(Dennefors et al., 1982; Bennegard et al., 1984) macaque (Sotrel et al., 1981;
Zelinski- Wooten et al., 1990) and marmoset luteal cells in vitro (Michael and
Webley 1993).
1.5.3 Luteal Blood Flow and PGF2a
PGF2a receptors are found on steroidogenic luteal cells (Rao et al., 1977; Powell et
al., 1974), but are not found in the vasculature either in the corpus luteum nor in the
rest of the ovary (Orlicky et al., 1992), so although PGF2a is a potent
\
vasoconstrictor its immediate luteolytic effects upon the corpus luteum are unlikely
to be mediated by vasoconstriction and decreased blood flow. Intraluteal injection of
PGF2a in humans did not cause any changes in blood flow or oxygen saturation
(Bennegard et al., 1991) and in rabbits, luteal blood flow was decreased by only 29%
eight hours after adminstration of PGF2a (Bruce and Hillier, 1974) Additional
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animal studies support the premise that functional luteolysis precedes decreased
luteal blood flow (Wiltbank et al., 1989; Wiltbank et al., 1990)
1.5.4 Oxygen Free Radicals and PGF2a
Oxygen free radicals are atoms or molecules which contain unpaired electrons, and
their reactivity is related to their ability to oxidise (remove electrons from) other
molecules (Halliwell and Gutteridge, 1989). The superoxide anion radical (O2") is
mildly reactive and is usually degraded to the even less reactive hydrogen peroxide
radical (H2O2) by superoxide dismutase. H2O2 in turn is degraded to water and
oxygen by catalase or by glutathione peroxidase (Halliwell and Gutteridge, 1989).
However O2" can react with H2O2 in the presence of transition metals such as iron to
form the highly reactive hydroxyl radical OH" by the Haber-Weiss reaction
(Fridovich, 1986). The hydroxyl radical is capable of extracting a hydrogen atom
from unsaturated fatty acids and so can initiate lipid peroxidation of cell membranes,
a process which can result in the formation of cytotoxic aldehydes which have longer
half-lives than oxygen radicals and can attack enzymes, receptors and other
membrane proteins (Riley and Berhman, 1991). Lipid peroxidation causes a
reduction in membrane fluidity, aggregation and rearrangement of membrane
phospholipids, increased permeablility, loss of compartmentalisation and eventually
complete loss of membrane architecture (Riley and Berhman, 1991). One defense
mechanism against lipid peroxidation is the removal of peroxidized fatty acids by
phospholipase A2, and lipid peroxides stimulate phospholipase A2 pathways.
Corpora lutea have high concentrations of antioxidants: oestradiol (Murdoch 1998),
a-tocopheral, ascorbic acid and P-carotene, as well as superoxide dismutase,
glutathione peroxidase and catalase (Behrman et al., 1993). P450 enzymes, which
contain a cytochrome iron group, generate free radicals during steroidogenesis, and it
is likely that high concentrations of luteal antioxidants are required to scavenge these
free radicals (Young et al., 1994). There are a number of interactions between the
antioxidants. Vitamin E plays a major role in terminating lipid peroxidation chain
reactions and in protecting cell membranes from oxygen free radical attack (Behrman
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et al., 1993). Cytoplasmic water-soluble ascorbic acid recycles oxidised inactive
lipid-soluble a-tocophoral back to the active, reduced state, hence ascorbic acid
depletion can be an indicator for the presence of oxygen free radicals (Behrman et
al., 1993). Ascorbic acid concentrations are depleted during luteal regression, but a-
tocopherol levels increase (Aten et al., 1992).
Nitric oxide is a highly reactive free radical gas which is produced by vascular
endothelial cells and macrophages (Bredt and Snyder, 1994) and which can inhibit
the conversion of cholesterol to pregnenolone in a hCG-stimulated murine Leydig
cell line. Nitric oxide also inhibits LH-stimulated testosterone production in rat
Leydig cells (Punta et al., 1996) and inhibits steroidogenesis in human granulosa
lutein cells (Van Vooris et al., 1994). Inhibition of nitric oxide synthesis caused an
increase in estradiol production but did not affect progesterone production by rat
luteal cells in vitro (Olson et al., 1996). Nitric oxide can be generated by the enzyme
nitric oxide synthase (NOS) and there are two different isoforms of NOS, the
constituitively expressed endothelial NOS (eNOS) and the inducible isoform of NOS
(iNOS). Immunocytochemistry has demonstrated positive eNOS immunoreactivity
around the blood vessels of the corpora lutea in rats (Zackrisson et al., 1996), but
iNOS immunoreactivity is highest in non-steroidogenic cells during luteal regression
(Jablonka-Shariff and Olson, 1997).
Ovaries collected from rats at various times after PGF2a administration have been
used as a source of plasma membrane preparations. Plasma progesterone
concentrations in rats are significantly reduced 20 minutes after administration of
PGF2a, and continue to decline thereafter. Sawada et al.( 1991) noted a significant 3-
fold increase in membrane superoxide radical levels in ovaries removed 10 minutes
after PGF2a injection, but O2" levels were reduced to pre-treatment values in ovaries
removed 40 minutes after PGF2a injection, and did not increase again in the
subsequent 2 hours. Phospholipase A2 activity was significantly elevated 20 minutes
after PGF2a treatment and lipid peroxidation was significantly higher than controls 2
hours post PGF2a although activities of superoxide dismutase, catalase and
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glutathione peroxidase remained unchanged (Sawada and Carlson, 1991). Major
sources of superoxide include the enzymes NADPH oxidase and xanthine oxidase
which has luteolytic effects in rat luteal cells (Gatzuli et al., 1991). In endothelial
cells, xanthine oxidase is activated after ischemic insult, but it has also been shown
that neutrophils stimulate conversion of xanthine dehydrogenase to xanthine oxidase
in endothelial cells in a dose dependent fashion. This is not caused by neutrophil
generated oxygen free radicals, but by cell-cell contact (Phan et al., 1989).
Hydrogen peroxide is also produced during luteolysis (Riley and Behrman 1991b)
and it inhibits LH-stimulated cAMP-dependent transport of cholesterol into
mitochondria in rat luteal cells in vitro with a consequent decrease in steroidogenesis
(Behrman and Aten, 1991). It has also been suggested that hydrogen peroxide
inhibits cAMP production by uncoupling the G-protein (Behrman and Preston,
1989), thus disconnecting the LH-receptor from its secondary messenger pathway.
In summary, hydrogen peroxide and the superoxide radical (Sawada et al. 1991) are
generated during PGF2ot-induced luteolysis. Hydrogen peroxide (H2O2) directly
inhibits steroidogenesis (Behrman and Aten, 1991; Behrman and Preston, 1989).
Hydrogen peroxide and superoxide can generate a third radical, hydroxyl (OH"),
which causes lipid peroxidation. Subsequent membrane perturbation may cause
generalised disruption of luteal cell support by gonadotrophins and other factors.
Nitric oxide inhibits luteal steroidogenesis (Van Vooris et al., 1994) and nitric oxide
synthesis increases during luteolysis (Jablonka-Shariff and Olson, 1997).
1.5.5 LH Receptor: Structure, Secondary Messenger Pathways and
Interaction with PGF2a
PGF2a does not affect basal progesterone production in isolated corpora lutea and in
human granulosa-lutein cells in vitro, but it does inhibit LH and hCG-stimulated
progesterone production (Michael et al., 1994). PGF2a does not inhibit LH
production in marmosets (Webley et al., 1991) or macaques (Sotrel et al., 1981)
therefore its inhibitory effects on LH and hCG-stimulated progesterone production
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may occur by (i) decreasing ligand binding or by (ii) decreasing functional LH
receptor levels or by (iii) inhibiting intracellular LH receptor secondary messenger
signalling.
LH and hCG both bind to the same glycoprotein cell surface receptor, found on
steroidogenic cells in corpora lutea (Fitz et al., 1982; Harrison et al., 1987) The
LH/hCG receptor has an extracellular hormone-binding domain (Rodriguez and
Segaloff, 1990), seven transmembrane domains and a small intracellular domain
which binds to G-proteins.
Ligand-binding activates the GTP-binding G(s) protein and activates adenylate
cyclase, which can trigger off three different intracellular secondary messenger
pathways. The cyclic adenosine-3',5'-monophosphate (cAMP)-protein kinase A
(PKA) signal transduction pathway has been shown to mediate gonadotrophin-
stimulated steroidogenesis (Marsh, 1970; Behrman et al., 1993). Adenylate cyclase is
also known to activate phospholipase C (PLC) which can hydrolise
phosphotidylinositol to form diacylglycerol (DAG) which can remain as a
membrane-bound second messenger that regulates the activation of protein kinase C
(PKC) while the inositol triphosphate (IP3) fragment can move into the cytoplasm
and regulate calmodulin-dependent kinase activity by releasing cytosolic stores of
Ca2+. The third intracellular pathway regulated by activated adenylate cyclase is
protein kinase mediated phosphorylation of glycoprotein porous channels to permit
9+
an influx of Ca which depolarizes the membrane.
1.5.5.1 Effects of PGF2a on binding affinity of the LH/hCG receptor.
Luteal membrane preparations were obtained from rats treated with luteolytic doses
of PGF2a and the amount of iodinated hCG bound by these fractions was
determined. There was no decrease in receptor affinity or binding two hours after
administration of PGF2a, although there was a 70% decrease in progesterone
concentration at this time (Grinwich et al., 1976). Similarly, levels of iodinated LH-
binding to sections of human corpora lutea were not decreased 14 days after
ovulation when progesterone levels were falling (Duncan et al., 1996) and luteal LH
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receptor binding affinity is also maintained while progesterone production decreases
in macaques (Cameron and Stouffer, 1982; Sotrel et al., 1981). Therefore PGF2a
does not exert its inhibitory effects on LH and hCG-stimulated progesterone
production by decreasing LH binding or LH affinity for its receptor.
1.5.5.2 Effects of PGF2a on functional LH/hCG receptor levels.
In humans, LH receptor numbers correlate to progesterone levels and are low during
the early luteal phase, high during the mid luteal phase and decrease after functional
luteal regression (Lee et al., 1973; McNeilly et al., 1980). PGF2a causes decreased
expression of functional LH receptors in rats (Grinwich et al., 1976), and macaques
(Cameron and Stouffer, 1982) but only after progesterone levels have decreased,
indicating that the loss of LH receptor is not the cause of functional regression.
LH/hCG receptor mRNA expression increases in the early luteal phase but then
remains constant throughout the rest of the luteal phase in cynomologus monkeys
(Ravindranath et al., 1992) and in humans (Duncan et al., 1996) but decreases in the
late luteal phase when functional luteal regression is well advanced (Nishimori et al.,
1995).
Messenger RNA splice variants which encode a truncated LH-R without a
transmembrane domain but with regions of the hCG and LH-binding extracellular
domain have been found in rat, human, pig and sheep corpora lutea (Bacich et al.,
1994). The A-form is the full length functional mRNA for the receptor, but there is
3.5 times more B-form than A-form splice variant in mid luteal phase sheep corpora
lutea. The B-form lacks a protein kinase-C phosphorylation consensus site, so
although its protein product would be indistiguishable from the A-form protein
product in binding studies and mRNA assays, its functional effect upon
steroidogenesis may differ significantly. It is not known what proportion of mRNA
splice variants are translated, if any, neither is it known how proportions of differing
splice variants change with increasing luteal age, nor whether PGF2a upregulates
functionally inactive LH receptor.
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1.5.5.3 Effects of PGF2a on LH receptor secondary messenger pathways.
Like the LH receptor, the PGF2a receptor is also coupled to signal transduction
enzymes and ion channels by GTP-binding proteins, but unlike the LH receptor
PGF2a stimulates cyclic guanosine phosphate (cGMP) accumulation (Sotrel et al.,
1981). PGF2a also stimulates the calcium-dependent protein kinase C (PKC), which
has been shown to mediate the antigonadotrophic actions of PGF2a in ovine luteal
cells (Wiltbank et al., 1990) and human granulosa-lutein cells (Abaysekara et al.,
1993). Classically PKC activation is by phospholipase C catalysed hydrolysis of
membrane phosphoinositides with consequent generation of diacylglycerol (DAG)
and inositol triphosphate (IP3), but phosphoinositides are not generated during
luteolysis in the rat (Lahav et al., 1988) or marmoset (Michael and Webley 1993)
therefore PGF2a may cause activation of phospholipase A2 (Sawada and Carlson,
1991; Riley and Carlson 1987) which is capable of generating arachidonic acid
which in turn can activate PKC (Lopez-Ruiz et al., 1992). PGF2a also activates
cyclic nucleotide phosphodiesterases which inactivate cAMP, and it has been shown
that cAMP phosphodiesterase activity is mediated by PKC-dependent mechanisms
(Michael and Webley, 1991). Formation of LH-dependent cAMP was inhibited 15
minutes after administration of PGF2a in rats (Thomas et al., 1978, Dorflinger et al.,
1983) and this is due to uncoupling of the G(s) protein from adenyl cyclase
(Abayasekara et al., 1993). PGF2a inhibited cAMP accumulation in LH-stimulated
marmoset slices from mid luteal phase corpora lutea in vitro, but did not affect basal
progesterone production or basal cAMP accumulation (Michael and Webley, 1993).
In rat corpora lutea PGF2a increased membrane phospholipase A2 activity and lipid
peroxidation (Sawada and Carlson, 1991) with a subsequent decrease in membrane
fluidity and inhibition of LH receptor and G-protein diffusion. This is a potential
mechanism for uncoupling G-proteins from the catalytic subunit of adenyl cyclase
(Michael et al., 1994).
In summary, PGF2a does not decrease LH binding, nor LH affinity for its receptor,
but it does cause disconnection of the LH receptor from its intracellular signaling
pathway.
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1.5.6 PGF2a and Luteal Cells in vitro.
Administration of PGF2a to dispersed rat (Thomas et al., 1978) or marmoset
(Webley et al., 1989) mid luteal phase cells in vitro stimulates progesterone
production. Since in vivo administration of PGF2a inhibits progesterone production,
it seems that the vasculature may be involved in mediating the luteolytic effects of
PGF2a in vivo. However, this is a somewhat paradoxical conclusion because PGF2a
receptors have not been identified in luteal vasculature (Orlicky et al., 1992). It is
possible that cell dispersion techniques modify PGF2a receptors on the steroidogenic
cells in a way that prevents inhibition and permits stimulation of steroidogenesis. It is
also possible that PGF2a binds to its receptors on luteal steroidogenic cells which
respond by producing factors which stimulate oxygen free radical production by
endothelial cells of the vasculature, or by vascular leukocytes. Another possiblity is
that PGF2a acts directly on endothelial cells by a mechanism that does not require a
classical PGF2a-receptor.
1.5.7 Summary of the Luteolytic Actions of PGF2a
The first luteolytic action of PGF2a is to stimulate the production of the superoxide
and hydrogen peroxide radicals. PGF2a-stimulated radical production may be
mediated by vascular leukocytes or endothelial cells. Hydrogen peroxide inhibits
LH-stimulated cholesterol transport into mitochondria, so immediately inhibits
steroidogenesis.
Superoxide and hydrogen peroxide can generate hydroxyl radicals, which can cause
lipid peroxidation. Lipid peroxides stimulate phospholipase A2 pathways, which
stimulate protein kinase C, which mediates cyclic nucleotide phosphodiesterase
inactivation of cAMP. Lipid peroxidation may also cause dissociation of G-proteins
from the catalytic subunit of adenyl cyclase (Michael et al., 1994). The second
luteolytic action of PGF2a is therefore to disconnect the LH receptor from its
intracellular signaling pathway. The third luteolytic action of PGF2a, inhibition of
LH receptor expression, occurs after progesterone production has decreased. The
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main luteolytic action of PGF2a is therefore to prevent LH-stimulated progesterone
production.
1.5.8 Leukocytes, Cytokines and Growth Factors During Functional
Luteal Regression.
Immunosuppressive glucocorticoid prevents natural, but not PGF2a-induced
luteolysis in the rat, which suggests a role for the immune system in luteolysis (Wang
et al., 1993). Changing LH pulsitility does not directly affect the duration of the
functional luteal phase, but it may regulate steroidogenic cell production of factors
which attract leukocytes into the corpus luteum. Luteal steroidogenic cells secrete
granulocyte macrophage colony stimulating factor (Jasper et al., 1996) which is a
chemoattractant for lymphocytes, neutrophils and macrophages, and macrophage
numbers increase as the luteal phase proceeds in rabbits (Bagavandoss et al., 1988),
sheep and humans (Lei et al 1991, Gillim et al., 1969) and pigs (Zhao et al., 1998).
Monocyte chemoattractant protein-1 (MCP-1) increases during luteolysis in bovine
corpora lutea (Penny et al., 1998). Hehnke et al (1994) found that macrophage
numbers were significantly increased 6 hours after intraluteal administration of
PGF2a to pigs in the mid luteal phase, whereas progesterone levels were only
significantly decreased 12 hours after administration. Implants containing vehicle
resulted in an increase in macrophage numbers but no change in progesterone
concentration, indicating that the presence of macrophages alone did not induce
luteolysis, but that the combination of macrophages and PGF2a was necessary for
induction of functional luteolysis (Hehnke et al., 1994).
Macrophages secrete interleukin 1, which stimulates oxygen free radical production
by both neutrophils and monocytes (Behrman et al., 1991). Interleukin 1 also
stimulates steroidogenic cell PGF2a production (Benyo-Fairchild and Pate 1992),
although IL-1P mRNA did not change prior to or during luteolysis in bovine corpora
lutea (Petroff et al., 1999). Additionally, macrophages secrete tumour necrosis factor
a (TNFa). Intraluteal administration of TNFa induced luteolysis in pigs (Wuttke et
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al., 1992) probably by inhibiting gene expression of P450scc, 3PHSD and
P450aromatase (Wuttke et al 1995). TNFa also inhibited LH-stimulated
progesterone production and stimulated PGF2a production in bovine luteal cells in
vitro (Benyo and Pate 1992) but did not inhibit progesterone production by human
luteal cells in vitro, although it did significantly potentiate IFNy-induced
progesterone inhibition (Wang et al., 1992).
TNFa immunoreactivity was found in the endothelial cells of porcine corpora lutea,
but this immunoreactivity diminished during functional luteal regression (Hehnke-
Vagnoni et al., 1995). However, another study using porcine corpora lutea found that
TNFa immunostaining was associated primarily with macrophages in the
vasculature, but not the microvasculature, and appeared to increase as the luteal
phase progressed (Zhao et al., 1998). These contradictory results may be attributable
to the greater specificity of antibodies used in the latter study. TNFa immunostaining
was also found in granulosa lutein and theca lutein cells of human corpora lutea.
Immunostaining intensity peaked during the mid luteal phase, decreased in the late
luteal phase and diminished further as regression proceeded (Kondo et al., 1995).
Regressed corpora lutea, however, were bordered by macrophage-like cells which
exhibit intense immunostaining for TNFa (Kondo et al., 1995). TNFa mRNA was
not found within luteal tissue after PGF2a-induced luteolysis in sheep (Ji et al.,
1991), although it increased during the late luteal phase and after PGF2a induced
luteolysis in bovine corpora lutea (Petroff et al., 1999). It is possible that TNFa
inhibits the expression of Steroidogenic Acute Regulatory Protein (StAR) and
therefore inhibits progesterone production (Chen et al., 1999). TNFa therefore
appears to have luteolytic potential, but the mechanism of action in luteolysis in vivo
is presently unknown.
Neutrophilic granulocytes and lymphocytes are also present in regressing human
corpora lutea, but these cell numbers do not increase with increasing luteal age
(Wang et al., 1992). Lymphocytes secrete interleukin-2 (IL-2) and interferon y (IFN-
y), and these cytokines inhibit hCG-stimulated progesterone production by
granulosa-lutein cells in vitro (Wang et al., 1991; Wang et al., 1992). However,
mRNA for IL-2 nor its receptor were detected in bovine corpora lutea, and IFN-y
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mRNA decreased prior to luteolysis (Petroff et al., 1999). Neutrophils have been
shown to adhere to endothelial cells and induce nitric oxide production (Phan et al.,
1989).
Immunoreactive TGFpl and P2 have been detected in the steroidogenic cells of
human corpora lutea and in corpora albicantes (Chegnini and Flanders 1992).
In summary, immune system cells and cytokines occur in primate corpora lutea, and
they have the ability to inhibit LH-stimulated progesterone production, and to
stimulate the production of oxygen free radicals. Leukocyte and cytokine interactions
with PGF2a or the luteal vasculature have not been examined in primate corpora
lutea, and research in these areas is likely to yield data that would increase
understanding of luteolysis in primates.
1.5.9 Oestrogen in Luteal Regression
Administration of oestrogen caused luteal regression in macaques (Auletta et al.,
1976) and women (Gore et al., 1973). Sotrel et al (1980) demonstrated that
progesterone production was significantly decreased 3.5 hours after intraluteal
administration of oestradiol, but that intraluteal administration of PGF2a caused a
significant decrease in progesterone levels after only 40 minutes. There was no
concomitant decrease in LH levels, but the luteolytic action of oestradiol was
blocked by a prostaglandin synthesis inhibitor, which suggest that the luteolytic
effects of oestradiol were mediated by prostaglandin. In contrast to these findings
Hutchison et al (1987) found that oestrogen was only luteolytic in macaques in the
presence of a progesterone-mediated decrease in LH pulse frequency (Hutchison et
al., 1987). It appears that oestrogen may have two luteolytic sites of action, one in
the hypothalamus and another locally in the corpus luteum, and that its actions are
mediated by progesterone and PGF2a respectively. However, a physiological role
for oestradiol in luteolysis has yet to be established.
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1.5.10 Oxytocin in Luteal Regression
Ruminant luteal cells secrete oxytocin which binds to oxytocin receptors in the
uterus. Oxytocin receptors are expressed in the uterus in increasing numbers as the
luteal phase proceeds, and ligand binding initiates production of uterine
prostaglandin which in turn causes luteolysis (Roberts and McCracken 1976).
Oxytocin and oxytocin receptors are found in primate corpora lutea (Einspanier et
al., 1994; Dawood and Khan-Dawood 1986), and oxytocin infusion shortened the
luteal phase in rhesus macaques (Auletta et al., 1984). Oxytocin has been found to
both stimulate and inhibit progesterone production by luteal cells in vitro, and these
differential effects appear to be related to stage of the luteal phase (Wuttke et al,
1995). Low numbers of oxytocin receptors were found in baboon corpora lutea
collected during the early luteal phase, receptor numbers peaked during the mid
luteal phase, but were not detectable during the late luteal phase (Khan-Dawood et
al., 1993). It is likely that estrogen, progesterone and oxytocin interact to regulate
oxytocin receptor expression, so although it appears that oxytocin does play a role in
paracrine regulation within the corpus luteum, the lack of oxytocin receptors during
the late luteal phase suggests that oxytocin does not play a role in primate luteal
regression.
1.5.11 Apoptosis and Luteolysis
Primate luteal regression does not seem to occur in response to a clearly defined
extra-ovarian signal, therefore it has been suggested that an intra-ovarian mechanism
may play a role in controlling luteal regression in primates (Zeleznik, 1991). What
instigates the gradual decrease in serum progesterone levels during the late luteal
phase? An alternative hypothesis to endogenous PGF2a-induced regression is that
steroidogenic cell numbers decrease, thus reducing the steroidogenic capacity of the
corpus luteum (Zeleznik, 1991). This hypothesis requires a mechanism that would
selectively delete luteal cells without affecting other ovarian compartments such as
follicles or stroma. It also requires regulation of the time of cell death since
inappropriate early or late steroidogenic cell death would disrupt the normal
reproductive cycle.
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Apoptosis is one form of cell death in which specific cells die in response to
intracellular genetic stimuli (Kerr 1971; Bellamy et al., 1995; Cohen 1991; Majno
and Joris, 1995). Apoptosis has been demonstrated in the regressing corpora lutea of
rabbits (Dharmarajan et al., 1994), rats (Orlicky et al., 1992), sheep (O'Shea et al.,
1977, Sawyer et al 1990, Kenny et al., 1994) and cows (Juengel et al., 1993, Zheng
et al., 1994; Rueda et al., 1995), but these studies have not determined the temporal
relationship between luteal regression and apoptosis. Additionally, apoptosis had not
been examined in the corpora lutea of a primate species when these studies
commenced in 1993.
In order that apoptotic cell death can be differentiated from other types of cell death,
an examination of the different forms of cell death follows. The specific features of
apoptosis will then be described within this context.
1.5.11.1 Types of Cell Death
There are numerous causes of cell death, for example, increases or reductions in
physiological supplies: oxygen, substrates or trophic support. The disruption of
cellular regulatory processes; osmotic control, ion transport or protein production,
can also cause cell death (Haecker and Vaux 1994). Physical damage is yet another
cause of cell death. Cell death can be the consequence of multiple circumstances:
ischemia, viral infection, wounding or toxic shock, to name but a few (Vaux and
Haecker, 1995). Cell death caused by processes originating from within the body is
sometimes classified as being physiological, whereas cell death resulting from an
external source such as wounding or exposure to a toxic substance is sometimes
classified as being non-physiological (Vaux and Haecker, 1995). In practice, the
source of the death-inducing agent is irrelevant to the cell, it is the mechanism of
action of that agent combined with the internal status of the cell, which determines
the cellular response (Hockenberry, 1995). It seems that initial cell responses to fatal
stimulants may be as varied as the death-agents themselves, but later responses are
common to all cells regardless of the initial mechanism by which death was induced
(Majno and Joris 1995). To take one example, cell death caused by ischemia is
characterised by the impaired action of ion pumps and decreased intracellular
calcium and sodium regulation. Consequent increases in intracellular calcium levels,
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acidosis and osmotic shock follow (Bowen 1984). This is associated with nuclear
swelling and flocculation of the chromatin (Ueda and Shah 1994). The process
continues with lysosome swelling, dilation and vesiculation of the endoplasmic
reticulum and loss of compartmentalisation and cell oedema (Bowen 1984; Trump et
al., 1981; Cohen 1991). Rupture of the cells' contents frequently invokes an
inflammatory response (Ueda and Shah, 1994). If swelling does not result in cell
rupture, cells can then enter the pathway common to all cells regardless of the initial
mode of death. This pathway has been termed 'necrosis' (Majno and Joris, 1995) and
is characterised by irreversible changes in the nucleus (random DNA fragmentation
and disappearance) and in the cytoplasm: condensation, eosinophilia and cell
shrinkage.
Some forms of cell death do not appear to be initiated by changes in the extracellular
environment, but are apparently under intracellular genetic control, and perhaps
represent a form of'terminal differentiation' (Majno and Joris, 1995). Intracellular,
genetically-derived death signals have been termed 'programmed cell death', and can
result in a variety of cell death pathways, only one of which is apoptosis (Majno and
Joris, 1995). Programmed cell death occurs at specific times and locations during
embryonic development; the formation of digits is due to the death of web-space
cells and formation of the central nervous system also utilises this mechanism
(Saunders, 1966; Hamburger and Levi-Montalcini, 1949). Programmed cell death
also occurs after withdrawal of a growth factor or hormone (Kyprianou et al., 1988).
Apoptosis is a particular type of programmed cell death defined by a specific series
of morphological and biochemical characteristics (Kerr et al., 1972). The first visible
morphological features of apoptosis are cytoplasmic and nuclear condensation
accompanied by the loss of microvilli and cell-cell junctions, and the formation of
cell surface convolutions (Schwartzman and Cidlowski, 1993). There is little or no
swelling of mitochondria or other cytoplasmic organelles. This is followed by
chromatin margination, the condensation of chromatin into crescent-shaped
aggregates lining the nuclear membrane convolutions (Schwartzman and Cidlowski,
1993). The nucleus fragments into membrane-bound 'beads' of very dense
chromatin; a process termed nuclear fragmentation or karyorhexis. This is followed
by fragmentation of the entire cell into membrane bound apoptotic bodies some of
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which contain chromatin. Alternatively the cell may shrink into a dense, rounded
mass and so form one apoptotic body (Hsueh et al., 1994). Apoptotic bodies are
removed from intercellular spaces through phagocytosis by neighboring or immune
system cells, or by being shed into the lumen of the gut or capillaries of the
vasculature (Kerr et al., 1972; Wyllie and Morris, 1982; Morris et al., 1984).
Apoptosis is a relatively fast process, in one case taking only 34 minutes from initial
blebbing to the formation of apoptotic bodies (Majno and Joris 1995; Bursch et al.,
1990), therefore a small amount of apoptosis detected in tissue sections can indicate
quite a substantial rate of cell loss and tissue degeneration. However, subsequent
phagocytosis or removal of apoptotic bodies can take hours (Bursch et al., 1990). A
biochemical feature specific to apoptosis is a characteristic DNA fragmentation
pattern caused by specific endonucleases which cleave the DNA at 185bp intervals
(Wyllie, 1980, Arends et al., 1990). This can be examined by labelling the 3' ends of
the DNA fragments with a radioisotope prior to gel electrophoresis and visualising
the resulting 185bp ladder pattern by autoradiography (Tilly and Hsueh 1993) or the
DNA fragments can be visualised in situ by labelling 3' ends of the DNA fragments
with digoxigenin-11-UTP (Gavrieli et al., 1992). However, there are some instances
in which cells display morphological characteristics of apoptotic cell death but do not
display this characteristic DNA ladder (Walker et al., 1993) and other instances in
which specific DNA fragmentation occurred in the absence of morphological
markers of apoptosis (Enright et al., 1994).
1.5.11.2 Ubiquitin: A Protein Associated With Cell Death
Ubiquitin is a highly conserved 76-amino acid polypeptide which covelantly
conjugates to cytoplasmic proteins and marks them for subsequent proteolytic
degradation through an ATP-dependent process . Ubiquitin ligation has also been
found to modify protein function; ubiquitin-histone conjugation results in a
decreased histone turnover rate and may regulate chromatin structure during
transcription. Ubiquinylated histones may also have a role in mitosis since they
disappear during metaphase and reappear shortly afterwards (reviewed by Hershko,
1988). Others have also demonstrated that ubiquitin-protein ligation is important for
cell cycle progression and viability and that ubiquitin can be immunochemically
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detected in both cytoplasm and nucleus (Haas and Bright 1985). Ubiquitin
upregulation has been associated with apoptosis. In the tobacco hawkmoth Manduca
sexta the developmental^ programmed cell death of intersegmental muscles is
associated with a 10-fold increase in total ubiquitin polypeptide (Haas et al., 1996;
Myer and Schwartz, 1996). The colonial sea squirt Botryullus schlosseri also
undergoes a cyclical death process which is characterised by cell shrinkage,
chromatin condensation and margination followed by nuclear and cytoplasmic
fragmentation into membrane bound parcels of ultrastructurally intact organelles
which are either shed into the lumen of the stomach or phagocytosed by
macrophages: these are all classical features of apoptosis (Wyllie and Morris, 1982;
Cohen, 1991). In the sea squirt a second form of cell death was also observed in
conjunction with apoptotic cell death; it was characterised by flocculation of the
nuclear chromatin, mitochondrial swelling and cellular lysis. A marked increase in
cytoplasmic ubiquitin immunoreactivity was noted in all dying cells, including
apoptotic cells phagocytosed by macrophages (Lauzon et al., 1993). Murine
myoblasts committed to apoptosis show an increased expression of ubiquitin (Sandri
et al., 1997) and ubiquitin mRNA is upregulated and nuclear proteins are ubiquinated
in human lymphocytes induced to undergo apoptosis (Delic et al., 1993). In contrast,
embryonic neurones can be induced to undergo apoptosis in vitro by withdrawing
nerve growth factor from the culture medium, but under these conditions ubiquitin
mRNA is not upregulated (D'Mello and Galli, 1993) which indicates that the role
and sub-cellular localisation of ubiquitin during apoptosis is not entirely clear.
1.5.11.3 The Genetic Control of Apoptosis
Apoptosis probably evolved as a means of regulating and repairing DNA damage
(Basu and Haldar 1998) and counteracting viral infection (Haeker and Vaux, 1994).
The specific morphological and biochemical events that occur during apoptosis are
controlled by genes that become activated in specific sequences (Majno and Joris
1995). There are also numerous signals that activate suicidal apoptotic programmes:
receptor mediated specific inducers of apoptosis typified by hormones or growth
factors, cytotoxic immune system cells, anticancer drugs, toxins and injury
(Schwarzman and Cidlowski, 1993).
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Professor Wyllie (Pathology, School of Medicine, Edinburgh University) presented a
seminar (Western General Hospital, November 1994) in which he related cell cycle
to the expression of genes associated with apoptosis. His hypothesis was the basis for
Figure 1.0, to which additional genes were added as they were discovered. Tissue
maintenance occurs through proliferative cell cycles and the removal of damaged
cells by cell death, and these process are mediated by the activation of genes in
specific sequences (Basu and Haider 1998). Cells that are arrested in the Go stage of
the cell cycle do not express growth factors or c-myc. Environmental changes that
result in the entrance of cells to the G1 stage of the cell cycle are often mediated by
the proto-oncogene transcription factors c-fos, c-jun or c-myc (Cole 1986, Evan et
al., 1992). Further progression around the cell cycle requires the expression of
additional genes such as the inner mitochondrial membrane protein Bcl-2
(Schwarzman and Cidlowski, 1993). Wyllie hypothesised that cells could only enter
an apoptotic cycle from the G1 phase of the cell cycle, and that the genes that
regulated movement between different stages of the cell cycle might also play a role
in the regulation of apoptosis. One example of this is the gene Bcl-2, which
suppresses apoptosis (Hockenbery et al., 1991) whereas p53 promotes it (Clarke et
al., 1993). Bcl-2 stimulates cell proliferation, whereas a Bcl-2 homologous protein,
Bax competes with Bcl-2. Bax-Bax homodimers therefore induce apoptosis, but Bax-
Bcl-2 heterodimers suppress apoptosis (Basu and Haldar 1998). Bcl-2 and Bax are
transcriptional targets for p53, which induces cell cycle arrest and initiates apoptosis
in response to DNA damage (Basu and Haldar 1998).
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Apoptotic gene pathways may be initiated only from the cell turnover, G1 phase of
the cell cycle (Figure 1). Ligand binding to four different receptors, Fas, TRAMP,
TRAIL and the TNF receptor 1, individually or in combination trigger intracellular
apoptotic pathways (Irmler et al., 1997). Bax also stimulates apoptosis by causing the
release of cytochrome c from mitochondria into the cytoplasm where it stimulates the
processing of caspases 3 and 6 (Deveraux et al., 1997). Fas receptor binding recruits
or activates caspase 8, (also known as FLICE or Mach or Mch5) which in turn
associates with Fas and TNF-R1 receptor complexes and initiates a cascade that
results in caspase 3 activation and subsequent apoptosis (Deveraux et al., 1997). The
X chromosome linked Inhibitor of Apoptosis (IAP) gene, also known as FLIP (for
FLICE-inhibitory protein, Irmler et al., 1998) inhibits caspases 3 and 7, and therefore
prevents apoptosis stimulated by the death receptors (Deveraux et al., 1997).
Intracellular calcium levels increase after apoptotic stimuli, and may be a
prerequirement for the activation of endonucleases (Schwarzman and Cidlowski,
1993) which cause the internucleosomal fragmentation characteristic of apoptosis.
The proto-oncogene c-myc has been associated with apoptosis, and has been
identified in the corpus luteum of the marmoset (Fraser et al., 1995) and human
(Illingworth et al., 1994). Bcl-2 also occurs in human corpus luteum (Rodger et al.,
1995), but its expression did not decrease prior to luteolysis. Lluman granulosa cells
luteinised in vitro expressed Fas, and binding of Fas ligand caused apoptosis. This
was enhanced by culturing with interferon gamma and hCG (Quirk et al., 1995).
Genes associated with apoptosis were expressed in rat corpora lutea: sulfated
glycoprotein 2, Y81, Gas-1 and Integrin-Associated Protein (Guo et al., 1998) and
expression was upregulated in the early stages of functional luteolysis.
1.5.11.4 Control of Apoptosis in the Ovary
The majority of follicles in the ovary undergo atresia (Tilly et al., 1991, Giebel et al.,
1997) during which granulosa cells undergo apoptosis. A number of factors have
been found to affect follicular apoptosis (Tilly et al., 1992; Witty et al., 1996).
Estrogen prevents and testosterone stimulates apoptosis in atretic rat follicles (Billig
et al., 1993), however it has been found that steroid hormone regulation of apoptosis
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is tissue specific, with the same hormone having differing effects in different tissues
(Hseuh et al., 1994). The gonadotrophins LH and FSH prevented spontaneous
apoptosis in rat follicles in vitro (Chun et al., 1994). The withdrawal of trophic
support from in vitro cultured rabbit corpora lutea also resulted in increased levels of
apoptotic DNA fragmentation, whereas the addition of the gonadotrophin hCG dose-
dependently suppressed luteal apoptosis (Dharmarajan et al., 1994). Granulosa cell
apoptosis is also associated with decreased levels of FSH and LH receptor mRNA
(Tilly et al., 1992). Changed LH pulsitility or LH serum levels do not induce luteal
regression in vivo (Zeleznik 1991) therefore apoptosis in primate corpora lutea is
unlikely to be caused by decreasing LH or LH pulsitility.
Gonadotrophin levels are controlled by gonadotrophin releasing hormone (GnRH),
and GnRH receptors are present in granulosa and theca cells of the rat (Hsueh and
Jones, 1981). Treatment of estrogen-replaced hypophysectomised rats with a GnRH
agonist stimulated granulosa cell apoptosis. Simultaneous administration of a GnRH
antagonist prevented agonist-induced apoptosis, but apoptosis in animals treated with
GnRH antagonist alone was not different from untreated controls (Billig et al., 1994).
Macrophage numbers increase as the luteal phase proceeds (Lei et al 1991, Gillim et
al., 1969), and macrophages secrete TNFa, which has been found to upregulate
intracellular ceramide and induce apoptosis in granulosa cells (Witty et al., 1996).
Intraluteal administration of TNFa induced luteolysis in pigs (Wuttke et al., 1992)
and was found during the mid luteal phase in human corpora lutea (Kondo et al.,
1995). TNFa may therefore play a role in the early induction of apoptotic pathways
in vivo.
In summary, one form of programmed cell death, apoptosis, occurred during luteal
regression in a number of non-primate species (Dharmarajan et al., 1994; Orlicky et
al., 1992; O'Shea et al., 1977, Sawyer et al 1990, Kenny et al., 1994; Juengel et al.,
1993, Zheng et al., 1994; Rueda et al., 1995). It was therefore hypothesised that
functional luteal regression in primates might occur by the apoptotic cell death of
steroidogenic luteal cells.
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1.5.12 Luteal vasculature and luteolysis.
Approximately 50% of the cells in primate corpora lutea are endothelial cells (Lei et
al., 1991; Christenson and Stouffer, 1996), and an extensive capillary network
penetrates the corpus luteum, so much so that every steroidogenic cell is in contact
with at least one capillary (Redmer and Reynolds 1996). The primary function of the
corpus luteum is the production of steroid hormones, and steroidogenesis is entirely
dependent upon the delivery of cholesterol substrates and regulatory gonadotrophins
through the vasculature. Peak progesterone production does not occur until the luteal
vasculature is fully developed. Early luteal phase corpora lutea cultured in vitro and
stimulated with gonadotrophins secrete more progesterone than mid and late luteal
phase corpora lutea (Hild-Petito et al., 1989), but maximal secretory activity does
not occur in vivo until the mid luteal phase, and it is thought that this is due to
inadequate development of the luteal vasculature in the early luteal phase (McClellan
et al., 1975). It is believed that the vasculature is absolutely vital to normal
functioning of the corpus luteum, but it is not clear what role it plays in luteal
regression. It is not known whether changes in the vasculature, or changes in blood
flow, precede functional luteal regression in the primate, and neither is it clear when
or how the vasculature changes during the process of structural regression.
1.5.12.1 Blood Flow in the Corpus Luteum.
Blood flows through the corpus luteum at the rate of approximately 10 - 15 ml per
minute per gram of tissue (Abdul-Karim and Bruce 1973; Bruce and Moor 1976) and
this rate of flow is higher than that to any other organ of the body; flows of 0.61,
1.86, and 1.78 ml per minute per gram of heart, brain and kidney respectively have
been observed (Bruce and Moor, 1976). Within the ovary rates of blood flow are
2.66 and 6.68 ml per minute per gram of stroma or follicles respectively, showing
that blood flow to the follicles is of the same order as that seen to corpora lutea
(Bruce and Moor, 1976). It is not known why blood flow through the corpus luteum
is so much higher than through other tissues. Blood flow to the ovary bearing the
corpus luteum, and also through the corpus luteum, decreases as the luteal phase
advances (Niswender et al., 1976; Bruce and Moor, 1976) and studies utilising
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radioactive microspheres indicate that approximately 90% of the blood flowing to
the ovary goes through the corpus luteum during the mid luteal phase (Niswender et
al., 1976; Abdul-Karim and Bruce, 1973), but that this decreases to 28% in the late
luteal phase (Bruce and Moor, 1976). It has been suggested that a mechanism for
reducing luteal blood flow exists, and an arteriole-venule shunting system which
results in reduced blood flow to individual steroidogenic cells has been proposed
(Niswender et al., 1976).
1.5.12.2 Effects of Luteolytic Agents on Luteal Blood Flow.
LH may have effects on luteal blood flow. Administration of anti-LH antibodies to
sheep causes a decrease in serum progesterone levels and a concomitant decrease in
blood flow to the ovary, and infusion of additional LH causes an increase in serum
progesterone levels and an increase in blood flow (Niswender et al., 1976) but the
temporal relationships between changes in steroid hormone production and changes
in luteal blood flow are unclear. Administration of PGF2a in vivo to rabbits does
not, however, cause a decreased blood flow to the corpora lutea until 6 hours after a
significant decrease in plasma progesterone concentration has occurred (Bruce and
Hillier, 1974), so the luteolytic action of PGF2a is unlikely to be mediated by
reduced blood flow. It does, however, appear to be mediated by endothelial cells
because steroidogenesis was not inhibited by PGF2a in pure cultures of bovine
luteal steroidogenic cells, but steroidogenesis was inhibited in mixed cultures of
endothelial and steroidogenic cells (Girsh et al., 1995). Disruption of the vasculature
also prevents the luteolytic effect of PGF2a on dispersed rat or dispersed marmoset
luteal cells in vitro (Thomas et al., 1978; Webley et al., 1989). In addition, PGF2a
has longer term effects on luteal vasculature; 24 hours after in vivo administration of
PGF2a to sheep 28% of endothelial cells were morphologically abnormal and
capillary lumina were occluded with cellular debris (Sawyer et al., 1990; Stacey et
al., 1976). It has also been suggested that vascular occlusion during luteal regression
could result in hypoxic conditions, and that ischemia could therefore be a component
of structural luteal regression.
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A number of studies have quantified different cell types of the corpus luteum. In one
study, the cellular composition of sheep corpora lutea was determined by a 'hit'
technique whereby luteal components were classified as large or small luteal cells,
capillaries or connective tissue. The number of 'hits' in endothelial cells or capillary
lumina decreased by approximately 50% from the mid to late luteal phase, but the
number of 'hits' in leukocytes and in intracapillary debris increased during the same
time period, while connective tissue quantification remained constant (Niswender et
al., 1976). The decrease in the number of endothelial cell 'hits' occurred before
serum progesterone levels decreased, suggesting that changes in luteal vasculature
may instigate functional regression. The majority of workers, however, have found
that in ruminants structural changes are first seen in the vasculature concomitant
with falling serum progesterone values, and that during luteal regression there
appears to be a change in the vasculature bought about by the loss of small
capillaries and an increase in larger microvessels (Zheng et al., 1993; Redmer and
Reynolds 1996). The mid-phase bovine corpus luteum has a dense capillary network
made up of fully differentiated endothelial cells with a flattened elongated
morphotype and numerous tight junctions (Modlich et al., 1996). Early luteal
regression is characterised by the dissociation of endothelial tight junctions,
widening capillary basal lamina and disruption of osmotic regulation. Endothelial
cell nuclei condense and may fragment in a process which closely resembles the
initial stages of apoptosis, and the cells then slough off into the lumen of the blood
vessel, so forming localised blockages (O'Shea et al., 1977; Modlich et al., 1996).
This loss of endothelial cells further perturbs the integrity of capillary basal lamina
and probably accelerates the loss of osmotic equilibrium. Occlusion of the capillaries
may also cause ischemia (O'Shea et al., 1977). Parenchymal steroidogenic cells then
undergo degenerative changes (Deane et al., 1966), either by the formation of
vacuoles, or by apoptosis (Modlich et al., 1996). The loss of steroidogenic cells
appears to be accompanied by the loss of small capillaries and their replacement with
larger microvessels (Modlich et al., 1996).
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In summary, luteal regression in non-primates is associated with decreased blood
flow through the corpus luteum, and with decreased numbers of endothelial cells.
Luteal vasculature has not been examined during the late luteal phase in primates,
and the importance of vascular morphology to the process of luteolysis is unknown.
1.6 Conclusions
It is possible that luteal regression in primates is mediated by a combination of
prostaglandin production, immune system cells and products, luteal vasculature and
oxygen free radicals. Apoptotic deletion of steroidogenic cells might result in
decreased plasma progesterone concentrations, and decreased steroidogenesis might
stimulate the endogenous production of PGF2a, with subsequent oxygen free radical
production and a further decrease in steroidogenesis. This thesis examines factors
which have the potential to initiate and regulate luteal regression in the marmoset
monkey.
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Chapter 2: Materials and Methods
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2.0 Marmoset Housing and Maintenance
Marmosets were 18 months old when first recruited into the study. Femoral vein
blood samples were taken three times a week and assayed for progesterone.
2.0.1 Housing
Cages were 1 x 1 x 0.65 m in size, with wooden perches and wood shavings on the
floor to allow foraging behaviour. Nesting boxes were positioned at the highest point
of the cage. There were 6 cages in each room, and each cage contained one
vasectomised male and one adult female.
2.0.2 Diet
Animals were fed once a day on a selection of the following:
• Peanuts, raisins, dates, sunflower seeds, brown bread,
• Fruit - apple, orange, pear, tomato, banana, grapes
• Porridge Mix: Casilan, Farex baby rice, multi vitamin drops, complan and
vitamin D3.
2.0.3 Environmental Cues.
High level glass windows meant the animals experienced a normal diurnal light-dark
cycle. Animal house staff however, noted no seasonality in the breeding animals.
2.1 Progesterone Concentrations and Reproductive Cyclicity
2.1.1 Progesterone Radioimmunoassay.
Marmoset blood samples (300pl) were collected every two or three days by femoral
venipuncture into 1ml heparinized syringes. The syringes were sealed with a cap and
centrifuged at 1 OOOg for 20 minutes at 4°C. The separated plasma was transferred to
an eppendorf tube and stored at "18°C until progesterone concentrations were
measured by radioimmunoassay. Marmoset samples were thawed, vortexed and
2.5pl of serum diluted into 147.5pi of progesterone assay buffer (1M phosphate
citrate and 1% gelatin, pH 6). Each standard or sample was assayed in duplicate.
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The progesterone assay standard curve comprised 100 pi of progesterone standard
diluted to the following concentrations; 2.5, 5, 10, 25, 50, 100, 250, 500 and 1000
ng/ml. In addition non-specific binding was calculated by omitting primary antibody
and using 200pl assay buffer instead of progesterone standard, and Bo zero counts
were calculated by using lOOpl of assay buffer instead of progesterone standard.
2.5pl of human post-menopausal serum (PMS) diluted in 47.5pl of assay buffer was
added to each of the above items in order that the volume and components of the
standard curve remain consistent with the samples, with the exception that PMS does
not contain progesterone. Three quality control (QC's) samples of progesterone
concentrations equivalent to the highest, mid and lowest ranges of the assay were
incorporated into the assay. The QC's were dispensed in the same manner as
unknown samples of serum. The primary antibody, sheep anti-progesterone, was
diluted 1:1000 in assay buffer and 1 OOpl added to all samples and standards except
for those measuring non-specific binding. The radioactive tracer was iodinated
1 9 S • •
thymidine progesterone ( I PGT, Amersham, Bucks., England) which was stored in
ethanol at 4°C until required. An aliquot of tracer was diluted in 1:5000 in tracer
buffer (1M phosphate citrate pH6) and the number of radioactive counts per minute
(cpm) in an aliquot of 1 OOpl was determined. The tracer concentration was adjusted
to generate 15000cpm/100pl. ANSA (8-anilino-l-naptha-lenesulfonic-acid) was then
added at 0.1% w/v., and lOOpl of tracer added to each tube in the assay. In addition
two tubes containing only lOOpl of tracer each were added to the assay, in order to
determine the total number of counts possible. Assay tubes were vortexed briefly
then incubated at room temperature for 3 hours.
The secondary antibody was donkey anti goat serum diluted 1:64 in assay buffer, and
lOOpl was added to each tube except those measuring total radioactive counts.
Normal sheep serum was diluted 1:32000 in assay buffer and 100 pl/tube added.
Assay tubes were vortexed then incubated at 4°C overnight. 1 ml of 0.9%
saline/tritonX/polyethylene glycol was added to each tube, they were centrifuged at
3000rpm at 4°C for 30 minutes and the supernatant removed from the resulting
pellet. Pellets were left to dry before counting the amount of radioactivity
incorporated into each pellet on a gamma counter.
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The sensitivity of the assay was 0.07 pmol per tube (0.022 ng/ml) and the inter-
and intra-assay coefficients of variation were 15% and 4% respectively.
2.1.2 Analysis of Reproductive Cyclicity.
The following study was conducted in order to determine the length of the
reproductive cycle in the animals of the MRC Primate Centre.
Progesterone assay results for all animals sampled during the three years of these
studies, and for the two years prior to these studies, were collected and analysed. Mi-
Keith Morris and staff of the MRC primate colony collected blood samples, and Mrs
Gwen Cowen processed blood samples and performed the progesterone assays which
generated the data analysed here. Data were only included in the analysis if a
minimum of 2.5 consecutive reproductive cycles were available, and if sampling
frequency during those cycles were <4 days. Approximately one third of the animals
included in this study had blood samples taken every two days with three day
intervals occurring over weekends, whereas the remaining animals had progesterone
values every third or fourth day. The follicular phase was defined as that period
during which progesterone concentrations were 31.9 nmol/L or less, and animals
were assumed to have entered the luteal phase when progesterone concentrations
rose above 32 nmol/L and remained elevated.
Because there were up to three days between progesterone values, a further set of
criteria were used to determine which part of the cycle the animal was in. At the end
of the follicular phase, if progesterone was >16 nmol/L, the luteal phase was
assumed to begin the following day and progesterone values were assumed to be
higher than 32 nmol/L 24 hour later. If progesterone was <16 nmol/L, the luteal
phase was assumed to begin 48 hours later. At the end of the luteal phase, if
progesterone values were <200 nmol/L the follicular phase was assumed to begin 24
hours later, and if values were greater than 200nmol/L, it was assumed that the
follicular phase began 48 hours later. In total, 87 complete cycles were studied in 24
different animals. Many animals were not included in this analysis because one or
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two samples were taken less frequently than 4 days, which excluded that cycle from
the analysis, and therefore reduced the number of consecutive cycles available.
Since the estimated lengths of cycles and estimated lengths of luteal phases were ±
one day, analysis was conducted on range intervals, and each cycle or luteal phase
was put in its appropriate range. Hence the frequency with which a particular length
of cycle or luteal phase occurred could be calculated. Data was then pooled by
redistributing the animals in every second range interval evenly to the group either
side, so halving the total number of range groups, but maintaining the frequency
distribution of luteal phase lengths. This was expressed as the total number of
animals per frequency interval, and is presented as a histogram with no standard
error bars.
Marmosets in the MRC Primate Centre had a reproductive cycle of 30.17 ± 11.30
days (mean ± S.D., n=87, range 13-70 days, median 27 days, Figure 2.1) and a
luteal phase of 20.26 ± 10.34 days (mean ± S.D, n=87, range 6 - 63 days). Median
length of luteal phase, however, was 18 days (Figure 2.1). No animal had a luteal
phase which was shorter than 5 days, but 31 % of the cycles had extended luteal
phases of 23 to 60 days. Extended luteal phases often included periods of time in
which progesterone levels were decreased to approximately 60nmol/L but failed to
fall below the 32nmol/L threshold which defined a follicular phase.
Others have found captive marmosets to have a 28-30 day long reproductive cycle
with an 8 - 9 day follicular phase and a 16 - 22 day luteal phase (Harding et al., 1982;
Harlow et al., 1984; Summers et al., 1985). The mean length of 87 complete cycles
in 24 different animals was 30.17 ± 11.3 days, which is in remarkably good
agreement with Harding et al (1982) who found that the total cycle length in female
marmosets was 30.1 ±3.8 days over a decade earlier in the same colony of animals.
Reports of shorter cycle lengths were from a different colony (Harlow et al., 1984;
Summers et al., 1985) and may reflect the influence that a limited number of animals
has on establishing a colony; natural variation in cycle length in a wild population
may not be represented by founding members of a colony and lead to the formation
of'clines' in isolated populations such as those seen in closed captive colonies.
Alternatively the method of analysis may lead to discrepancies in estimated cycle
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length. In this study one criteria for inclusion was that data for at least 2.5
consecutive cycles be available, however, progesterone values >32nmol/L for >40
days may have been excluded from other studies on the grounds that they were
indicative of abnormal cycling. Excluding cycles with extended luteal phases would
result in lower estimates of mean cycle length. In this study it is possible that luteal
phases which appeared to last 50-60 days may have actually been two separate cycles
in which progesterone concentrations did not decrease beneath the defined threshold
during the follicular phase.
Mean luteal phase lengths were 20.26 ± 10.34 with a median of 18 days, and this
shows good agreement with the 19.2 ± 0.6 day luteal phase reported by Harlow et al
(1984) and is slightly shorter than the 21.5 ± 2.2 days (mean ± SD, median 21.5)
reported by Harding et al (1982).
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Figure 2.1: Frequency of Different Luteal Phase
Lengths in Marmosets.
The lengths of 87 different luteal phases in 24 different
animals in the MRC Reproductive Biology Unit Primate
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Figure 2.1: Frequency of Different Luteal Phase Lengths in Marmosets.
2.1.3 Progesterone Values at Time of Ovary Collection
In the cycle preceding luteolytic treatment and ovarian collection animals used in the
in situ 3' end labelling study had progesterone concentrations in the follicular phase
of 16±4 nmol/1 (mean ± SD. n=18). Progesterone levels increased to 172±50 nmol/1
by day 2 of the luteal phase, were 206±64 nmol/1 from luteal days 3 to 12, and were
decreased to 39±9 nmol/1 by day 18 (Figures 2.2 and 2.3).
Progesterone concentrations for animals whose ovaries were collected on days 10
and 18 of the luteal phase were 206±104 nmol/1 (n=4) and 226±51 nmol/1 (n=3)
respectively at time of collection (Figure 2.2). Animals whose ovaries were collected
on day 22 of the luteal phase had progesterone concentrations of 12.7±0 6nmol/l
(n=3) at time of collection (Figure 2.2). Animals treated with GnRH antagonist or
PGF2a had plasma progesterone concentrations of 372±284 (n=4) and 289±213
(n=4) nmol/1 respectively on luteal day 9. Luteolytic treatment resulted in a marked
decrease to 32±23 nmol/1 and 23±10 nmol/1 for GnRH ant. and PGF2a treated
animals respectively (Figure 2.3).
Different animals were used in the study examining ubiquitin expression after
induced luteal regression. Follicular phase values were 16±2.6 nmol/1 (mean±s.e.m.
n=9),.85±27 nmol/1 (mean±s.e.m. n=9), by day 2 of the luteal phase, and were
292±66 nmol/1 (mean±s.e.m. n=9) from days 3 - 9 of the luteal phase. Mid luteal
phase day 10 values were 311±48 nmol/1 (mean±s.e.m. n=3), and this was
significantly decreased 24 hours after administration of a luteolytic dose of GnRH
antagonist (36.35±16, mean±sem, p<0.01) or PGF2a (18.33±3.7, mean±sem,
p<0.01).
Ovaries were collected 12 hours after administration of luteolytic agents. Animals
had progesterone concentrations of 513±153 nmol/1 (mean±s.e.m, n=3) on luteal day
10 at time of administration of PGF2a, and had progesterone concentrations of
364+60 nmol/1 (mean+s.e.m, n=3) at time of GnRH antagonist administration.
Progesterone concentrations 12 hours later when ovaries were collected were 19±6
nmol/1 (mean+s.e.m) and 13±0 nmol/1 (mean+s.e.m) for PGF2a and GnRH
antagonist treated animals respectively. These six animals were used in all studies
with a 12 hour post-induced regression time-point.
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Progesterone concentrations reported here are for a total of 33 animals from three
separate studies, but are representative of values obtained from all the animals
described in this thesis, and amply illustrate the wide variation in both cycle length
and progesterone concentrations found in these animals. However, progesterone
values for corresponding stages of the cycle were essentially similar in all studies.
Previously reported progesterone concentrations for marmoset monkeys in the luteal
phase were 30 - 250nmol/L (Abbott et al., 1988), 20-140ng/ml (Abbott and Hearn,
1978) and 87.4 ± 3.7ng/ml (mean maximum ± SD, n=30) on day 10 of the luteal
phase (Harding et al., 1982) and these are simular to levels reported here; 206±64
nmol/1 from luteal days 3 to 12 (mean ± SD., n=18).
Harding et al (1982) noted that intra-animal cycle variance was due to changes in
both follicular and luteal phase length, and that it was difficult to predict phase length
using data obtained from a previous cycle. This is illustrated in our studies which
used naturally regressing corpora lutea. In one example progesterone concentrations
were 226±51 nmol/1 (mean±s.e.m, n=3) on luteal day 18 when the corpora lutea were
collected, whereas the same animals had progesterone values of 39±9 nmol/1 on
luteal day 18 of the previous cycle. Although 226±51 nmol/1 is still within the mid
luteal range of progesterone concentration, it was assumed that in this instance the
corpora lutea were regressing because progesterone levels had been decreasing for
the previous 5 days in these particular animals.
Treatment with either the PGF2a analogue, cloprostenol, or the GnRH antagonist,
antarelix, caused a decrease in circulating progesterone indicative of functional
luteolysis as shown previously (Summers et al., 1985; Michael and Webley, 1993;
Hodges et al., 1987). Progesterone values bothl2 hours and 24 hours after
administration of luteolytic agents were less than 32nmol/L, suggesting collection at
an earlier time point would be necessary in order to observe changes associated with
functional luteal regression. Since these two methods for inducing luteal regression
gave results in our hands similar to those described by other workers, we judged
them suitable techniques to use in studies investigating the instigation and regulation
of luteal regression.
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Figure 2.2: Serum Progesterone Concentrations in the
Marmoset.
Mean (± SEM) concentrations of plasma progesterone
(nmol L"l) in marmoset ovulatory cycles and in the
subsequent cycle of ovarian collection. Ovaries were
collected on luteal day 10 (n=4,—□—-), luteal day 18
(n=3, —O—) and luteal day 22 (n=3, —▲ —). Arrows





Figure 2.3: Progesterone Concentrations in the
Marmoset after Induced Luteal Regression.
Mean (±SEM) concentrations of serum progesterone
(nmol L~l) in marmoset ovulatory cycles and before and
safter administration of a prostaglandin 2a analogue (n=4,
cloprostenol lpg i.m., A-) or a GnRH antagonist (n=4,
antarelix lmgKg-1 s.c., —on day 9 of the luteal
phase. Ovaries were collected 24 hours later on day 10 of
the luteal phase. Control marmosets (n=4,—□—) were
given no treatment and ovaries were collected on day 10
of the luteal phase. Arrows indicate progesterone
concentration at time of ovarian collection.
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2.2 Collection ofMarmoset Ovaries.
The follicular phase was defined as that period during which progesterone
concentrations were 31.9 nmol/L or less. Day 1 of the luteal phase was defined as the
day when progesterone concentrations rose above 32 nmol/L.
2.2.1 Spontaneous Luteal Regression
Control ovaries were obtained during the mid luteal phase on day 10, ovaries
containing functionally regressing corpora lutea were collected from animals in the
late luteal phase on day 18, and ovaries containing structurally regressing corpora
lutea were collected from animals in the early follicular phase (days 20 - 24 of the
preceding luteal phase) and the late follicular phase (days 25 - 28 of the preceding
luteal phase).
2.2.2 Induced Luteal Regression
GnRH antagonist, antarelix (Deghenghi et al., 1993; Hodges et al., 1988; Fraser et
al., 1995a; Fraser et al., 1995b) lmg/kg s.c., or a PGF2a analogue (Summers et al,
1985; Michael and Webley, 1993; Hodges et al., 1987) lpg cloprostenol (Planate,
Coopers Animal Health Ltd., Crewe, Cheshire, UK) i.m., were administered on day 9
of the luteal phase. Ovaries were collected 12 hours, or 24 hours later on day 10 of
the luteal phase. In addition, some animals had either GnRH antagonist or PGF 2a
administered for 48 hours on luteal days 8 and 9 prior to ovarian collection on luteal
day 10. Corpora lutea induced to undergo luteal regression were compared with
ovaries collected from untreated animals on day 10 of the luteal phase.
LH pulsitility decreases (Zeleznik, 1991) but serum LH concentrations are
maintained during the luteal phase in macaques and humans (Salamonsen et al 1973;
Hutchison et al., 1986; Sotrel et al., 1981) and this suggests that GnRH levels are
also maintained. Therefore the use of GnRH antagonist to deplete LH concentrations
during the mid luteal phase is a non-physiological induction of luteal regression.
PGF2a concentrations change during the luteal phase in humans (Challis et al.,
1976; Swanston et al., 1977; Valenzuela et al., 1983), and it is likely that intra-luteal
PGF2a concentrations change during regression in marmosets, although no data has
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been published in this regard. The endogenous production of PGF2a might
disconnect the LH receptor from its secondary messenger pathway (Michael and
Webley, 1993; Michael et al., 1994), so reducing the ability of luteal cells to respond
to LH. Administration of a PGF2a analogue may therefore mimic the natural,
physiological process of luteal regression.
One way to test the hypothesis that the main luteolytic action of PGF2a causes a
reduction in the ability of steroidogenic cells to respond to LH by inhibiting LH
receptor secondary messenger pathways, was to deplete serum LH by the
administration of a GnRH antagonist. If the hypothesis were correct, 'removal' of
LH by GnRH antagonist should give similar results to the effective, functional
'removal' of LH by administration of PGF2a. In order that LFI 'removal' should be
equivalent and comparable, the doses selected for these experiments were intended to
prevent LH-stimulated steroidogenesis in the case of PGF2a, and to remove
circulating LH in the case of GnRH antagonist.
2.2.3 Tissue Collection and Preparation
Ovaries were collected after animals were sedated with 100pi ketamine
hydrochloride (Parke-Davies Veterinary, Pontypool, Gwent, UK) i.m. and
euthanased with 400pl Euthetal i.v. (sodium pentobarbitone, Rhone Merieux, Essex,
UK). A terminal blood sample was taken before removing ovaries and organs used in
other studies. Animals and treatments are summarised in Appendix 1, and described
in further detail below.
2.2.3.1 Tissue Collected for Analysis of Oligonucleosome Formation
The ovary with the largest, most obvious corpus luteum was taken first, weighed, and
the largest corpus luteum was dissected out of the ovary. This was labeled as 'CL1
and snap frozen immediately in liquid nitrogen. Additional corpora lutea were
collected in the same way, and labeled according to the sequence in which they were
dissected out of the ovarian tissue. The time the animal died, and the times each CL
was snap frozen were noted. The last corpus luteum taken was frozen 12 minutes or
less after death of the animal. Samples of liver were dissected free and snap frozen
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after collection of corpora lutea was completed. It was thought that if death and
dissection were to cause DNA fragmentation, the liver samples would act as controls
for this. After transportation to the laboratory corpora lutea and liver samples were
stored at "80°C until required for DNA extraction.
In some cases (see Appendix 1) only one corpus luteum was dissected free and
frozen for analysis of oligonucleosome formation. The remaining ovary and corpora
lutea were then fixed in paraformaldehyde as described below.
2.2.3.2 Tissue Collected for Histology and Immunocytochemistry
Ovaries were dissected free, weighed, and fixed in 4% (w/v) buffered
paraformaldehyde for 24 hours before embedding in paraffin according to standard
procedures. Paraffin embedded sections (4pm) were mounted on poly-L-lysine
(50pg/L) coated slides. Only ovaries containing corpora lutea were used. One ovary
was taken as being representative of the animal. For example, marmoset number 1
had corpora lutea of the current cycle in both ovary A and ovary B. Sections from
ovary A may have been used in one study, and sections from ovary B used in another
study. In each case, they both fulfilled the purpose of being representative of one
animal.
It was assumed that corpora lutea in each ovary were functionally equivalent to each
other, in that they were produced in the same cycle. Possible differences in the time
of ovulation may have generated corpora lutea of different ages within the same
cycle. This possible source of intra-animal variation is discussed in a subsequent
section. Fixed ovaries were used for the following studies (see Appendix 1):
• Examination of morphology after haematoxylin and eosin (H&E) staining
• In situ 3' end labeling in the apoptosis study
• Immunocytochemistry to identify cells which were
• steroidogenic,
• endothelial
• vascular endothelial growth factor postitive
• proliferating
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In the course of the three years of these studies, the number of animals in each of the
nine experimental groups utilised for immunocytochemistry were as follows:
• Early luteal phase, days 2-5, n=7
• Mid luteal phase, day 10, n=8
• Late luteal phase, day 18, n=6
• Follicular phase, luteal day 22-25, n=6
• Late follicular phase, luteal day 25-28, n=4
• 12 hours after administration of PGF2a, n=3
• 24 hours after administration of PGF2a, n=6
• 12 hours after administration of GnRH antagonist, n=3
• 24 hours after administration of GnRH antagonist, n=6
The number of animals indicated in each group were those in which stage or
treatment was confirmed by the progesterone concentration of blood sample
collected at the time of death. More animals were originally allocated to each of the
luteal day 18 and follicular phase groups, but some had elevated progesterone levels
suggesting that they were not undergoing luteal regression, and were therefore
excluded from these groups. Animals were included in the luteal day 18 group when
three progesterone measurements (the third being the terminal bleed) were each
lower than the preceding measurement, ie. a consistent decrease in plasma
progesterone concentrations indicating functional luteal regression. Follicular phase
corpora lutea were included when terminal bleed progesterone levels were less than
31.8 nmol/L.
2.2.3.3 Tissue Collected for Assessment of Proliferation after In Vivo
Incorporation of Bromo-deoxyuridine
Animals were administered bromodeoxyuridine (BrdU, Boehringer Mannheim,
Essex, UK) intravenously by slow infusion at a dose of 20mg in 1ml saline and
ovaries were collected one hour later.
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Ovaries containing corpora lutea were collected from marmosets in the early luteal
phase on luteal days 2-4 (n=3 animals), in the late luteal phase during functional
luteal regression on luteal day 18 (n=3 animals) and during structural luteal
regression after progesterone levels had fallen to follicular phase values on luteal
days 22-25 (n=3). These are included in the numbers indicated above.
2.2.3.4 Tissue Collected for Lipid Study
Ovaries were embedded in OCT (Miles Laboratories, Berks, UK) and transported to
the laboratory in liquid nitrogen where 6pm sections were cut using a cryostat (2800
Frigocutt; Reichert-Jung, Cambridge Instruments, Cambs, U.K.) and thaw mounted
onto slides coated with poly-L-lysine (50ug/l). Slide-mounted sections were stored at
70°C.
Ovaries were collected on day 10 of the luteal phase (n=4 animals), 24 hours after
luteolytic treatment with GnRH antagonist (n=3 animals) and 24 hours after PGF2a
(n=3 animals).
2.2.4 Overview of Ovaries Used
The total number of animals used in the course of these studies is detailed in
Appendix 1. Collection of ovaries was an ongoing process throughout the three years
of these studies. As paraffin blocks were used up, new ovaries were collected to
replace them. To illustrate the process of ovary usage, immunocytochemistry with
the antibody against von Willebrand Factor VIII antigen (vW), an endothelial cell
marker, is described. Immunocytochemistry for vW was carried out on three separate
occasions on the following tissues:
mid luteal phase, n=3
PGF2a, 12 hr, n=3
PGF2a, 24 hr, n=4
GnRH antagonist 12 hr, n=3
GnRH antagonist 24 hr, n=4
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The first procedure examined PG24 treated ovaries 1-4, procedure 2 examined PG24
treated ovaries 2-5, and procedure 3 included ovaries 3-6. Ideally, all sections would
have been included in one assay procedure, however, there were two reasons why
this was not done. The first was because only four ovaries were available at the
commencement of study, additional immunocytochemistry procedures were
conducted as more ovaries became available. The oldest ovaries, however, had been
used up by the time the fifth and sixth ovaries were collected. The second reason was
one of technical limitations, intra- and inter-assay variation were decreased by
keeping the number of sections in each assay constant. The three
immunocytochemistry procedures could be compared with each other because at
least two sections in each experimental group were included in at least one other
procedure. Quantification of different procedures also indicated that there was no
significant difference between procedures carried out at different times with different
ovaries. This is illustrated by the area of vW positive staining in mid luteal phase
control ovaries in the induced regression experiment (4167±1130, n=3), and the mid
luteal phase day 10 ovaries in the spontaneous regression experiment (3517+491,
n=4). Two ovaries were used in both experiments, the remaining three ovaries were
different, but the area of vW-positive staining was not significantly different. Similar
results were obtained for all treatment groups and within all immunocytochemistry
procedures. In summary, ovaries used in the representative procedure for each study
are indicated in Appendix 3, but in the majority of cases, all the ovaries collected
during the three years of these studies were examined by each of the techniques
described.
2.3 Luteal Morphology
2.3.1 Morphometric Analysis of H&E Stained Sections
Sections were stained with H+E as described then subjected to morphometric
analysis using a Highly Optimised Microscope Environment (Brugal et al., 1992), a
microscope with an integrated mouse and computer. The orientation and size of the
microscope slide were recorded, thereby allowing the establishment of a coordinate
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grid system, in which the precise position of each cell in the tissue section was
recorded. A computer generated overlay was superimposed over the optical field
image. Electronic labels (symbols corresponding to steroidogenic, non-steroidogenic,
apoptotic etc.) were attached to cells in the assessed area of luteal tissue by using the
mouse to drag an icon from a menu to the identified cell. The location of each cell,
and identificatory labels, were saved by the computer. The slide could be replaced by
another section, and the procedure repeated. The first slide could be replaced on the
stage, its corresponding data file opened, and identification symbols reviewed.
Alternatively, the same area minus the identification symbols could be reviewed,
allowing two individuals to assess the same area and compare cell identification.
This system made it possible to count every cell in a unit area, by marking each
counted cell with an identificatory symbol. Cells were not counted twice, and no
cells were left uncounted. It also allowed more than one individual to review
precisely the same cells. This system was the equivalent of taking a microphotograph
of luteal tissue, and marking individual cells on the photograph with a pen.
For this study a 100pm grid was superimposed on the field of view of a x40
2
objective lens. Each square in the grid had an area of 10000pm . Six squares were
scored for each animal, these were taken semi-randomly from the luteal tissue visible
on the slide. Accessory corpora lutea, and areas of luteal tissue which were smaller
2
than 10000pm were excluded from analysis. At least one square was scored in each
of the remaining areas of luteal tissue, therefore all the corpora lutea in each ovary
examined were analysed. Selection of the square(s) scored within each corpus luteum
was random. In the majority of cases, individual corpora lutea were identifiable in
ovarian sections, however it could not be ruled out that a single corpus luteum might
be distorted during processing, and that adjacent areas of luteal tissue might therefore
originate from the same corpus luteum. Therefore, no attempt was made to count the
number of corpora lutea in each ovary.
2
Every individual cell in each 10000pm square was identified as being either
steroidogenic, vacuolated steroidogenic, non-steroidogenic or apoptotic as described
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below. In this way, the total number of cells in a 10000pm square area of luteal
tissue could be determined, as could the numbers of different cell types. Each cell in
2
the 10000pm square had an identificatory symbol drawn over it within the computer
generated overlay. The exact location of the cell and its symbol were stored on the
computer. This information was later retrieved and identification confirmed by a
pathologist (Dr. David Harrison), who is experienced in assessing apoptosis and
oncosis from morphological criteria (Clarke et al., 1993; Howie et al., 1994).
Agreement was >99%, disagreement was predominantly over the identification of
apoptosis, and in such instances apoptosis was underscored and that score was either
added to the non-steroidogenic cell or to the normal steroidogenic cell class.
Cell types for each section were summed and expressed as means±SEM per
2
60000pm for each experimental group.
2.3.1.1 Identification of Cell Types.
Immunocytochemistry for the steroidogenic enzyme 313 HSD in these studies
(Duncan et al., 1997) and in other studies (Webley et al., 1990; Fehrenbach et al.,
1995) identified steroidogenic cells as being >12pm in diameter with regular circular
outlines in section, abundant cytoplasm and circular nuclei. Cells with these
dimensions in H&E stained serial sections were therefore labelled as 'steroidogenic
cells'. It was not possible to identify individual cells in serial sections with accuracy,
therefore some cells may not have contained the steroidogenic enzyme 313 HSD, and
may therefore have been functionally inactive. The 'steroidogenic cell' label in this
instance meant that the identified cell had the same gross physical and morphological
dimensions as cells which were found to be 313 HSD immunopositive in serial
sections.
Some cells had the same dimensions as steroidogenic cells, but contained
cytoplasmic vacuoles. Many were 313 HSD immunopositive in serial sections. These
were therefore labeled as 'vacuolated' or 'morphologically abnormal steroidogenic
cells'. These varied from essentially intact cells containing small vacuoles (2- 4pm in
diameter) to extreme disruption of the cytoplasm leaving a remnant around the
nucleus combined with the presence of three to five large vacuoles (6 - 10pm
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diameter). It is possible that vacuolation observed in mid luteal day 10
paraformaldehyde fixed corpora lutea was artifactual, since mid luteal phase
vacuolated steroidogenic cells were qualitatively different from those observed after
both spontaneous and induced luteal regression. Additionally, vacuolation was not
observed in cryostat sections of mid luteal phase corpora lutea, whereas the same
vacuolated architecture appeared in cryostat sections of regressing corpora lutea. Mid
luteal phase vacuolated data was included in the analyses to maintain a consistent
definition. Their inclusion also decreased differences between experimental groups,
so that errors in identification detracted from, rather than added to, the strength of
statistical analyses of data.
Cell types that were not >12pm in diameter with regular circular outlines, abundant
cytoplasm and circular nuclei, and were not 36 HSD immunopositive in serial
sections, were labeled 'non-steroidogenic cells'. These were generally elongated with
the long axis of 4 - 8 pm, and had large nuclei and little cytoplasm. Since they
frequently enclosed lumina containing red blood cells the majority of these cell types
were assumed to be endothelial cells. Cells with this morphology were also
immunopositive for the endothelial cell marker, von Willebrand Factor VIII related
antigen. However, fibroblasts and leukocytes would have also been included in this
category.
Apoptosis was characterised both by individual clusters of apoptotic bodies, where
each cluster was assumed to have originated from the fragmentation of one cell, and
by condensed cells with clearly fragmented nuclei. Apoptotic bodies with the
morphological appearance seen in our sections have previously been shown to
contain the condensed chromatin and intact organelles characteristic of apoptosis
when examined by electron microscopy (Howie et ai, 1994).
2.3.1.2 Identification of Corpora Lutea Accessoria
Corpora lutea accessoria are formed when non-ovulated follicles become luteinised
(Behrman et al., 1993). In marmosets, large antral follicles undergoing atresia have
wide spaces between granulosa cells and disrupted granulosa cell layer architecture.
Apoptotic cell death is often observed around the periphery of the antrum. Accessory
corpora lutea are formed when the outer theca cell layer and the granulosa cell layer
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closest to the basement membrane luteinise (Wehrenberg et al., 1997). Resultant
corpora lutea accessoria therefore have a central cavity, and steroidogenic cells
which appear to be arranged in layers, reminiscent of the layers of a follicle. They
also stain more intensely for lipid (see chapter 3), and are smaller than true corpora
lutea of the cycle. Areas of luteal tissue with an obvious central cavity and a
arrangement of steroidogenic cells reminiscent of the layers seen in follicles were not
included in any analyses of luteal tissue in these studies.
2.3.1.3 Statistical Analysis of Morphological Data
Data were subjected to one-way analysis of variance taking the stage of the cycle as a
between-subject variable. Differences between the mean values obtained from the
morphological analysis of corpora lutea induced to undergo regression with
cloporstenol or antarelix were compared among experimental groups and with
untreated corpora lutea from day 10 of the luteal phase in a separate one-way
analysis of variance taking the nature of treatment as a between-subject variable.
When a significant F value was obtained the data were further analysed by Scheffe's
test and significance was assigned at P<0.05.
2.3.1.4 Optimisation of Area for Quantification
2
The number of 10000pm areas that needed to be assessed was counted by scoring a
number of squares from different areas of the luteal tissue for four different animals,
mid luteal (day 10, n=l), GnRH antagonist (n=l), PGF2a (n=l) and early follicular
2
(day 20-25, n=T). The numbers of each cell type found in successive 10000pm
squares were added to the numbers from the previous fields and a series of
cumulative mean values was generated. Accumulative means are shown for a GnRH
antagonist treated and an untreated animal from day 10 of the luteal phase (Figure
2.4). Mean numbers of each cell type present stabilized after examining four
2
10000pm fields and scoring further squares did not significantly change the values
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observed. Therefore quantification of cell types were based on counts of six
10000pm fields.
Numbers of non-steroidogenic cells in untreated mid-luteal phase and GnRH
antagonist treated animals were similar, whereas numbers of vacuolated
steroidogenic cells in GnRH antagonist treated corpora lutea were less than the
numbers of morphologically normal steroidogenic cells in untreated mid-luteal phase
corpora lutea. The difference in accumulative means of morphologically normal and
vacuolated steroidogenic cells was two, which corresponded to the accumulated
mean of apoptotic cells, which implied that out of every 14 steroidogenic cells, two
became apoptotic and 12 became vacuolated.
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Figure 2.4: Accumulative Means of Luteal Cell Types.
2
Twelve randomly selected 10000pm areas of luteal tissue
were analysed. Every cell in each unit area was identified,
and the numbers of each cell type were determined for
each unit area. The mean number of cells for two unit
areas was calculated and shown, and the mean was
recalculated as successive unit areas were analysed.
Untreated mid luteal phase day 10 corpora lutea were
comprised of steroidogenic (-*-)and nonsteroidogenic
cells (-•-). Corpora lutea collected 24 hours after in vivo
administration of GnRH antagonist were comprised of
vacuolated steroidogenic cells (-A-), apoptotic cells or
apoptotic bodies (-□-) and nonsteroidogenic cells (-♦-).
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Field of View
2.3.2 The Effect of Location on Morphology Within Corpora Lutea.
Different immunocytochemistry procedures necessarily examined different sectional
planes of the corpora lutea. Studies were therefore conducted to determine whether
there were differences in morphology according to location in one plane, ie.
comparing the centre to the periphery of the corpus luteum. H&E stained sections of
one corpus luteum from each of the following experimental groups were examined:
mid luteal phase day 10
PG 24
Gn 24.
Sections were chosen in which one, discrete rounded area of luteal tissue comprised
40 - 70% of the total ovarian area. Smaller corpora lutea were found after the
administration of luteolytic agents. Areas of luteal tissue which were less than 40%
of the ovarian section after induced regression, or less than 70% during the mid luteal
phase, or which were an irregular shape, were assumed to be non-equatorial sections,
or parts of corpora lutea which had been distorted during collection and fixation. The
numbers of steroidogenic cells were counted in six randomly selected areas from the
middle of the area of luteal tissue, and six from the periphery of the tissue as defined
by the close juxtaposition of stroma or capsule connective tissue. The mean of each
group of six areas was determined, and compared with the mean of the group
obtained from the other location within the same corpus luteum. There was no
significant difference in the number of steroidogenic cells according to location
within the corpus luteum.
2.3.3 Comparison of Morphology between Corpora Lutea from the
Same Animal.
Marmosets in these studies had one to four corpora lutea distributed between both
ovaries. Ovulations can occur up to 24 hours apart (Tardiff et al., 1993), therefore it
was possible that three corpora lutea collected from the same cycle may be of
varying ages, and therefore display different characteristics. Four corpora lutea from
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one mid luteal phase day 10 animal were dissected free of the ovary and fixed in 4%
(w/v) buffered paraformaldehyde as described. Sections were taken from 3 planes of
each of the corpora lutea, roughly corresponding to the top, middle and bottom of the
luteal sphere. These were stained with H&E and subjected to morphological analysis.
These data confirmed that the number of steroidogenic cells per unit area did not
vary according to location within each corpus luteum. Data collected from the
equatorial plane of each of the four corpora lutea are presented below.








Six unit areas were scored in each corpus luteum and two one-way analyses of
variance were conducted on the steroidogenic and non-steroidogenic cell data
respectively, and significance was assigned at p<0.05. There was no significant
difference between the number of steroidogenic cells in four different corpora lutea.
There was also no significant difference between the number of non-steroidogenic
cells in three corpora lutea, although the fourth had a significantly higher (p<0.01)
number of non-steroidogenic cells than the other three. It was concluded that the
majority of corpora lutea of the cycle within each animal were morphologically
similar to each other.
2.4 Immunocytochemistry and Histology
All fixed sections of ovaries containing corpora lutea were rehydrated by transferring
the slides through xylene, 100% ethanol, 95% industrial methylated spirits (IMS),
70% IMS and water. Some procedures then required antigen retrieval by one of the
following methods.
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• exposure to four 5 minute cycles of microwave irradiation at 700w in 0.01M
Na citrate buffer pH 6.0 (Shi et al., 1993). Citrate buffer was replenished to
the original volume after each 5 minute cycle of microwaving. Sections were
then cooled at room temperature for 20 minutes before washing with TBS.
• a 30 minute incubation at 37°C in 0.1% trypsin (Sigma, Poole, UK), 0.1%
CaCl2, pH 7.4, followed by washing in Tris buffered saline (TBS, 0.05M Tris,
NaCl 9g/L).
Procedures utilising diaminobenzidine tetrahydrochloride (DAB) as a visualisation
substrate required endogenous peroxidase activity to be blocked by incubating in 3%
hydrogen peroxide in methanol for 20 minutes at room temperature.
Sections were then washed three times with Tris buffered saline (TBS, 0.05M Tris,
NaCl 9g/L) before application of primary antibody, diluted in TBS. A serial section
of each section was included as a negative control. If the primary antibody was a
polyclonal, the negative control was treated with pre-immune serum of the same
species the primary antibody was raised in. If a monoclonal antibody was used, the
negative control sections were treated with the appropriate immunoglobulin (IgG).
Negative control serum or IgG's were diluted to the same concentration as the
primary antibody. Sections were incubated with antibodies and the appropriate
negative controls under various conditions as described in Appendix 2.
After washing with TBS, biotinylated secondary antibodies (anti primary antibody
species) in a block (20% serum of the species the secondary antibody was raised in
and 5% BSA (w/v) in TBS) were applied to all positive and negative control sections
and incubated for 1 hour at room temperature. Visualisation was with avidin biotin
complex conjugated to one of:
• alkaline phosphatase (AP, Vector, Peterborough,UK) made up according to
manufacturers instructions and applied for 45 minutes at room temperature
followed by application of Vector Red (Vector, Peterborough, UK) until pink
colouration appeared approximately 2 minutes later.
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• horseradish peroxidase (HRP, Vector, Peterborough, UK) made up according
to manufacturers instructions and applied for 45 minutes at room temperature
followed by application of diaminobenzidine tetrahydrochloride (DAB, 0.04%
3,3'-diaminobenzidine (w/v, Sigma, Dorset, U.K.) in 0.05M TrisCl (Sigma,
Dorset, U.K.) pH 8 and 3% H202 (BDH Laboratory Supplies, Dorset, U.K.)
until brown colouration appeared approximately 1 minute later.
Sections exposed to primary antibody were always removed from DAB or Vector
Red solution before their corresponding negative controls.
The use of alkaline phosphatase was unaffected by endogenous peroxidase activity,
and so allowed omission of the hydrogen peroxide incubation, which shortened the
protocol. Since DAB is carcinogenic, the use of Vector Red was considered to be
safer, and Vector Red is also fluorescent, which allowed it to be used in studies
utilising double labelling.
Comparison of the two visualisation systems: HRP and DAB, or AP and Vector Red,
indicated no difference in the amount of immunopositive staining. This was
confirmed on three separate occasions when used with von Willebrand Factor VIII
related Antigen (vW), Ki67 and Vascular Endothelial Growth Factor (VEGF)
antibodies and quantified as described.
Immunocytochemistry procedures were optimised until results were consistent and
repeatable, then the procedure was repeated 3 times. Each procedure was assessed
semi-quantitatively, and the average procedure quantified rigorously, and presented
as the results of that experiment. Specific animals used in the presented,
representative procedure are described in Appendix 1. All immunocytochemistry
data presented in this thesis were therefore obtained at least three times. All the
ovaries available were assessed within the three procedures.
For details of antibodies used, their source, method of antigen retrieval, and the
number of animals used in each immunocytochemistry study, please see Appendix 2.
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2.4.1 Bromoxydeuridine (BrdU) Protocol I
Ovarian sections were rehydrated as described. BrdU antigen retrieval was by
exposure to microwave irradiation as described above. Sections were then cooled at
room temperature for 20 minutes and washed with TBS. Detection of BrdU was by
using a kit (5-bromo-2'-deoxyuridine Labelling and Detection Kit II, Boehringer
Mannheim) according to the manufacturers instructions. Sections were incubated for
10 minutes with Washing Buffer from the kit. Primary antibody (mouse monoclonal
antibody to 5-bromo-2'-deoxyuridine-5'-monophosphate containing nucleases in
PBS/glycerine) was diluted 1:10 in Incubation Buffer (Tris 66 mmol, MgCL
0.66mmol, 2-mercaptoethanol 1 mmol) and negative control sections were treated
with mouse immunoglobulin G (Vector Laboratories, California, USA) and this was
also diluted 1:10 in incubation buffer before being incubated for 2 hours at 37°C.
After washing with TBS, kit secondary antibodies (antimouse immunoglobulin
conjugated to alkalline phosphatase in triethanolamine buffer) were diluted 1:10 in
TBS and sections incubated for 1 hour at room temperature. Sections were then
washed twice with Substrate Buffer (Tris 1M, NaCl 1M pH 9.7, MgCL 0.5M).
Visualisation was with 300|igmlnitro blue tetrazolium in buffer (lOOmmol Tris
pH 9.5, lOOmmol NaCL and 50mmol MgCL) with 175pgml5-bromo-4-chloro-3-
indolyphosphate and 240pgmllevamisole. After washing with water sections were
counterstained with haematoxylin and Light Green, rinsed in water then quickly
rinsed in absolute ethanol, fixed in xylene and mounted in pertex. Sections from each
of the nine ovaries (ie. both ovaries from each animal were examined) were
subjected to BrdU ICC on at least two separate occasions. This procedure was
carried out on four different occasions and gave consistent results.
2.4.2 BrdU Protocol II
The kits used in protocol I were expensive, therefore a cheaper, alternative
methodology was developed. Ovarian sections were brought to water and
endogenous peroxidase activity blocked as described previously. Sections were
washed three times in TBS. BrdU antigen retrieval was by exposure to two 5 minute
cycles of microwave irradiation at 700W in glycine-HCl buffer pH 7.4 (0.2M
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glycine, 0.2M HC1). Buffer was replenished to the original volume after each 5
minute cycle of microwaving. Sections were then washed three times with TBS
before application of primary antibody (mouse monoclonal antibody clone BMC
9318 to 5-bromo-2'-deoxyuridine-5'-monophosphate, Boehringer Mannheim) which
was diluted 1:30 in TBS. Negative control sections were treated with mouse
immunoglobulin G (Vector Laboratories, California, USA) which was also diluted
1:30 in TBS before all sections were incubated for 18 hours at 4°C. After washing
with TBS, rabbit anti mouse IgG (DAKO) was applied at a dilution of 1:60 in block
(20% normal rabbit serum, 5% BSA (w/v) in TBS) for 30 minutes at room
temperature. This was followed by 3 washes with TBS and incubation with mouse
peroxidase anti peroxidase (mouse PAP, DAKO) diluted 1:100 in TBS for 30
minutes at room temperature. Visualisation was by application of DAB as described.
Sections from each ovary were subjected to BrdU Protocol II on at least two separate
occasions and gave results consistent with Protocol 1.
2.4.2.1 3(3 Hydroxysteroid Dehydrogenase (3(3 HSD) colocalised with BrdU
Detection of BrdU was by Protocol 1, but instead of counterstaining and mounting,
sections were washed with water. 3pHSD immunocytochemistry proceeded as
described above. Sections were counterstained with haematoxylin and Light green
before fast dehydration in absolute ETOH, fixation in xylene and mounting in Pertex.
2.4.2.2 Von Willebrand Factor VIII (vW) colocalised with BrdU
VW immunocytochemistry was as described above, followed by application of BrdU
Protocol II.
2.4.3 Haematoxylin and Eosin (H&E) Staining
Fixed sections were rehydrated as described for immunocytochemistry, then stained
in haematoxylin dye for 5minutes. Sections were placed in running water until the
water ran clear, this was found to 'blue' the stain satisfactorily. Sections were
counterstained briefly (40 s) in eosin, washed well in running tap water, then
dehydrated through increasing concentrations of alcohol and xylene - the reverse
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procedure to that followed for rehydration. A drop of mounting medium (Depex) was
added to each section, and a coverslip applied. H&E stains nuclei blue and cytoplasm
pink.
2.4.4 Light Green Counterstaining
Sections were washed with water before being counterstained with haematoxylin as
described. Light Green (0.5% w/v aqueous) was sometimes used as a counterstain
instead of eosin, particularly when Vector Red was used.
2.4.5 Oil Red O Staining
Cryostat sections were stained with 0.5% Oil Red O in isopropanol (Sigma, Dorset,
U.K.) for 15 minutes at 37°C, differentiated in 60% isopropanol for 5 minutes,
washed in water and counterstained with haematoxylin. Unsaturated hydrophobic
simple lipids stain red with this system (Bayliss High, 1982).
In summary, each ovary was examined in at least two separate immunocytochemistry
procedures, and at least three ovaries (from three different animals) were included in
each treatment.
2.5 Quantification and StatisticalAnalysis of
Immunocytochemical Procedures
2.5.1 Quantification of von Willebrand Factor VIII and
Proliferating Cell Nuclear Antigen (PCNA)
Sections were examined through a lOx objective lens and a 3.3x phototube, and this
field of view measured 31400pm of luteal tissue in our system. These sections were
not counterstained, so any colouration was due to either vW or PCNA
immunoreactivity, and contrasted markedly with unstained areas of tissue. vW or
PCNA positive staining per 31400pm unit area was measured using NIH Image 1.57
software, and this converted the colour image to black and white so that unstained
areas were white and stained areas dark greys through to black. It was possible to
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determine the optical density which corresponded to the lightest immunoreactivity,
and to measure the total area of immunostaining, and also the total number of
discrete areas of immunostaining, which had optical densities higher than that
threshold. The area of immunostaining was proportional to the number of vW
positive endothelial cells, whereas each discrete area of PCNA positive staining
corresponded to one proliferating nucleus, so the number of discrete areas indicated
the number of proliferating cells in that section. Optical density levels were
standardised between slides by viewing a blank part of the slide which did not have
any tissue on it, and adjusting the light intensity of the microscope to a
predetermined number of optical density units.
Four 31 400pm unit areas of luteal tissue were randomly selected and measured for
each section. Accessory corpora lutea were excluded, but at least one area in each of
the distinct areas of luteal tissue visible in the ovarian section was included in the
analysis. This utilised the assumption that each distinct area of luteal tissue
corresponded to one corpus luteum, and therefore a measurement was made from
each corpus luteum in that ovary. The mean of all the 31 400pm unit areas of luteal
tissue measured was then taken as being representative for that animal. Measuring
more than four unit areas did not significantly alter the mean. Negative control
sections were measured in the same way, and if an area had an optical density equal
to or higher than the lowest threshold for vW or PCNA immunoreactivity, that area
was subtracted from the mean value for the corresponding experimental section, so
removing the influence of any non-specific staining.
2 2The area of vW immunoreactivity (pm ) per 31 400pm of luteal tissue was
calculated for each animal, and expressed as mean area±SEM for each experimental
group. The percentage of luteal area stained was also calculated for each animal, and
expressed as mean percentage±SEM for each experimental group.
The number of discrete areas of PCNA immunoreactivity per 31 400pm of luteal
tissue was calculated for each animal, and expressed as mean number±SEM for each
experimental group.
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2.5.2 Statistical Analysis of von Willebrand Factor VIII
Analysis of variance tests the hypothesis that means from two or more samples are
equal. If the means are equal, it indicates that the samples are drawn from the same
population. In this experiment, if the mean of the samples taken after administration
of luteolytic treatments were the same as the mean of the untreated luteal day 10
control, it would indicate that the treatment had had no effect upon the vasculature.
Similarly, if there was no difference in means between samples taken at different
time points during the luteal phase, it would indicate that the variable 'age of corpus
luteum' had no effect on the vasculature. However, when sample means differ, the
samples are probably from different populations, and an F-test tests this by analysing
the sample variances. A Fishers procedure ensures that the data are normally
distributed, and calculates the probability that a given confidence interval will not
contain the difference in group means. This procedure is exact when samples of
unequal sizes are used.
Corpora lutea from the mid luteal phase were compared with corpora lutea after
induction of luteolysis with either PGF2a or GnRH antagonist in a one way analysis
of variance which used treatment as a between subject variable. Differences in areas
of vW positive staining in early, mid, late and follicular phase corpora lutea were
also investigated by one-way analysis of variance using stage of the luteal phase as a
between subject variable. When the F-test was significant (p<0.05) differences
between groups were evaluated by using the Fishers PLSD test.
2.5.3 Identification of PCNA-Positive Cells.
PCNA-positive cell types were identified on the basis that endothelial cell nuclei are
elongated and asymmetrical, whereas steroidogenic cell nuclei are spherical and
regular. Initial identification of endothelial cells was based on the morphological
appearance of cells which were immunopositive for the endothelial cell marker, von
Willebrand Factor, and which frequently enclosed lumina containing red blood cells.
Initial identification of steroidogenic cells was based on the morphological
appearance of cells which were immunopositive for the steroidogenic enzyme, 3(3
FISD. A typical field of view of luteal tissue was frozen on the NIH 1.57 Image
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Analysis visual display unit, and a drawing tool used to delineate endothelial cell
nuclei, and steroidogenic cell nuclei. A number of parameters were recorded for each
nucleus: the ellipse long axis and the ellipse short axis, the length of the perimeter of
the nucleus, the area of the nucleus and the mean optical density of the nucleus.
Nuclei were measured in each of a representative corpus luteum collected on day 10
of the luteal phase, in a corpus luteum collected 24 hours after luteolytic treatment
with PGF2a, and in a corpus luteum collected 24 hours after treatment with GnRH
antagonist. The ellipse axes ratio of steroidogenic cells was consistently less than
1.69, and the ellipse axes ratio of endothelial cells was consistently higher than 1.7
(Figure 2.5). The area of nuclei in section, and the perimeter of PCNA
immunopositive areas, were not reliable indicators of different cell types. In addition,
the optical density of PCNA immunostaining was the same for both steroidogenic
and nonsteroidogenic cells (Figure 2.6); optical density of PCNA immunostaining
did not vary according to the size of the nucleus.
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Figure 2.5: Nuclear Morphometry of
Steroidogenic and Nonsteroidogenic Cells in
Marmoset Corpora Lutea.
Ovaries containing corpora lutea were collected on
luteal day 10, 24 hours after administration of A.
PGF2a analogue, B. GnRH antagonist and C. no
treatment. Luteal parenchymal steroidogenic cells
and nonsteroidogenic cells were identified using
morphological criteria and the length of the major
ellipse axis and the minor ellipse axis was
determined for each nucleus. The ratio of the
ellipse axes is shown plotted against the frequency
interval for each ratio. In addition, the cell type of
each nucleus measured is identified as being either
steroidogenic (black bars) or nonsteroidogenic
(white bars).
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Figure 2.6: The Relationship Between Optical Density
and Ratio of Elliptical Axes in PCNA Immunostained
Luteal Cell Nuclei.
Each data point represents one PCNA immunopositive
nucleus. The data set were obtained from one unit area of
luteal tissue from a corpus luteum collected on luteal day
10.
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The automatic cell identification method highlighted every area of PCNA
immunostaining, then measured the ellipse long and short axes, the optical density,
and the area. These data were transferred into Excel spreadsheets, and the ratio of the
ellipse long axis to the ellipse short axis determined. The number of areas with ratios
less than 1.69 were designated as steroidogenic cell nuclei, and the number of areas
with ratios higher than 1.7 were recorded as nonsteroidogenic cell nuclei.
In addition, a comparison was made between the automated method for scoring cells
and the standard method of counting and identifying cells by eye. Randomly selected
fields of view from representative corpora lutea collected on luteal day 10, 24 hours
after PGF2a, and 24 hours after GnRH antagonist were assessed in this comparative
study.
The same fields of view were scored using the automated system, and also laser
printed in black and white onto standard A4 paper. The number of steroidogenic and
nonsteroidogenic cells were assessed by simple observation and by marking cells
with a pen to prevent double-counting. The three fields of view were scored by three
different individuals, Dr. Hamish Fraser, Dr. Faye Roger and the author. The scorers
were unaware of the automatic cell counts until after their assessments were
completed.
The automated scoring system overestimated the number of steroidogenic cells and
underestimated the number of nonsteroidogenic cells, and these two effects
combined to give an overall value for automatic scoring which was 7.7±3.7%
(mean+SD, n=4, Figure 2.7) lower than manual scoring. The automatic scoring
system did not distinguish between overlapping nuclei, and as nonsteroidogenic cells
were usually in closer juxtaposition than steroidogenic cells, the automatic system
tended to score two or three overlapping nonsteroidogenic cell nuclei as one.
Flowever, the ellipse ratio of overlapping nonsteroidogenic cell nuclei still tended to
fall within the range designated as nonsteroidogenic. Automatic steroidogenic cell
scoring tended to be higher than manual counts because a subpopulation of
nonsteroidogenic cells had rounded nuclei which had a simular nuclear ellipse ratio
to steroidogenic cells. These nonsteroidogenic cells with rounded nuclei may have
been macrophages or other immune system cells.
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Figure 2.7: Comparison of Luteal Cell Nuclei
Identification by Manual and Automatic Scoring
Methods.
Ovaries containing corpora lutea were collected on luteal
day 10, or 24 hours after PGF2a analogue, or 24 hours
after GnRH antagonist. Luteal parenchymal steroidogenic
cells and nonsteroidogenic cells were either identified
using an automated system, or were identified by three
independent observers using morphological criteria.
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Manual Auto Manual Auto Manual Auto
Steroidogenic 18 20 17 17 12 15
Non-
Steroidogenic 33 29 27 22 26 20
Total No. Nuclei
Counted
51 49 44 39 38 35
2.5.4 Statistical Analysis of Proliferating Cell Nuclear Antigen
Rationale for using analysis of variance are given in section 2.5.2. Numbers of
PCNA immunopositive cells per unit area in mid luteal phase corpora lutea were
compared with corpora lutea after induced regression with either PGF2a or GnRH
antagonist in a one way analysis of variance using treatment as a between subject
variable. Differences in numbers of non-steroidogenic cells in early, mid, late and
follicular phase corpora lutea were also investigated by one-way analysis of variance
using stage of the luteal phase as a between subject variable. Confidence intervals for
the differences between means were evaluated by using Fisher's LSD procedure.
This calculates the probability that a given confidence interval will not contain the
true difference in group means and is exact when samples of unequal sizes are used.
2.5.5 Quantification and Statistical Analysis of Ubiquitin
Slide identification and treatment were obscured. Independent assessment by two
observers (FY and HF) agreed that there were qualitative differences between
treatments as described. Quantitative analysis was also conducted blind using a x40
objective lens. Six randomly selected fields of view of luteal tissue were scored for
each animal and the mean number of ubiquitin positive cells per x40 field of view
was calculated for each animal. Scoring more than five fields of view did not
significantly alter the accumulative mean. Localisation of ubiquitin to either nucleus
or cytoplasm was also recorded. Mean numbers were calculated for each
experimental group and expressed ± SEM. A 2-tailed paired Student's t-test was
applied to luteal day 10 controls and each of the two treatment groups. Significance
was assigned at p<0.05.
2.5.6 Quantification of Ki67
Ovaries collected after induced regression with either GnRH antagonist or
PGF2a, and the untreated luteal day 10 corpora lutea they were compared with
were quantifed in the same manner as described in the PCNA study above.
Briefly, four 31400pm areas of luteal tissue were analysed using NIH 1.57
Image Analysis softwear, and every discrete area of Ki67 immunopositivity was
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assumed to be one proliferating nucleus. The mean number of Ki67 positive cells
was calculated from the four areas measured, and this was taken as being
representative for that animal. Cells were also classified as being either
steroidogenic or nonsteroidogenic on the basis of the nuclear ellipse ratio as
described above.
Untreated corpora lutea collected through the luteal phase and during regression
were analysed using a Highly Optimised Microscope Environment as described
previously (Brugal et al., 1992). Six 10 700pm unit areas of luteal tissue per
section were randomly selected and the mean of the six unit areas was taken as
being representative for that animal. Measuring more than four unit areas did not
alter the calculated mean. Cells were scored according to their morphological
appearance and classified as being either steroidogenic or non-steroidogenic (see
Morphometric Analysis of H&E Stained Sections - Identification of Cell Types),
and also whether they were Ki67 positive or negative. The number of Ki67
positive steroidogenic and non-steroidogenic cells per 10 700pm unit area were
expressed as a meaniSEM for each experimental group. The number of Ki67
positive steroidogenic cells per 10 700pm unit area for each animal was also
expressed as a percentage of the total number of steroidogenic cells per unit area
for that animal, and the number of Ki67 positive nonsteroidogenic cells was
similarly expressed as a percentage of the total number of nonsteroidogenic cells
per 10700pm2 unit area. The mean percentage! SEM was calculated for each
experimental group.
2.5.7 Statistical Analysis of Ki67
Data from mid luteal phase corpora lutea were compared with corpora lutea after
induced regression with either PGF2a or GnRH antagonist in a one way analysis
of variance using treatment as a between subject variable. Differences in
numbers of Ki67 immunopositive cells in early, mid, late and follicular phase
corpora lutea were also investigated by one-way analysis of variance using stage
of the luteal phase as a between subject variable. Confidence intervals for the
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differences between means were evaluated by using the Fishers LSD procedure,
and significance was assigned at p<0.05.
Percentages and proportions are non-parametric because the distribution curve is
only from 0 - 1(00), and therefore does not have the 'tails' of a normal
distribution curve. It is possible to conduct a chi square test on percentage data,
but this is not rigourous, and it is preferable to transform data to give a normal
distribution, and then conduct a rigourous, parametric test upon that data.
Percentages of Ki67 positive cells in corpora lutea from the early, mid, late and
follicular phases were examined by one way analysis of variance using stage of
the luteal phase as a between subject variable. Percentage data were transformed
before conducting analysis of variance. Data transformation was by converting
the percentage to a ratio <1, then taking the square root and the arc sin of each
percentage. Radians were converted into degrees, and one way analysis of
variance were conducted on these data. Confidence intervals for the differences
between means were evaluated by using Fisher's LSD procedure, and
significance was assigned at p<0.05.
2.5.8 Quantification of Bromoxydeuridine
BrdU labelled ovarian sections were viewed with an Olympus BH-2 microscope and
a 40x objective lens. The field of view was adjusted to contain only luteal tissue.
Every BrdU immunopositive cell in that field of view was counted, and further
classified as being either steroidogenic or non-steroidogenic. BrdU immunonegative
cells were similarly counted and classified as being either steroidogenic or non-
steroidogenic. Three fields of view were scored for each ovarian section, and the
mean scores of the fields of view were taken as being representative for that animal.
Each ovary was examined in at least two separate BrdU runs, and results were
consistent between runs as shown in Figure 2.8. Data were expressed as mean±SEM
for each experimental group. The number of BrdU immunopositive steroidogenic
cells per 40x field of view for each animal was also expressed as a percentage
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of the total number of steroidogenic cells per 40x field of view for that animal,
and the number of BrdU positive nonsteroidogenic cells was similarly expressed
as a percentage of the total number of nonsteroidogenic cells per 40x field of
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Figure 2.8 : Range of Results in 3 Separate BrdU Procedures in
One Marmoset Corpus Luteum Collected During the Early Luteal
Phase.
Marmoset ovarian sections were viewed with a 40x objective lens and three
fields of view of luteal tissue were randomly selected. Data points represent the
total number of BrdU immunopositive cells in each field of view. Serial sections
of the same corpus luteum were subjected to BrdU immunocytochemistry on
three separate occasions. Fields of view were randomly selected, so the 9
points represented here were all of different areas of luteal tissue.
2.5.9 Statistical Analysis of Bromoxydeuridine
Differences in numbers of BrdU immunopositive cells in early, late and follicular
phase corpora lutea were investigated by one-way analysis of variance using stage of
the luteal phase as a between subject variable. Confidence intervals for the
differences between means were evaluated by using Fisher's LSD procedure, and
significance was assigned at p<0.05.
Percentages of BrdU positive cells in corpora lutea from the early, late and follicular
phases were also examined by one way analysis of variance using stage of the luteal
phase as a between subject variable. Percentage data were transformed before
conducting analysis of variance. Data transformation was by converting the
percentage to a ratio <1, then taking the square root and the arc sin of each
percentage. Radians were converted into degrees, and one way analysis of variance
were conducted on these data. Confidence intervals for the differences between
means were evaluated by using Fisher's LSD procedure, and significance was
assigned at p<0.05.
2.5.10 Quantification of von Willebrand Factor VIII and BrdU
Colocalisation
BrdU and vW colabelled ovarian sections were viewed with an Olympus BH-2
microscope and a 40x objective lens. The field of view was adjusted so that it
contained only luteal tissue. Every BrdU immunopositive cell in that field of view
was counted, and further classified as being either vW positive or negative. Three
fields of view were scored for each corpus luteum, and the mean scores of the fields
of view were taken as being representative for that animal.
2.5.11 Statistical Analysis of von Willebrand Factor VIII and
BrdU Colocalisation
Bessels Correction for small samples was applied to the data obtained from
quantification of von Willebrand Factor VIII and BrdU colocalisation luteal day 2-5
and luteal day 18 corpora lutea. The F-value was assumed to be significant at p>0.05.
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2.6 Oligonucleosome Formation in Corpora Lutea.
2.6.1 Positive Controls for Oligonucleosome Formation
2.6.1.1 Thymocytes.
Wyllie (1980) demonstrated that thymocytes exposed to glucocorticoid in vitro
underwent apoptotic cell death during which cell chromatin became cleaved into
fragments which were multiples of 185bp and which could be viewed on a 1.8%
agarose gel (Wyllie and Morris, 1982; Wyllie et al., 1984). This model served as a
positive control in our study of oligonucleosome formation in primate corpora lutea.
Three male BalbC mice were killed by cervical dislocation and their thymus glands
dissected free into hepes buffered Dulbeccos Modified Eagles Medium (hDMEM).
The thymus glands were minced in a petri-dish at room temperature in hDMEM,
then passed through a strainer into a centrifuge tube. The cells were washed by
adding 5ml of media and centrifuged for 5 minutes at 250G. The resulting
supernatant was disposed of and the cell pellet resuspended in media before counting
the cells on a haemocytometer. The cell suspension was centrifuged again and the
pellet resuspended in DMEM (hepes omitted) at a concentration of 12.5 x 106 cells
per ml. One ml of cell suspension was dispensed to each well of a 25 well tissue
culture plate. Dexamethasone (9a fluoro-16a-methylprednisolone, Sigma, Poole,
England) was dissolved in ethanol to give a 0.01 M solution. This was further diluted
in DMEM to a concentration of 10"4M. Aliquots (500|ul) of this stock solution were
stored at T8°C. lOpl of dexamethasone stock solution were added to each of 20
wells to give a final concentration of 10"6 M. Cells were incubated for 22 hours at
37°C in 5% CO2, then centrifuged at 150g for 10 minutes and the cell pellets stored
at "70°C until required for DNA extraction.
2.6.1.2 Bovine Corpora Lutea
Juengel et al. (1993) were the first to show that 185bp fragments of DNA were
formed 12 hours after PGF2a-induced luteolysis in the cow, and that the amount of
oligonucleosome formation increased 24 and 48 hours after luteolytic treatment.
Zheng et al. (1994) also showed oligonucleosome formation in naturally regressing
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bovine corpora lutea. We therefore used bovine corpora lutea which were collected
12 hours (n=2) and 24 hours (n=2) after administration of a luteolytic dose of PGF2a
(5mg/ml, 25mg/cow Dinaprost given on luteal day 10) as positive controls for
oligonucleosome formation. These corpora lutea were kindly donated by Denise
Lawler, Royal (Dick) Veterinary School, Edinburgh University.
2.6.2 Negative Controls for Oligonucleosome Formation
A sample of liver was also collected from each marmoset after corpora lutea had
been frozen to serve as a negative control tissue.
2.6.3 DNA Extraction and Oligonucleosome Detection
2.6.3.1 DNA Extraction
Cellular DNA was extracted and 3' end labelled by a method modified from Tilly
and Hsueh (1993). Ten to 30mg of frozen luteal tissue, or one pellet of cultured
thymocytes, were homogenized in 400pl buffer (0.1M NaCl, 0.3M Tris, 0.01M
EDTA and 0.2M sucrose, pH 8) with a handheld electric homogeniser (Polytron PT
1200B92, Phillip Elarris Co. Ltd, Glasgow). The homogenate was transferred to
1.5ml eppendorfs containing 25pl 10% sodium dodecyl sulphate (SDS), to which
was added 12pl 10 mg ml"1 proteinase-K (Sigma). Samples were incubated in a 65°C
water bath for 2-3 hours until the homogenated appeared to be digested. Samples
were examined briefly and shaken by hand at approximately 30 minute intervals
during this incubation. Samples were then centrifuged (5000G for 20 minutes at
4°C), the supernatant collected, and an equal volume (400pl) of
phenol:chloroform:isoamyl alcohol (25:24:1 v:v:v) added. After vortexing and
microcentrifugation (13 OOOrpm for 5 minutes at room temperature), the upper phase
was collected and an equal volume (400pl) of chloroform:isoamyl alcohol (24:1 v:v)
added. Vortexing and centrifugation were repeated, and the upper phase collected.
The supernatant volume was determined, and 5M NaCL was added to 10% of the
supernatant volume. Glycogen (20pg/p,l, Boehringer Mannheim, Lewes) was added
to 1% supernatant volume and 100% ethanol (2.5x supernatant volume) was also
added, and inversion mixed before incubation at "70°C for 12 hours. After
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centrifugation (13 OOOrpm for 30 minutes at 4°C) the supernatant was discarded and
the DNA pellet resuspended in 25pl sterile water, and stored at 4°C until used.
2.6.3.2 2% Agarose Gel Production
50x concentrated TAE buffer (40mM Tris acetate, ImM EDTA) stock was made by
adding 121 g Tris base to 28.55ml glacial acetic acid and 50ml 0.5 M EDTA (pE18),
then making up to 500ml with distilled water. To make a 2% agarose gel, 50ml
lxTAE buffer were added to lg agarose and microwaved until all agarose is
dissolved. 2 pi of ethidium bromide were added to the agarose before pouring into a
mold, inserting a comb and leaving to set at room temperature.
2.6.3.3 DNA Quantification
Lambda DNA (365pg/ml stock, Promega) was used as a DNA standard on a 2%
agarose gel. Adjacent lanes contained increasing concentrations of DNA (0.1, 0.2,
0.3, 0.4, 0.5, 1 pg DNA/lane). 2pl of each extracted sample were also examined on
the same gel, and the concentration of genomic DNA in each sample calculated from
the DNA standards. Extraction from 10-30mg of tissue yielded 0.1-0.5pg/pl DNA
per sample. Oligonucleosome 'laddering' was not apparent in these ethidium
bromide stained gels.
2.6.3.4 3' End Labeling
15pl of sample DNA and the following reagents: 15pl 5x reaction buffer (1M
potassium cacodylate, 0.125M Tris-Cl, 1.25 mg ml"1 BSA, pH 6.6), 5pl 25mM CoCl
and lpl of 25 U pT1 terminal transferase (Boehringer Mannheim, Lewes). 2pl
(20pCi) of radiolabeled dideoxynucleotide ([a-32P]-dd ATP (3000 Ci mmol"1,
Amersham) were incubated at 37°C for 60 minutes. The reaction was terminated by
the addition of 20pl 0.25M EDTA., Samples were loaded onto Sephadex G50 Nick
Spin Columns (Pharmacia, Uppsala, Sweden) and centrifuged at 500 G for 5 minutes
to separate DNA-bound from free radionucleide. 3' end labelled samples were
therefore recovered in 50-60pl volumes, lpg of labelled DNA per sample was
electrophoresed on a 2% agarose gel for 2.5 hours at 85V using a 1XTAE (40mM
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Tris-acetate, ImM EDTA) running buffer. Gels were dried and exposed to Kodak X-
Omat AR film for 2 hours at ~72°C initially, followed by a 12hour exposure of the
same gel in order to confirm that oligonuclosome formation was absent from
negative control samples. Two dried gels were also applied to a Phosphorlmager for
5 hours for quantification of oligonucleosomes.
DNA extraction and labeling were conducted at least twice on each sample, and
representative gels are shown.
2.6.3.5 Quantification of Oligonucleosomes.
All samples were run on the same gel. The optical density of the lowest three
fragments in each sample was determined and their mean calculated. Unequal lane
loading was compensated for by adjusting the optical density of the genomic DNA
band in each lane to 100%, and then multiplying the mean optical density of
oligonucleosome bands by the same correction factor. The mean and SEM of each
experimental group was then determined.
2.6.4 In situ 3' End Labelling of Marmoset Corpora Lutea.
Paraformaldehyde fixed sections were hydrated by transferring the slides through
two troughs of xylene (5 min in each) and 1 minute in each of 100%, 95% and 70%
ETOH. Endogenous peroxidase was blocked with a 30 minute incubation in 3%
H702 (BDH Laboratory Supplies, Dorset, U.K.) in methanol. Washing with PBS was
followed by a 45 minute incubation in 5ug/ml proteinase K (Sigma, Dorset, U.K.) in
PBS at 37°C. Slides were transferred to Sequenza racks (Life Sciences International,
Hampshire, U.K.) and rinsed 3 times in PBS. Positive control sections were
incubated for 10 minutes at 37°C in 5ug/ml DNase (Bohringer Mannheim, Essex,
U.K.) in buffer (30mM TrisCl (Sigma) pH 7.2, 140 mM Na-cacodylate (Agar
Scientific Ltd., Essex, England), 4mM MgCl2 (Analar, Poole, England) O.lmM DTT
(Promega, Hampshire, U.K.) then rinsed once in TE buffer (TrisCl 0.1M, EDTA
0.05M) and 3 times in PBS. 3'-OH ends of DNA fragments were labelled with 0.5nM
digoxigenin-11-UTP (Bohringer Mannheim, Essex, U.K.) by 50U/ml terminal
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deoxynucleotidyl transferase (TdT, Bohringer Mannheim, Essex, U.K.) in buffer
(30mM TrisCl (Sigma, Dorset, U.K.) pH 7.2, 140 mM Na-cacodylate (Agar
Scientific Ltd., Essex, U.K.), 1.5mM CoCb (Bohringer Mannheim, Essex, U.K.) for
1 hour at 37°C. Negative control sections had the TdT replaced by the equivalent
amount of buffer. Four rinses with PBS were followed by incubation with
horseradish peroxidase-conjugated sheep anti-digoxigenin antibodies (Bohringer
Mannheim, Essex, U.K.) 1.5 U/ml in buffer (lOOmM TrisCl (Sigma, Dorset, U.K.)
pH 7.5, 150mM NaCl) for 30 minutes at room temperature. Three PBS washes were
followed by visualisation with 0.04% 3,3'-diaminobenzidine (w/v,Sigma, Dorset,
U.K.) in 0.05M TrisCl (Sigma, Dorset, U.K.) pH 8 and 3% H702 (BDH Laboratory
Supplies, Dorset, U.K.).
2.6.4.1 Positive and Negative Controls
Positive control serial sections were treated with DNase prior to labeling. The DNase
caused DNA fragmentation in every nucleus, therefore this positive control had the
potential to yield 100% 3' end labeling. It was found that the amount of labeling in
test samples was dependent upon the proteinase K treatment, therefore parameters
were adjusted in order that DNase treated sections would have 99% labeling. In this
way the amount of apoptosis indicated by 3' end labeling would be a conservative
underestimate, rather than a falsely high estimate. The second, internal positive
control was based on work demonstrating that follicular atresia occurs through a
process of granulosa cell apoptosis (Tilly et al., 1991). Apoptosis occurs in the
granulosa cell layer, but not the theca cell layer of primate atretic follicles, and this
was demonstrated in 3' end labeled baboon (Tilly 1993) and marmoset (Giebel 1997)
ovarian sections. The internal positive control was therefore that granulosa cells
would be 3' end labeled in atretic antral follicles in the marmoset ovarian sections
used in these studies. The corresponding internal negative controls were that theca
cells of atretic follicles, and granulosa cells of morphologically healthy preantral
follicles, were not undergoing apoptosis and would not become 3' end labeled. The
external negative control was to omit TdT, the enzyme responsible for the tailing
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reaction, from the labeling procedure. Even apoptotic cells would not be labeled in
these negative controls, and the incidence of 3' end labeling would be 0%.
2.6.4.2 Quantification of 3' End Labeled Sections
Each ovary was 3' end labeled on at least three separate occasions. Results are taken
from one representative 3' end labeling run. DNase positive controls and test sections
were viewed with a x20 objective lens. 3' end labeled nuclei were counted in three
randomly selected fields of view of luteal tissue using an NIH Image Analysis 1.57
programme and the mean calculated to give the number of positive nuclei per x20
field of view. Amount of 3' end labeling in test sections was expressed as a
percentage of that seen in DNase positive controls.
2.6.4.3 Statistical Analysis of 3' End Labeled Sections.
Results from the 3' end labelled sections are expressed as means of
percentages±SEM of 3' end labelled cells. The data were subjected to a chi square
analysis and significance was assigned at P<0.05.
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Chapter 3: Cell Morphology and Cell Death in the
Corpus Luteum ofthe Marmoset Monkey.
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3.0 Introduction
This investigation into the instigation and process of luteal regression starts by
examining the cells of the corpus luteum in order to determine the relative
proportions of different cell types, and to ascertain whether cell numbers change
during luteal regression. Removal of luteal tissue, or structural regression, is most
likely to occur through cell death and tissue reorganisation but the nature of luteal
cell death, and the temporal relationship between cell death and luteal regression in
marmosets, is not clear.
3.0.1 The Cellular Composition of Corpora Lutea.
Corpora lutea are composed primarily of parenchymal steroidogenic cells, fibroblasts
and capillary endothelial cells. Immune system cells such as macrophages and
eosinophils are also part of the resident population of the corpus luteum.
Parenchymal steroidogenic cells are further sub-divided into those which were
derived from the granulosa cells of the follicle, granulosa-lutein or large luteal cells,
and those derived from the theca cells of the follicle, theca-lutein or small luteal cells
(Corner 1956; Behrman et al., 1993; Sawyer et al., 1991; Hild-Petito et al., 1989;
Clement 1987; Webley et al., 1990; Sasano et ah, 1989). Small and large
steroidogenic cells can be identified using a light microscope by determining
differences in size and morphological features. In most species small luteal cells
form the majority of steroidogenic cells, they have a diameter in the range of 12 to 22
pm, an irregularly shaped nucleus with an infolded nuclear membrane and an
irregular stellate shape. Large luteal cells have a diameter in the range of 22 to 35pm,
a regular polyhedral shape and regularly shaped spherical nuclei containing
prominent nucleoli (O'Shea et al., 1986; O'Shea et al., 1989; Brannian et al., 1993;
Deane et al., 1966; Ohara et al., 1987) Electron microscopy reveals the presence of
large amounts of smooth endoplasmic reticulum and mitochondria, which is
consistent with the steroidogenic function of large and small luteal cells (Ohara et al.,
1987; Webley et al., 1990), and in many species large luteal cells also have secretory
granules and the organelles required for protein secretion. In ruminants secretory
granules in large luteal cells have been shown to contain oxytocin or relaxin
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(Gemmell et al., 1974; Paavlova and Christensen, 1981) and in rats and pigs they
contain relaxin (Fields 1984; Fields and Fields 1985). Secretory granules are not
common in human luteal cells, although they do produce oxytocin and relaxin
(Khan-Dawood et al., 1989).
In sheep, small and large luteal cells, and endothelial cells, decrease in number and in
size from the mid to late luteal phase, but fibroblast numbers remain constant. There
are six times more small than large luteal cells in ovine and bovine corpora lutea
(Sawyer et al., 1991; O'Shea et al., 1986; O'Shea et al., 1989). Human corpora lutea,
however, have twice as many large as small luteal cells, and this proportion remains
constant throughout the luteal phase (Lei et al., 1991). Both bovine and human
corpora lutea contain more non-steroidogenic cells than steroidogenic cells, with the
majority of these being fibroblasts. In the human corpus luteum there are
approximately the same number of macrophages as there are fibroblasts during the
mid luteal phase, and three times more macrophages by the late luteal phase (Lei et
al., 1991). Macrophages are more numerous in human corpora lutea than they are in
ruminant species in which PGF2a from the uterus is the luteolytic signal (Sawyer et
al., 1991).
The mid-phase bovine corpus luteum has a dense capillary network made up of fully
differentiated endothelial cells with a flattened elongated morphotype and numerous
tight junctions (Modlich et al., 1996). Early luteal regression is characterised by the
detachment of endothelial cells from capillary basal lamina, and Modlich et al (1996)
found ultrastructural evidence of steroidogenic cell apoptosis at this time. In rodents
luteal regression is characterised by infiltration of the luteal mass by connective
tissue and by vacuolisation of steroidogenic cells. The resulting regressing corpus
luteum has been described as having 'a honey-comb-like structure in which each
space is occupied by a degenerating luteal celF (Van Blerkom and Motta 1978).
Corner (1956) noted that human corpora lutea are in a process of development from
days 1-8, with peak steroidogenic activity occurring on luteal days 7 and 8. Thecal
cells form an irregular layer several cells thick around the corpus luteum, and also
extend into the central cavity along vascular septa, in an arrangement reminiscent of
the spokes of a cartwheel. Luteal regression begins on luteal day 9 and is
characterised by granulosa-lutein cell shrinkage and vacuolation. Vacuolation
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apparently caused by lipid accumulation was either in the form of a number of
different sized vacuoles within the cytoplasm, or giant vacuoles which obscured any
remaining cytoplasm, or in the formation of "mulberry cells" in which the cytoplasm
was packed with uniformly small vacuoles. "Mulberry cells" were only seen on
luteal days 13 and 14, and nuclei degenerating into densely-staining irregular masses
reminiscent of apoptotic bodies were also seen on luteal day 14. Ongoing fibrosis
and shrinkage continued over several months with the eventual formation of a corpus
albicans (Clement, 1987). This process has not been described in the marmoset
monkey.
3.0.1.1 Characteristics of Marmoset Luteal Cells.
Marmoset corpora lutea do not appear to have two different types of steroidogenic
cells based on the criteria of morphology or size. Instead cells positive for 3(3 HSD,
and therefore identified as being steroidogenic using functional criteria, are of
uniform size and regular polygonal shape, and have diameters in the range 14-32pm
(Webley et al., 1990). Electron micrographs indicate that these cells contain
euchromatic and slightly lobed nuclei with one or two nucleoli, smooth endoplasmic
reticulum which varies in extent of dilatation between cells, and numerous
mitochondria with round to elongate rod shapes and tubular cristae (Fehrenbach et
al., 1995; Webley et al., 1990).
3.0.2 Mechanisms of Cell Death
Cell death can be caused by an extra-cellular event, or by an intracellular event
(Hockenberry, 1995). In the latter case, extra-cellular conditions appear to stay
constant, but an individual cell enters a death pathway. The lack of an extra-cellular
impetus for cell death suggests some change in the intracellular environment, and
gives rise to the premise that this type of death is 'programmed' - a set of death
instructions encoded in the cells' DNA (Majno and Joris, 1995). Apoptosis is one
type of programmed cell death, defined by specific morphological and biochemical
criteria (Kerr et al., 1972; Schwartzman and Cidlowski, 1993). A common
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intracellular signal for apoptosis is DNA damage: if the damage can be repaired the
cell continues normal cycling, but if it is irreparable the cell enters an apoptotic
pathway (Basu et al., 1998). It is also possible that apoptotic pathways evolved as a
defense against viral infection (Haecker and Vaux, 1994).
Cell death caused by changes in the extra-cellular environment may occur through
myriad mechanisms (Haecker and Yaux 1994). Conditions that impair cell
membrane function commonly result in the loss of osmotic and ionic regulation, but
may leave the DNA intact until a later stage of the death process. Other extra-cellular
changes may be mediated by receptor binding and transduction pathways, and
therefore affect intra-cellular function and DNA integrity relatively early in the death
process.
Ubiquitin is a 76-amino acid polypeptide associated with a number of cell death
mechanisms, including apoptosis in murine myoblasts (Sandri et al., 1997). Its main
role is to mark proteins for degradation (Hershko, 1988) and it is expressed in the
nucleus and the cytoplasm (Haas and Bright 1985) of both dying and cycling cells
(Lauzon et al., 1993).
3.0.2.1 Apoptosis
During the initial stages of apoptosis the cells shrink, and the chromatin condenses
and packs into smooth masses making crescent shapes alongside the nuclear
membrane (Kerr et al., 1972). In H&E sections a cell in the initial stages of apoptosis
is likely to lack physical contact with neighboring cells, and also might appear
slightly smaller than average, with intensely stained nuclei, but in fact would be very
difficult to distinguish from non-apoptotic or necrotic cells. In the next phase of
apoptosis, endonucleases cleave DNA at 185 base pair (bp) intervals, or at multiples
of 185bp's (Wyllie, 1980, Arends et al., 1990). DNA is wound around histones to
make nucleosomes which in turn are linked together by 185bp lengths of DNA: the
nucleosomes are 'beads' separated by 185bp 'links' (Hsueh et al., 1994). Linker
DNA is susceptible to cleavage by endonucleases, and the first fragments to be
formed are high multiples of 185bp, and as cleavage proceeds, fragments which are
lower multiples of 185bp are generated (Basnakian and James, 1994). If DNA is
extracted from apoptotic cells and electrophoresed on an agarose gel, the fragments
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of DNA form a characteristic 'ladder' pattern with the 'rungs' of the ladder
consisting of fragments of sizes which are multiples of 185bp (Hsueh et al., 1994). If
DNA is extracted from a population in which the majority of cells are apoptotic, the
'ladder' can be visualised on ethidium bromide stained gels (Wyllie, 1980, Arends et
al., 1990). If only a small percentage of the total population of cells are apoptotic, the
quantity of fragmented DNA is too low to be seen on ethidium bromide stained gels
(Juengel et al., 1993). A more sensitive visualisation technique employs an enzyme,
32terminal transferase, to attach a label, either P or digoxigenin onto the 3' ends of
the fragments, which are then subjected to electrophoresis as before (Tilly and Hsueh
1993). DNA fragments generated during apoptosis can also be visualised in situ, in
tissue sections, using the same method (Gavrieli et al., 1992).
Random DNA fragmentation occurs during cellular necrosis, but generates fragments
of different lengths that appear as a smear of DNA after electrophoresis, as opposed
to the distinct 185bp 'rungs' of apoptosis (Hsueh et al., 1994). However, in situ 3'
end labeling does not distinguish between necrotic and apoptotic DNA in tissue
sections, therefore 3' end labeled nuclei in tissue sections should be assessed in
conjunction with other methods (Phelouzat et al., 1996). Cell death caused by plasma
membrane damage and disrupted osmotic regulation is indicated morphologically by
the presence of cytoplasmic vacuoles, or ruptured cells, or the presence of leukocytes
associated with an inflammatory response. These cells may then progress to necrosis,
which is difficult to differentiate from the latter stages of apoptosis. However, there
is one major difference between necrosis and apoptosis. Cells in the latter stages of
apoptosis undergo nuclear fragmentation or karyorhexis, and the cell buds off
apoptotic bodies which contain pyknotic nuclear fragments which may be
phagocytosed by macrophages or neighboring cells (Hsueh et al., 1994). Therefore
the presence of 3' end labeled fragmented nuclei or apoptotic bodies, either in inter¬
cellular spaces or in the cytoplasm of otherwise healthy cells, is strongly suggestive
of apoptotic DNA fragmentation.
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3.0.2.2 Oncosis
Cell death caused by ischemia has been described in detail, and the term 'oncosis'
has been suggested for this form of cell death in which cytoplasmic swelling is the
most characteristic feature (Majno and Joris 1995). Oncosis is initiated by plasma
membrane changes which result in the impaired action of ion pumps and consequent
loss of calcium and sodium balance (Bowen 1984). Increased calcium is associated
with chromatin aggregation and pyknosis (similar to that seen in apoptosis), followed
by karyolysis during which chromatin appears to disappear from the nucleus
(dissimilar from the karyorhexis that occurs during apoptosis). Oncosis proceeds
with lysosome swelling, dilation and vesiculation of the endoplasmic reticulum and
loss of compartmentalisation and cell oedema (Bowen 1984; Trump et al., 1981;
Cohen 1991) and would appear as swollen, vacuolated cells in H&E stained tissue
sections. Oncosis contrasts with apoptosis in that cells swell, as opposed to the
shrinkage that occurs during apoptosis. The nuclei of cells undergoing oncosis
remain essentially intact throughout the process, whereas apoptotic nuclei fragment
into apoptotic bodies within 34 minutes (Majno and Joris 1995; Bursch et al., 1990).
Specific DNA fragmentation characteristic of apoptosis occurs relatively early, but
the random, non-specific DNA fragmentation associated with necrosis occurs up to
24 hours after the onset of oncosis (Majno and Joris 1995).
3.0.2.3 Necrosis
Necrosis is a term commonly used to indicate non-apoptotic cell death, however cell
death and necrosis are two different things. A process leading to cell death occurs in
liver cells as soon as they are exposed to ischemic conditions, but the point of no
return, or actual death, occurs approximately 150 minutes after instigation of the
ischemic conditions (Majno and Joris 1995). Necrotic changes are only visible after
the cell has actually died, and are analogous to the rigor mortis of a cadavar, necrotic
changes are similar no matter what the cause of death (Majno and Joris 1995).
Necrosis is characterised by random DNA fragmentation and disappearance, and
cytoplasmic condensation and cell shrinkage. This resembles the latter stages of
apoptosis, with the exception that necrotic cells do not form apoptotic bodies.
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3.0.3 Aims of Study.
A morphometric tissue analysis requires that different cell types are identifiable,
therefore the first aim of this study is to identify steroidogenic luteal cells by
immunocytochemistry for the steroidogenic enzyme 3 beta hydroxysteroid
dehydrogenase isomerase, and to derive morphological criteria for identifying
steriodogenic cells in H&E stained sections based on this functional definition.
The second aim is to determine the number of steroidogenic and nonsteroidogenic
cells in corpora lutea collected during different stages of the luteal phase and after
induced luteal regression. Any changes in cell numbers or ratios of cell types will be
related to stage of the luteal phase or luteal regression.
The third aim is to examine cell death at different stages of the luteal phase and
during regression, with the specific aim of establishing the presence or absence of
apoptosis. Three different methods will be used to identify and quantify apoptosis; (i)
identification of apoptotic bodies in H&E stained sections, (ii) gel electrophoresis of
radioisotope labeled DNA and (iii) in situ 3' end labeling. A fourth aim is to examine
the expression of ubiquitin in the corpora lutea of the marmoset monkey after
induced luteolysis, and to assess ubiquitin as an early indicator of apoptotic cell
death.
3.1 Results
3.1.1 Identification of Steroidogenic Cells by
Immunocytochemistry for 3|3 Hydroxysteroid Dehydrogenase
Isomerase (3(3 HSD).
Red 3p HSD immunoreactivity was localised to the cytoplasm of large, circular cells
with spherical nuclei (Figure 3.1), and these had the same morphological appearance
as the cells which were defined as steroidogenic by Webley et al., (1990) and which
were shown in both light and electron micrographs. In addition, Fehrenbach et al.
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(1995) found cells with this morphological appearance to have 3(3 HSD activity in
mid-luteal phase marmoset corpora lutea.
The majority of parenchymal cells in mid-luteal phase day 10 corpora lutea were 3p
HSD immunopositive, but the number of 3p HSD immunopositive cells in early or in
late luteal phase corpora lutea was extremely variable, and ranged from less than a
third of the cells with the morphological appearance of steroidogenic cells being 3p
HSD immunopositive, to nearly 100% of the parenchymal cells being 3p HSD
positive. Some 3p HSD immunopositive cells were present in very late corpora lutea
collected in the early follicular phase after progesterone concentrations had
decreased to follicular phase values. Within each section, 3p HSD immunostaining
appeared to be fairly constant, and generally there was not a gradation of
immunostaining to indicate that some cells contained more 3p HSD than others. This
was not the case after induced luteolysis, however and 24 hours after treatment with
either GnRH antagonist or PGF2a (Figure 3.1C and E), some parenchymal cells
appeared more intensely immunostained than others. This intense 3p HSD
immunopositivity tended to occur in cells which were vacuolated or showing other
morphological signs of degeneration, whereas cells which appeared morphologically
normal had less intense immunostaining. Cells with the morphological appearence of
fibroblasts or endothelial cells were 3p HSD immunonegative. Negative control
sections had some non-specific cytoplasmic staining (Figure 3.IB, D and F), but this
was of a much lower intensity than that seen in sections which had been exposed to
primary antibody.
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Figure 3.1: 3(3 Hydroxysteroid Dehydrogenase
(3PHSD) Immunocytochemistry in Marmoset
Corpora Lutea After Induced Luteal Regression.
Marmoset ovaries collected after in vivo administration of
luteolytic agents. Panels A and B; 3PHSD positive and its
antibody negative control serial section respectively.
Granulosa and theca cells visible in a follicle in top left
hand corner, and the remainder is untreated luteal tissue
collected during the mid luteal phase on day 10. Panels C
and D; 3PHSD positive and its antibody negative control
serial section 24 hours after in vivo administration of a
GnRH antagonist, antarelix. Panels E and F; 3PHSD
positive and its antibody negative control serial section 24
hours after treatment with the PGF2a analogue,
cloprostenol. All ovaries were collected on luteal day 10.
3PHSD immunopositive cells are pink to dark crimson
red, and immunonegative cell nuclei are counterstained
blue with haematoxylin. Scale bars represent 20pm.
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3.1.2 Morphological Analysis Of Haematoxylin and Eosin Stained
Sections of Marmoset Corpora Lutea.
Steroidogenic cells in untreated day 10 corpora lutea were commonly in close
juxtaposition to non-steroidogenic cells, which appeared to form a network
surrounding the steroidogenic cells (Figure 3.2a and Figure 3.3a). Mid luteal phase
tissue had a regular close-packed structure which was in marked contrast with the
disorganised, irregular structure of tissues undergoing luteal regression (Figure 3.3b
and c).
The morphological appearance of non-steroidogenic cells did not appear to change
after luteolysis, unlike the parenchymal steroidogenic cells which exhibited a range
of cytoplasmic changes apparently bought about by the formation of vacuoles. The
vacuoles in naturally regressing corpora lutea from the early follicular phase were
small and discrete, and were not present in all steroidogenic cells (Figure 3.4b). The
proportion of vacuolated cells, and the size of the vacuoles, had increased by the late
follicular phase. Steroidogenic cell vacuolation also occurred after luteolytic
treatment (Figure 3.3b, c, d and e), but the vacuoles were larger than those seen in
naturally regressing corpora lutea and the steroidogenic cells had an oedematous
appearance commonly associated with oncosis (Bowen, 1984). The majority of
steroidogenic cells in the corpora lutea from animals treated with GnRH antagonist
appeared oedematous (Figure 3.3b and c), whereas in the animals treated with
PGF2a, the proportion of vacuolated cells was more variable (Figure 3.3d and c).
Some areas contained only a few vacuolated cells while other areas consisted of
predominantly vacuolated cells.
Apoptotic bodies were found in all corpora lutea and had the appearance of clusters
of small irregular spheres with intense haematoxylin staining (Figure 3.4). Cells in
the final stages of apoptosis had condensed cytoplasm and nuclear fragments which
exhibited the same intense haematoxylin staining as that seen in apoptotic bodies.
There was no obvious separation of apoptotic and vacuolated cells, with the two
types commonly found in close juxtaposition (Figure 3.3c and e and Figure 3.4
b,c,d).
128
Figure 3.2: Haematoxylin and Eosin Stained
Marmoset Corpora Lutea During Spontaneous
Luteal Regression.
Luteal tissue collected on (a) luteal day 10, (b) luteal day
18 during functional luteal regression, and (c) luteal day
22 during structural luteal regression. Panels (d) and (e)
show lower and higher magnifications respectively of the
section shown in (c). Steroidogenic and nonsteroidogenic
cells are apparent in all panels, vacuolated or apoptotic
cells are not visible in (a) or (b), but apoptotic cells are
indicated with arrows in (e). (d) although progesterone
concentrations are at basal levels and the follicular phase
is well under way, the amount of luteal tissue (upper half
of the image) is substantial. Scale bars represent 20pm.
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Figure 3.3: Haematoxylin and Eosin Stained
Marmoset Corpora Lutea After Induced Luteal
Regression.
Marmoset ovaries collected after in vivo administration of
luteolytic agents. Panel (a); untreated control corpus
luteum collected on day 10 of the luteal phase. Panels (b)
and (c); corpora lutea 12 hours and 24 hours respectively
after in vivo administration of a GnRH antagonist,
antarelix. Panels (d) and (e); luteal tissue 12 hours and 24
hours respectively after treatment with the PGF2a
analogue, cloprostenol. All ovaries were collected on
luteal day 10. Arrows indicate apoptotic bodies or




Figure 3.4: Haematoxylin and Eosin Stained Sections
of Marmoset Corpora Lutea.
Whole ovaries collected on: (a), luteal day 10, arrows
indicate nonsteroidogenic cells, 'S' indicates a
steroidogenic cell, (b). luteal day 22 during structural
luteal regression, (c).24 hours after in vivo administration
of PGF2a, and (d).24 hours after in vivo administration of
GnRH antagonist. Arrows indicate apoptotic cells or
apoptotic bodies, * indicates a vacuolated cell, 'S'




3.1.2.1 Quantification of Cells in Marmoset Corpora Lutea.
2
The number of morphologically normal steroidogenic cells per 60 000pm of luteal
tissue (Figure 3.5A) was similar in the mid and late luteal phase and in the early
follicular phase. The number of morphologically normal steroidogenic cells was
significantly decreased in naturally regressing corpora lutea from the late follicular
phase (18.3±5.2; P<0.001) as well as in corpora lutea in which regression was
induced with either PGF2a (12hr, 18.7±14 and 24hr, 34±12.7; PO.OOl) or GnRFI
antagonist (12hr, 0 cells and 24hr, 1.25+1.7; PO.OOl), when compared with the
number of normal steroidogenic cells in untreated mid-luteal phase corpora lutea
(104+25).
2
There were 120+30 non-steroidogenic cells in each 60000pm area on luteal day 10
(Figure 3.5B), and numbers remained at this level until luteal day 18 (135+31, n=3),
but increased significantly (249+63, n=3, p<0.05) after progesterone concentrations
had fallen to follicular phase values (Figure 3.6). Non-steroidogenic cell numbers
decreased significantly (97+69, n=3, p<0.05) late in the follicular phase after luteal
day 25.
Non-steroidogenic cells comprised 48+3% of the cells of the corpus luteum during
the mid luteal phase Figure 3.7), and this remained the same on luteal day 18. This
percentage increased to 68+0.63% on luteal day 22 after progesterone had fallen to
follicular phase values, then decreased to 36+18% after luteal day 25.
After induced luteal regression non-steroidogenic cell numbers were slightly reduced
12 hours after luteolytic treatment with PGF2a (98+10, n=3, and GnRFI antagonist
(69+18, n=3, Figure 3.6), but increased to the same levels as mid luteal phase corpora
lutea 24 hours after induction of luteolysis with PGF2a (135+58, n=4) and GnRH
antagonist (116+17, n=4, Figure 3.6). Interestingly, the percentage of non-
steroidogenic cells was the same before and after induced luteal regression (Figure
3.7), with the exception of corpora lutea collected 12 hours after treatment with
GnRH antagonist, in which the percentage of non-steroidogenic cells decreased to
35+6.8% (n=3).
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Figure 3.5: Mean Number of Cells per Unit Area in
Marmoset Corpora Lutea.
2
Mean (± SEM) cell numbers per 60 000pm area of luteal
tissue. A. Morphologically normal steroidogenic cells, B.
Non-steroidogenic cells, C. Apoptotic cells or apoptotic
bodies, D. Vacuolated steroidogenic cells in corpora lutea
of ovaries collected on days 10 (n=4, Mid. Lut.), 18 (n=3,
Late Lut.), 22 (n=3, Early Fob), and 26 (n=3, Late Fol.) of
the luteal phase. Ovaries were also collected 24 hr after
administration of prostaglandin 2a analogue (n=4,
cloprostenol lpg i.m.,) or GnRH antagonist (n=4, antarelix
lmgKg"! s.c.) on day luteal day 10. N-values indicate
different animals.
Different letters indicate significant differences between
untreated corpora lutea from different stages of the cycle
with p<0.01 in A, C and D, p<0.05 in B. PGF2a and
GnRH antagonist treated groups are compared only with
mid-luteal day 10 and with each other. Different symbols
are significantly different with pO.Ol. No symbol
indicates no significant difference between treatments or
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Figure 3.6: Number of Nonsteroidogenic Cells in
Marmoset Corpora Lutea.
Mean (± SEM) nonsteroidogenic cell numbers per
60000pm area of luteal tissue in haematoxylin and eosin
stained paraformaldehyde-fixed marmoset ovarian
sections. Ovaries containing corpora lutea were obtained
on luteal day 10 (n=4), 18 (n=3), 20-24 (n=3) and 25-28
(n=2). Ovaries were also obtained on luteal day 10, 12 and
24 hours after in vivo administration of the luteolytic
agents PGF2a (PG12, n=3 and PG24, n=4) and GnRH
antagonist (Gnl2, n=3 and Gn24, n=4). Asterisk indicates
significantly different (p<0.05) from mid luteal phase day
10. No symbol indicates no significant difference between
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Figure 3.6. Number of Nonsteroidogenic Cells in Marmoset Corpora Lutea
Figure 3.7: Percentage of Nonsteroidogenic Cells in
Marmoset Corpora Lutea.
Nonsteroidogenic cell numbers were expressed as a
percentage of the total number of cells per 60000pm2 area
of luteal tissue in haematoxylin and eosin stained
paraformaldehyde-fixed marmoset ovarian sections. The
mean percentage (± SEM) is shown for each experimental
group. Ovaries containing corpora lutea were obtained on
luteal days 10 (n=4), 18 (n=3), 20-24 (n=3) and 25-28
(n=2). Ovaries were also obtained on luteal day 10, 12 and
24 hours after in vivo administration of the luteolytic
agents PGF2a (PG12, n=3 and PG24, n=4) respectively,
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Figure 3'T Percentage of Nonsteroidogenic Cells in Marmoset Corpora Lutea
Clusters of apoptotic bodies were observed in all corpora lutea studied (Figure 3.4C,
Figure 3.8), including those in the mid-luteal phase (0.75±0.6). The incidence of
apoptosis was significantly increased to 15±4 (PO.OOl) in naturally regressing
corpora lutea from the early follicular phase, but was similar in corpora lutea from
the late luteal (2±0.94) and late follicular (3.66±3.2) phases. Apoptosis was
significantly increased 24 hours after PGF2a-induced regression (24+5.6; PO.OOl)
but not 12 hours after administration of PGF2a (1.33+0.8). Apoptosis was also
increased 12hr (4±1.2) and 24hr (7±4) after treatment with GnRH antagonist, but the
response was variable and not statistically significant (Figure 3.8). Apoptosis was
increased significantly from 0.3+0.42% (n=4, Figure 3.9) in the mid luteal phase to
3.46+1.45% (n=3, p<0.05, Figure 3.9) in naturally regressing corpora lutea from the
early follicular phase, but was similar in corpora lutea from the mid (0.3+0.42%),
late luteal (0.85+0.94%) and late follicular (0.63+0.72%) phases. Apoptosis was
2.8±0.28%(n=3) and 8.6±8%(n=3) 12 hours after induced regression with GnRH
antagonist and PGF2a respectively. This increased to 6.2+5.2% (Figure 3.9) 24
hours after treatment with GnRH antagonist, but this was not significantly higher
than in untreated mid-luteal phase corpora lutea, unlike PGF2a induced regression
which resulted in a significant increase 24 hours after treatment to 9.0+3.7% (n=4,
p<0.05, Figure 3.9) when compared to untreated mid-luteal phase corpora lutea.
The number of vacuolated cells increased gradually with advancing luteal age
(Figure 3.5D) and was significantly higher in naturally regressing corpora lutea from
the late follicular phase (101±26.9, p<0.01) compared with all other naturally
regressing corpora lutea. The numbers of vacuolated cells were similarly
significantly higher 12 and 24 hours after luteolytic treatment compared with
untreated mid-luteal phase corpora lutea (PO.OOl).
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Figure 3.8: Amount of Apoptosis in H&E Stained
Sections of Marmoset Corpora Lutea.
Ovaries containing corpora lutea were collected on luteal
day 10 (n=4), luteal day 18 (functional luteal regression,
n=3), luteal days 22-24 (structural luteal regression, n=3)
and luteal days 25-28 (n=3). Ovaries were also obtained
12 hours (PG12, n=3) and 24 hours (PG24, n=4) after in
vivo administration of the PGF2a analogue, cloprostenol,
and 12 hours (Gnl2, n=3) and 24 hours (Gn24, n=4) after
in vivo administration of a GnRH antagonist, anterelix.
Luteolytic agents were administered on luteal day 9, 24
hours before collection on luteal day 10. The total number
of apoptotic cells or clusters of apoptotic bodies per 60000
pm~ unit area were determined for each corpus luteum,
and shown as the mean+SEM for each stage of the luteal
phase.
Data were subjected to one way analysis of variance. The
number of apoptotic cells was significantly higher in
structurally regressing corpora lutea (luteal days 20-24,
p<0.001), and 24 hours after induction of luteolysis with
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Figure 3.8: Amount of Apoptosis in H&E Stained Sections of
Marmoset Corpora Lutea.
Figure 3.9: Percent Apoptosis in Marmoset Corpora
Lutea.
Mean ( ± SEM) number of apoptotic cells and apoptotic
bodies per 100 cells in marmoset corpora lutea collected
during the mid-luteal phase (luteal day 10), early follicular
phase (equivalent to structural regression, luteal days 20 -
24), mid-luteal phase 24h after administration of PGF2a,
and mid-luteal phase 24h after administration of GnRH
antagonist. Open bars apoptotic scores generated by
HOME analysis of haematoxylin and eosin stained
sections; closed bars apoptotic scores generated by image
analysis of in situ 3' end labelled ovarian sections.
Significant differences are indicated by asterisks (* P<
0.05; **P<0.001).
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3.1.3 Localisation of Lipids in Marmoset Corpora Lutea.
Examination of H&E stained sections indicated that the number of vacuolated
steroidogenic cells in each unit area of luteal tissue increased as the corpus luteum
aged, and that the number of vacuolated cells was also higher after induced luteal
regression. Vacuolation of the steroidogenic cells was considered to be a
morphological change which occurred during spontaneous or induced luteal
regression. It was possible that the induction of regression with luteolytic agents
caused a rapid decrease in steroidogenesis which resulted in the accumulation of
unprocessed lipid substrate in cytoplasmic vacuoles. In this scenario, the vacuoles
would retain lipid in cryosections but not in paraformaldehyde fixed sections, and
therefore ovarian sections were stained with the lipophillic stain, Oil-Red-O.
In mid luteal phase day 10 control ovaries, the most intense staining for Oil Red O,
with variable droplet size, was seen in localized areas of the stroma containing cells
having the appearance of steroidogenic cells and which were assumed to represent
differentiated interstitial cells (Figure 3.10a and e). In a proportion of antral follicles,
intense staining was also seen within the thecal layer while granulosal staining was
not recorded in follicles of any size. There was no staining in small antral or
preantral follicles. Within luteal tissue, staining was variable and generally more
intense in corpora lutea accessoria then in the true corpora lutea. In untreated mid-
luteal phase corpora lutea, steroidogenic cell cytoplasm often contained numerous
small Oil Red O-stained lipid droplets (3.10a and b). After treatment with either
GnRH antagonist (Figure 3.10c and d) or PGF2a (Figure 3.10e and f), the
distribution of staining within the non-luteal compartments remained unchanged. In
luteal tissue, there was little to suggest lipid accumulation; in particular, lipid
droplets were primarily extracellular and the vacuoles did not contain lipid (Figure
3.1 Od and f).
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Figure 3.10: Oil-Red-O Stained Lipid in Marmoset
Corpora Lutea After Induced Regression.
Cryosections of marmoset ovaries in which Oil-Red-O
stains lipids red, and nuclei are counterstained blue with
haematoxylin. The panels show: (a) An untreated control
ovary collected on luteal day 10. The corpus luteum of the
cycle is in the top right hand corner of the image.
Proceeding anticlockwise is intensely staining interstitial
tissue which may also be a luteinised follicle, an antral
follicle and an accessory corpus luteum in the bottom half
of the image, (b) shows the corpus luteum of the cycle
depicted in (a) at a higher magnification. Individual
steroidogenic cells contain numerous lipid droplets, (c)
shows a corpus luteum collected 24 hours after in vivo
administration of GnRH antagonist, and (d) shows the
same corpus luteum at a higher magnification. Faint grey
staining indicates the presence of cytoplasm lightly
counterstained with haematoxylin, and white areas
indicate the location of cytoplasmic vacuoles. Although
lipid droplets are present in the corpus luteum, they do not
exhibit the same dimensions or localisation as cytoplasmic
vacuoles. Panel (e) shows an ovary collected 24 hours
after in vivo administration of PGF2a, and the corpus
luteum of the cycle is in the top right hand corner of the
image. Intensely staining interstitial tissue is present at the
bottom left hand corner of the image, (f) shows the corpus
luteum depicted in (e) at a higher magnification.
Cytoplasmic vacuoles do not contain Oil-Red-O stained
lipid. All scale bars represent 20pm.
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3.1.4 Oligonucleosome Formation in Marmoset Corpora Lutea.
3.1.4.1 Positive Controls for Oligonucleosome Formation
Multiples of 185bp DNA fragments were found in thymocytes induced to undergo
apoptosis by treatment with the glucocorticoid analogue, dexamethasone (Figure
3.11, panel A, lane 1). Oligonucleosomes were also found in cow corpora lutea 12
(Figure 3.11, panel A, lane 5), and 24 hours (Figure 3.11, panel A, lanes 3 and 4)
after induction of luteolysis with PGF2a, indicating that technical procedures for
extraction, labeling and visualisation of apoptotic DNA were in accordance with
previous reports (Juengel et al., 1993; Tilly and Hsueh 1993). One PGF2a treated
marmoset corpus luteum with oligonucleosome formation (Figure 3.11, panel A, lane
2) confirms that marmoset luteal DNA fragmentation is of the same order as that
seen in bovine corpora lutea.
3.1.4.2 Oligonucleosome Formation in Marmoset Corpora Lutea
Low oligonucleosome formation was found in one mid luteal phase day 10 animal
(Figure 3.11, panel B, lane 1) but apoptotic DNA fragmentation was absent from
three other mid luteal phase animals (Figure 3.11, panel B, lanes 2 and 3 and Figure
3.12, lane 2). The non-specific DNA fragmentation apparent in the mid luteal phase
corpus luteum shown in Figure 3.12, lane 2 is a consequence of DNA overloading
for that sample, but although there is a high concentration of DNA in that lane, there
is no evidence of oligonucleosome formation. Oligonucleosome fragmentation was
present in all animals 24 hours (n=3, Figure 3.1 IB lanes 4 and 5, Figure 3.12 lane 4)
and 48 hours (n=l, Figure 3.12, lane 5) after induced regression with GnRH
antagonist and also 24 hours (n=6, Figure 3.1 IB lanes 6 and 7, Figure 3.12 lane 3)
after treatment with PGF2a. There was also smearing indicative of non-apoptotic
DNA degradation. This was inconsistent in control day 10 samples, but some non-
apoptotic DNA fragmentation was always present in the corpora lutea of animals
given luteolytic treatments. DNA fragmentation of any type was absent from liver
samples (n=8, Figure 3.1 IB lower lanes, each from the same animal as the corpus
luteum shown in the lane above).
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Figure 3.11: Oligonucleosome Formation in Bovine,
Human and Marmoset Corpora Lutea.
Autoradiogram of 3' end labelled DNA (lpg/lane)
electrophoresed on a 2% agarose gel. Panel A, lane 1,
thymocytes cultured with dexamethosone; lane 2,
marmoset corpus luteum collected 24 hours after in vivo
administration of PGF2a, lanes 3 and 4, bovine corpora
lutea collected from two different animals 24 hours after
in vivo administration of PGF2a; lane 5, bovine corpus
luteum 12 hours after in vivo administration of PGF2a;
lane 6 human corpus luteum obtained 12 days after the LH
surge. Lanes 2-6 from one gel exposed for 12hr, 24hr after
the completion of the labeling process. Lane 1 from a
separate gel, also exposed for 12hr.
Panel B, lanes 1-3, mid luteal phase day 10 control
corpora lutea; lanes 4 and 5, GnRH antagonist
administered in vivo luteal day 9; lanes 6 and 7, PGF2a
administered in vivo luteal day 9; all corpora lutea
collected on luteal day 10. Lower lanes show negative
control liver samples corresponding to the animal in the
lane above. Lanes 1-7 from one gel exposed for 12hr, 24hr
after the completion of the labeling process 1 pg DNA
loaded per lane. Molecular Weight markers on right hand
side.
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Figure 3.12: Oligonucleosome Formation in Marmoset
Corpora Lutea.
Autoradiogram of 3' end labelled DNA (lpg/lane)
electrophoresed on a 2% agarose gel. Lanes 1 and 2,
corpora lutea obtained from animals on luteal day 10; lane
3, 24 hours after in vivo administration of PGF2a, lanes 4
and 5, 24 and 48 hours after administration of GnRH
antagonist respectively. All samples on same gel exposed
for 4 hours immediately following labeling procedure.
Molecular weight markers shown on the right hand side.
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Oligonucleosome Formation in Marmoset CL
3.1.4.3 Quantification of Oligonucleosome Formation
# Mean P value Mean P value
animals OD Corrected
±SEM OD±SEM
Control 4 70 500 ± 14 ±6.5










PGF2a 4 301 400 103 ±41
24 hr ± 74 000 J J
Oligonucleosome formation in mid luteal phase control corpora lutea is lower (n=4,
14±6) than that seen 24 hours after in vivo administration of GnRH antagonist (n=3,
110±47) or PGF2a (n=4, 103±41). Both luteolytic treatments appear to result in the
same amount of oligonucleosome formation, although accurate conclusions are
confounded by the extremely high inter-animal variability.
3.1.5 In situ 3' End Labeling of Marmoset Corpora Lutea
3.1.5.1 Positive and Negative Controls
Granulosa cells undergoing apoptosis in atretic follicles were 3' end labeled in
ovaries from all experimental groups whereas no labeling was seen in theca cell
layers, nor in preantral follicles. 90-98% of nuclei were labeled in DNase pretreated
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positive control sections, and there was no labeling at all in negative control sections
where TdT was omitted from the labeling buffer.
3.1.5.2 3' End Labelled Corpora lutea
Corpora lutea from untreated animals collected on luteal day 10 had 0.675±0.4%
labeling (n=4, Figures 4.6 and 4.10). This was significantly increased to 5.54±1.4%
(n=3, p<0.05, Figures 4. 7 and 4.10) in corpora lutea collected on luteal day 22 in the
early follicular phase. Labeled cells had large regular nuclei and abundant cytoplasm,
both features characteristic of steroidogenic cells. Cells with elongated nuclei and
little cytoplasm were also 3' end labeled; these were identified as being non-
steroidogenic and possibly endothelial. In addition to these identifiable cell types,
there were also other labeled structures. Some had the morphological appearance of
apoptotic bodies whereas others were a condensed, labeled body of cytoplasm which
corresponded to the mass of cytoplasm seen in steroidogenic cells. Corpora lutea
induced to undergo regression with PGF2a and GnRFI antagonist had 8±1% (n=4,
Figures 4.9 and 4.10) and 7.4±1.5% (n=4, Figures 4.8 and 4.10) labeling
respectively, and these were significantly higher (p<0.05) than the labeling seen in
untreated corpora lutea from day 10 of the luteal phase. Labeling in GnRFI antagonist
treated corpora lutea was in apoptotic bodies, and only occasionally seen in bodies of
cytoplasm assumed to have originated from steroidogenic cells. Labeling in PGF2a
treated corpora lutea was nuclear in cells with abundant cytoplasm which were
therefore assumed to be steroidogenic in origin. Apoptotic bodies were also labeled
in PGF2a treated corpora lutea. The number of labeled non-steroidogenic cells was
lower in GnRH antagonist and PGF2a treated corpora lutea than in spontaneously
regressing corpora lutea.
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Figure 3.13: In situ 3' End Labelling in Mid Luteal
Phase Marmoset Corpus Luteum.
Marmoset ovary obtained on luteal day 10. Dark brown
DAB staining indicates 3' end labeled cells, (a) apoptotic
granulosa cells in an atretic follicle (AF), but very few
apoptotic cells in the corpus luteum (CL). (b) DNAse
positive control serial section of (a) in which majority of
cell nuclei are 3' end labelled, (c) Higher magnification of
luteal tissue also shown in (a). Scale bars represent 20p.m.
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Figure 3.14: In situ 3' End Labelling in Regressing
Marmoset Corpus Luteum.
Marmoset ovary obtained on luteal day 20 and
paraformaldehyde fixed. Dark brown DAB staining
indicates 3' end labelled cells, (a) shows brown 3'
end labelled cells in an atretic follicle (AF), but very
few apoptotic granulosa cells in a non-atretic follicle
(F). The corpus luteum (CL) has numerous apoptotic
cells (b) Higher magnification of luteal tissue with 3'
end labelled steroidogenic cells (large arrows), and 3'
end labelled non-steroidogenic cells or apoptotic
bodies (small arrows). Scale bars represent 20pm.
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Figure 3.15: In situ 3' End Labelling Marmoset
Corpus Luteum After Induction of Luteolysis With
PGF2a.
In vivo administration of cloprostenol on luteal day 9.
Ovary obtained 24 hours later on luteal day 10. Dark
brown DAB staining indicates 3' end labelled cells, (a)
apoptotic granulosa cells in an atretic follicle (AF) and
corpus luteum (CL). (b) Higher magnification of luteal
tissue with 3' end labelled cells or apoptotic bodies
(arrows). Some steroidogenic cells are vacuolated (V).
Scale bars represent 20pm.
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Figure 3.16: In situ 3' End Labelling Marmoset
Corpus Luteum After Induction of Luteolysis With
GnRH antagonist.
In vivo administration of anterelix on luteal day 9. Ovary
obtained 24 hours later on luteal day 10. Dark brown DAB
staining indicates 3' end labeled cells, (a) apoptotic
granulosa cells in an atretic follicle (AF) and apoptotic
cells in corpus luteum (CL), (b) DNAse positive control
serial section of (a) in which majority of cell nuclei are 3'
end labeled, (c) Higher magnification of luteal tissue with
3' end labeled cells or apoptotic bodies (arrows). Some
steroidogenic cells are vacuolated (*). Scale bars represent
20pm.
163
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3.1.6 Ubiquitin Expression During Luteal Regression
3.1.6.1 Progesterone Concentrations
On the day of ovary collection progesterone concentrations were at luteal phase
values 311+48 nmol L"1 (n=3) in all mid luteal phase day 10 control animals but were
significantly reduced to 18.33+3.75 nmol L"1 (P<0.01, n=3) after luteolytic treatment
with PGF2a and 36.35+16.32 nmol L"1 (P<0.01, n=3) after induction of luteolysis
with GnRH antagonist.
3.1.6.2 Results of Ubiquitin Immunocytochemisty
Ubiquitin immunostaining (Figure 3.17a) was localised in the nuclei of steroidogenic
cells (1.66+0.66 cells per x40 field of view, n=3, Figure 3.18) in mid luteal phase day
10 corpora lutea, but was not found in the nuclei of luteal cells after luteolytic
treatment. Cytoplasmic ubiquitin immunoreactivity was apparent in 0.4+0.3 mid
luteal phase cells per x40 field of view, and this was significantly increased to
12.24+1.6 cells (p<0.02, n=3, Figures 3.17c and 3.18) per field of view in PGF2a
treated animals. Ubiquitin immunoreactivity was not found after induction of
luteolysis with GnRH antagonist, nor was it found in negative control sections
(Figure 3.17e and f).
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Figure 3.17: Immunohistological Detection of
Ubiquitin in Marmoset Corpora Lutea.
Red-pink staining represents ubiquitin positive
immunoreactivity. (A) Ubiquitin-positive nuclei in a mid
luteal phase day 10 untreated corpus luteum. (b)
Corresponding negative control section for (a), with
primary ubiquitin antibody omitted there is no positive
immunoreactivity. (c) Ubiquitin-positive cytoplasm in
steroidogenic cells in regressed corpus luteum 24 hr after
administration of PGF2a analogue, (d) Corresponding
negative control section for (b), (e) No ubiquitin
immunoreactivity in regressed corpora lutea 24hr after
administration of GnRH antagonist, (f) Corresponding





These studies identified steroidogenic cells, and described and quantified
morphological changes occurring during natural and induced luteal regression.
Observations of steroidogenic cell vacuolation led to an examination of lipid
distribution in corpora lutea induced to undergo regression with PGF2a or GnRH
antagonist.
Apoptosis was identified and quantified using three different methods: (i)
morphological examination of H&E stained marmoset ovarian sections, (ii) gel
electrophoresis of DNA extracted from marmoset corpora lutea and (iii) in situ 3'
end labelling of marmoset ovarian sections. In addition, the localisation of ubiquitin,
a protein associated with cell death, was examined during luteal regression.
3.2.1 Identification of Steroidogenic Cells
3p HSD immunocytochemistry confirmed previous reports that large, circular
parenchymal luteal cells with regular spherical nuclei and a diameter >12pm are
steroidogenic (Webley et al., 1990; Fehrenbach et al., 1995). In macaque corpora
lutea, the levels of mRNA for steroidogenic enzymes did not parallel serum
progesterone concentrations thoughout the luteal phase (Basset et al., 1991). Levels
decreased gradually after the mid-luteal phase, but did not decrease dramatically
immediately before luteal regression (Basset et al., 1991; Fairchild-Benyo et al.,
1993). In this study in marmosets, the majority of parenchymal cells were 3(1 HSD-
positive in mid-luteal phase corpora lutea, concomitant with peak luteal progesterone
production. The number of 3p FISD immunopositive cells decreased in the late luteal
phase coincidental with decreasing steroid hormone production and functional luteal
regression. Interestingly, some luteal cells remained 3p HSD immunopositive after
progesterone concentrations decreased to follicular phase values, both in naturally
regressing corpora lutea and after luteolytic treatment with either GnRH antagonist
or PGF2a. This may have been artifactual, whereby morphologically abnormal,
degenerating cells had a non-specific reaction with 3p HSD antibodies, or it might
indicate the presence of cells responsible for basal levels of progesterone production.
However the presence of the steroidogenic enzyme 3p HSD does not necessarily
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mean that steroidogenic enzymes are being produced, since other components of the
steroidogenic pathway may be non-functional (Young et al., 1994). In addition, the
3p HSD protein persists in regressing bovine corpora lutea (Rodgers et al., 1995),
supporting the observation that regressing marmoset corpora lutea also retain the
protein.
3.2.2 Steroidogenic Cell Morphology During Luteal Regression.
The number of morphologically normal steroidogenic cells decreased with advancing
luteal age, and there was a concomitant increase in steroidogenic cell vacuolation.
Extensive steroidogenic cell vacuolation was suggested by an earlier study (Fraser et
al., 1995). In both this and the earlier study, luteolytic treatment resulted in the
development of large vacuoles, or vesicles, within the cytoplasm of the steroidogenic
cells. Steroidogenic cells in corpora lutea undergoing structural regression (luteal day
22) contained vacuoles which were smaller and qualitatively different from those
seen after induced luteolysis. Both the proportion of vacuolated cells and the size of
the vacuoles increased as the corpus luteum regressed spontaneously in the late
follicular phase (corresponding to days 24-28 of the preceding luteal phase).
Induction of luteolysis may occur through a rapid suppression of steroidogenesis,
raising the possibility that the vacuolation observed after induced regression was a
result of accumulation of lipid substrates. However, Oil Red O staining of frozen
sections indicated that vacuoles were not filled with lipid in pharmacological
luteolysis. Unfortunately it was not possible to do the equivalent study in naturally
regressing corpora lutea owing to the unavailability of suitable frozen tissue. It is
possible that the vacuolation observed in the naturally regressing marmoset corpus
luteum may have been a consequence of lipid accumulation. In sheep small luteal
cells have cytoplasmic lipid droplets, whereas large luteal cells do not, and it is
thought this is because basal progesterone production by large luteal cells is up to 20
times higher than small luteal cells (Sawyer et al., 1991). Lipid droplets accumulate
in the cytoplasm of large luteal cells when progesterone production ceases during
luteolysis, and this is presumed to be due to an accumulation of substrate. The lipid
droplets continued to increase in number and size until at the end of the oestrous
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cycle the outlines of the lutein cells were obscured. In the corpus albicans cells
contained coarse lipid droplets for another 15 days (Sawyer et al., 1991). Both large
and small cells in human corpora lutea contained numerous lipid droplets throughout
the luteal phase (Enders, 1973; Ohara et al., 1987). In a classic study of the human
corpus luteum (Corner, 1956) cells 'in which the cytoplasm is almost completely
obscured by several large vacuoles' were noted to appear by day 12 of the luteal
phase, and the number of vacuolated cells was found to increase as the corpus luteum
regressed. Vacuolation in steroidogenic cells was also reported in rat corpora lutea
after administration of the PGF2a analogue, cloprostenol (Salazar et al., 1976).
Steroidogenic cells described as 'vacuolated' had many of the morphological features
of cells undergoing death due to ischemia: chromatin aggregation, nuclear pyknosis,
loss of compartmentalisation and cell oedema (Trump et al., 1981). Vacuolated cells
within regressing corpora lutea had clearly intact nuclei, suggesting they were not
undergoing apoptosis. A non-apoptotic form of cell death which is characterised by
vacuolation has been reported in neuronal cell cultures (Regan et al., 1995) and in
developing tissues (Clarke, 1990) where it has been referred to as 'autophagic
degeneration'. In addition, Fehrenbach et al. (1995) reported vacuolisation in
marmoset corpora lutea after in vitro dialysis of culture media. It can therefore be
concluded that steroidogenic cells become vacuolated during the process of luteal
regression and that the vacuoles are not a consequence of lipid accumulation.
However, although it is possible that vacuolated steroidogenic cells were in the initial
stages of a type of non-apoptotic death analagous to the autophagic degeneration
observed in other systems, further investigations are required to confirm this.
3.2.3 Non-steroidogenic Cell Numbers During Luteal Regression.
Non-steroidogenic cell numbers appeared to increase in structurally regressing
corpora lutea, but were unchanged during the remainder of the luteal phase.
Interpretation of these data, however, has to take account of shrinkage of luteal tissue
during regression and also the type of quantification system used. During regression
steroidogenic cell numbers decreased and the tissue shrank, but in the system used
for quantification the area of luteal tissue measured was kept constant. The apparent
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increase in non-steroidogenic cell numbers was probably a consequence of tissue
shrinkage rather than an actual proliferative increase in non-steroidogenic cells. It is
likely that in absolute terms, non-steroidogenic cell numbers were similar during
functional and structural luteal regression, but that there was a real decrease during
very late structural regression. It was not possible to distinguish endothelial cells,
fibroblasts or leukocytes in H+E stained sections, and further work is required to
determine temporal changes in non-steroidogenic cell sub-populations.
3.2.4 Identification and Quantification of Apoptosis
Apoptosis was found to occur in marmoset corpora lutea after progesterone had
fallen to follicular phase values, therefore, functional luteal regression was not
initiated by apoptosis. Percent apoptosis calculated from 3' end labeled sections was
slightly higher, but not significantly so, than percentages calculated after
morphological analysis of H&E stained sections, as would be expected due to 3' end
labeling of cells in earlier stages of apoptosis, and also the occurrence of false
positives. Both the in situ methods of quantification showed remarkably good
correspondence with each other, and electrophoresis of extracted DNA concurred
with these results. The low oligonucleosome formation observed after
electrophoresis in mid luteal day 10 samples was in agreement with the low levels of
apoptosis observed in H&E stained sections and in 3' end labeled sections in which
only 0.67±0.4% (n=4) of cells were apoptotic. Luteolytic treatment with PGF2a and
GnRH antagonist increased apoptotic cell numbers to 8.0+1 and 7.4+1.5 percent
respectively in 3' end labeled sections, and there was a corresponding increase in
oligonucleosome formation seen after electrophoresis. Increased oligonucleosome
formation 24 hours after induction of luteolysis with PGF2a was also demonstrated
in bovine (Juengal et al., 1993; 1994; Rueda et al., 1995), ovine (Kennny et al.,
1994) and rabbit (Dharmarajan et al., 1984) corpora lutea, but there has been no
other demonstration of oligonuclosome formation after a luteolytic dose of GnRH
antagonist.
The percentage of 3' end labeled cells was less than 1% in naturally regressing mid-
luteal phase CL, and 5.54+1.4% (n=3) of all luteal cells in very late, structurally
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regressing CL. In a comparable study of human corpora lutea (Shikone et al 1996)
found 9±1.1% labeled granulosa-lutein and 12.3±1.2% labeled theca-lutein cells in
the mid-luteal phase, and 39.6±2.6% labeled granulosa-lutein and 56.6±5.4% labeled
theca-lutein in the late luteal phase, corresponding to functional regression. These
figures are extraordinarily high. Apoptosis is a relatively rapid process lasting from
several minutes to a few hours in duration. A low incidence of histologically
detectable apoptosis, 10% for example, therefore reflects a very substantial rate of
cell loss (Kerr et al., 1972; Bursch et al., 1990) whereby the entire tissue might have
disappeared in the order of 10 hours. Rates of apoptosis have been found to be
3±0.4% in late structurally regressing bovine corpora lutea (Zheng et al., 1994), 5-9%
(Sawyer et al., 1990) 24 hours after PGF2a induced regression in sheep and we
found 8±1% apoptosis 24 hours after PGF2a induced regression and 5.54±1.4% in
structurally regressing corpora lutea in marmosets. A total of 96.2% of luteal
steroidogenic cells undergoing apoptosis in regressing human corpora lutea (Shikone
et al., 1996) is substantially higher than other reports to date. Corpora lutea in the
study of Shikone et al (1996) were collected from women who had cervical cancer,
but who had regular menstrual cycles. One characteristic of cancer is that apoptosis
is inhibited, and it is possible that there may have been a physiological attempt to
compensate for the production of apoptosis inhibitors which resulted in increased
apoptosis in the corpus luteum. However, increased apoptosis in the presence of
cancer has not been observed or reported on, making this seem rather unlikely.
3.2.5 Temporal Expression of Apoptosis During the Luteal Phase.
These results are in agreement with others who have shown an increase in apoptosis
when progesterone concentrations have fallen after PGF2a-induced luteolysis in
sheep (Rueda et al., 1995) and cattle (Juengel et al., 1993; Zheng et al., 1994).
A number of reports have indicated that apoptosis occurs after progesterone has
fallen to follicular phase values. Apoptosis was found in 4 out of 5 bovine corpora
lutea after progesterone had fallen from 65.7 to 3.1pg/g of luteal tissue (Zheng et al.,
1994), was demonstrated morphologically in regressing ovine corpora lutea in which
progesterone content was <10pg/g of luteal tissue (O'Shea et al., 1977), and was
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found in pseudopregnant rabbit corpora lutea after in vitro progesterone production
had fallen significantly (p<0.05) (Dharmarajan 1994). Rueda et al (1995) found
oligonucleosome formation in two out of four ovine corpora lutea collected on luteal
day 14 when serum progesterone concentrations were decreasing, and in addition
found apoptotic DNA fragmentation 24 hours after administration of PGF2a when
progesterone concentrations had fallen. Juengal et al (1993) also showed
oligonucleosome formation in three bovine corpora lutea collected on day 19 of the
luteal phase after serum progesterone concentrations had fallen from >3ng/ml to
<1.2ng/ml.
The apoptotic process is fast, and may take only one hour from the apoptotic signal
to the formation of oligonucleosomal 'ladders' (Wyllie et al., 1984). Since PGF2a
and GnRH antagonist are administered 24 hours before apoptosis occurs, it is
unlikely that these are directly responsible for stimulating apoptosis. Apoptosis in
regressing corpora lutea appears to be related to the concentration of progesterone,
suggesting that progesterone inhibits apoptosis (Peluso and Pappalardo, 1998), and
its reduction below a critical threshold concentration removes an inhibitory barrier
and allows apoptosis to proceed.
3.2.6 Initiation of Apoptosis in Corpora Lutea
Rat follicles (Chun et al., 1994) and rabbit corpora lutea (Dharmarajan et al., 1994)
undergo spontaneous apoptosis in vitro which is prevented by the addition of
gonadotrophins to the culture media. These data suggest that LH, FSH and CG
inhibit apoptosis in corpora lutea. The administration of GnRH antagonist depletes
circulating gonadotrophin levels, and the resultant absence of LH and FSH in treated
marmosets may therefore result in spontaneous luteal apoptosis.
GnRH has been shown to stimulate apoptosis in follicles, and the amount of
apoptosis after GnRH antagonist treatment was the same as in estrogen-replaced,
hypophysectomised control rats (Billig et al., 1994), indicating that the binding of
antagonist to ovarian GnRFI receptors does not cause apoptosis.
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PGF2a may also stimulate luteal apoptosis by 'removing' gonadotrophins. PGF2a
receptors were present on luteal cells undergoing apoptosis in rat (Orlicky et al.,
1992) and mouse (Hasumoto et al., 1997). PGF2a can also disconnect the LH
receptor from its secondary messenger pathway by uncoupling the G(s) protein from
adenyl cyclase (Abayasekara et al., 1993) and inhibiting the formation of LH-
dependent cAMP (Thomas et al., 1978, Dorflinger et al., 1983).
Spontaneous apoptosis in vivo might therefore be effected by the endogenous
production of PGF2a. Variable steroidogenic cell PGF2a production may result in
one cell containing sufficient PGF2a to completely inhibit all LH-stimulated
steroidogenesis, and hence be well advanced down an apoptotic pathway, whereas a
neighboring cell might have produced only enough PGF2a to have halved LH-
stimulated steroidogenesis, and be less likely to undergo apoptosis. This scenario
concurs with observed results in which not all steriodogenic cells undergo apoptosis
at the same time. The gradual decrease in steroidogenesis over the latter part of the
luteal phase may therefore be proportional to gradually increasing intracellular
concentrations of PGF2a. Apoptotic pathways were not stimulated until all cells in
the corpus luteum had ceased steroidogenesis, suggesting that the local presence of
progesterone is sufficient to inhibit apoptosis in a cell which has ceased
steroidogenesis. Progesterone may have antioxidant properties (Sugino et al., 1996),
and may be able to enter cells by diffusion or by means of a non-classical
progesterone receptor (Rae et al., 1998) thereby equalising its antioxidant effects
across the whole corpus luteum. When the progesterone concentration of the entire
corpus luteum falls below a minimum threshold, oxygen free radicals generated by
PGF2a (Riley and Berhman, 1991; Sawada and Carlson, 1991) initiate apoptosis
(Tilly and Tilly 1995; Haecker and Vaux, 1994).
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3.2.8 Limitations of the Systems Used to Detect Apoptosis
The absolute quantification of apoptosis requires tissue-specific information about
the time taken to form apoptotic bodies, and the length of time apoptotic bodies
persist in the tissue being examined. Duration of apoptosis as measured from
induction to fragmented nuclei is 50 minutes in CD4+ T lymphocytes (Howie et al.,
1994) and 10 minutes in liver hepatocytes (Bursch et al., 1990). The duration of
luteal cell apoptosis has yet to be elucidated and requires the collection of corpora
lutea at consecutive time points after induction of luteolysis.
The length of time apoptotic bodies remain in luteal tissue is dependent upon three
factors; the integrity of the vasculature (O'Shea et al., 1977), on blood flow, which
decreases after functional regression (Bruce and Hillier, 1974; Niswender et al., 1976;
Bruce and Moor, 1976; Dharmarajan et al. ,1994) and on the influx of immune
system cells capable of phagocytosing apoptotic bodies (Lei et al., 1991). None of
these factors have been examined in marmoset corpora lutea.
The assumption that one cluster of apoptotic bodies originated from the
fragmentation of one cell may have been another source of error. Clusters of
apoptotic bodies were often seen within the vasculature, which raised the possibility
that they did not occur in situ, but were transported there. A cluster of apoptotic
bodies, therefore, may have reflected an obstruction in the vasculature and the build
up of apoptotic bodies which originated from a number of different cells.
The three methods used to detect apoptosis were complimentary to each other. The
identification of apoptotic bodies and condensed cells with clearly fragmented nuclei
in H&E stained sections was relatively simple and certainly inexpensive, but led to
possible underestimation because cells in the earlier stages of apoptosis, or cells
which were apoptotic but had not undergone nuclear fragmentation, were not
counted. In situ 3' end labeling probably identified more cells in the earlier stages of
apoptosis than were identified in H&E stained sections, but on the other hand may
also have given a falsely high score for apoptosis due to the labeling of randomly
fragmented necrotic DNA. The vacuolation of steroidogenic cells during luteal
regression may have been indicative of a non-apoptotic form of cell death which
eventually resulted in random, non-specific DNA fragmentation characteristic of
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necrosis. Necrotic cells would be 3' end labeled, and impossible to distinguish from
apoptotic cells in which the nucleus had not fragmented. Since electrophoresis of
luteal DNA revealed the presence of necrotic DNA, the occurrence of false positives
in the 3' end labeled sections was a distinct possibility. However, neither analysis of
H&E sections or electrophoresis of luteal DNA falsely identified necrotic cells or
DNA as apoptotic.
The number of 3' end labeled cells was also highly dependent upon the concentration
and duration of the proteinase K incubation, and on the nature of the tissue being
examined. In this study these parameters were optimised to achieve the amount of
positive 3' end labeling reported in healthy and atretic follicles (Giebel et al., 1997;
Tilly et al 1991; Billig et al, 1993; Tilly, 1993; Hsueh et al., 1994), and to slightly
under-label (90-98%) DNase positive controls. Under-labeling introduced a tendency
to underestimate the amount of apoptosis, and it is possible that this counteracted the
labeling of false positives, resulting in a final score for apoptosis in 3' end labeled
sections which was remarkably close to that obtained by analysis of H&E stained
sections. The persistence of apoptotic bodies within luteal tissue may have
contributed to an overestimation of apoptosis by all three methods.
Although electrophoresis of extracted DNA differentiated unequivocally between
necrotic and apoptotic DNA, quantification of oligonuclesome formation was highly
variable. This variability might have been decreased if aspects of the technical
procedure had been improved. One source of inaccuracy may have been inaccurate
determinations of DNA concentrations by comparison with lambda DNA standards.
Accuracy could have been improved by introducing a step to remove RNA from each
sample, which would have allowed spectrophometric determination of DNA
concentrations. Reprecipitation of labeled DNA would have improved sample
quality, and perhaps improved the correlation between amount of radioactivity in
genomic DNA and the concentration of genomic DNA. The quantification of
electrophoresed oligonucleosomes would also have been improved by counting the
radioactivity in each sample, and loading the same amount of radioactivity in each
lane. Most of the variation was probably due to inter-animal variation; each sample
came from a single corpus luteum from one animal. Corpora lutea can be formed at
20 hour intervals within the same cycle (Torii et al., 1996; Oerke et al., 1996), and
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our cycle tracking regime was accurate ±24 hours, therefore there may have been up
to 50 hours age difference between corpora lutea when they were subjected to
luteolytic treatments. Individual animal variation of age, weight and status would
have added to this variation. The variability due to different ages of corpora lutea
may have been decreased by analysing oligonucleosome formation in multiple
corpora lutea from each animal, and deriving a mean luteal score for each animal, as
was done for the in situ analyses of apoptosis.
3.2.9 Ubiquitin Expression During Luteal Regression.
Ubiquitin was upregulated in the cytoplasm of steroidogenic cells after PGF2a
induced luteolysis in the marmoset. GnRH antagonist induced luteolysis did not
cause an increase in ubiquitin expression. Since both in situ 3' end labelling and
oligonucleosome formation characteristic of apoptotic DNA fragmentation were
increased after induced luteal regression with both PGF2a and GnRH antagonist,
ubiquitin expression is probably unrelated to apoptosis in marmoset luteal regression.
Ubiquitin was found in the nuclei of a small number (how many?!!) of mid luteal
phase steroidogenic cells, and 0.67+0.427% steroidogenic cells were 3' end labeled
in situ at this time, suggesting that nuclear ubiquitin may be related to apoptosis
during the mid luteal phase. However it is also possible that it is playing a role in
transcription and cell cycle protein regulation (Levinger and Varhavsky, 1982;
Huang et al., 1986). Ubiquitin was also found in the cytoplasm of parenchymal luteal
cells 24 hours after induction of luteolysis with PGF2a. The shift from nucleus to
cytoplasm and the increase in number of cells expressing ubiquitin suggests that
ubiquitin plays different roles pre and post luteolysis, and may be involved in
cytoplasmic proteolysis or protein regulation during PGF2a-induced luteal
regression. Murdoch et al (1996) reported an increase in luteal ubiquitin mRNA and
protein as quickly as two hours after administration of a luteolytic dose of PGF2a to
ewes, which implicated ubiquitin in functional luteal regression, since structural
regression did not begin until at least 16 hours after administration of PGF2a. This,
however, does not preclude ubiquitin from also playing a role in structural
regression. Ubiquitin immunoreactivity was not found in any animal subjected to
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GnRH antagonist-induced luteolysis. It is possible that ubiquitin expression occurred
at an earlier time point and may be involved in functional luteal regression in GnRH
antagonist treated animals, but these data suggest that it did not play a role in
structural regression. Ubiquitin expression in luteal cells therefore may be a response
to PGF2a. Only cells with PGF2a receptors expressed ubiquitin in sheep corpora
lutea, and luteal ubiquitin expression may not be specific for luteolysis but be part of
a response to cellular stress in which ubiquitin is coexpressed with heat shock
protein-70 (Murdoch et al., 1995) which is also upregulated after PGF2a induced
regression in rats (Kanna et al., 1995).
Ubiquitin has been shown to be upregulated during apoptosis in a number of systems
(Haas et al., 1996; Myer and Schwartz, 1996; Lauzon et al., 1993; Sandri et al., 1997;
Delic et al., 1993) but there does not seem to be a relationship between ubiquitin
expression and apoptosis during luteal regression in the marmoset. Cells expressing
ubiquitin in PGF2a treated animals did not have the same morphology as 3' end
labeled cells in serial sections; ubiquitin positive cells appeared to be dying by a non-
apoptotic pathway. In addition to this, oligonucleosome formation indicative of
apoptosis occured 24 hours after administration of GnRH antagonist, but this was not
coincident with ubiquitin expression in these animals.
3.2.11 Summary.
In summary, 3p HSD immunocytochemistry facilitated the identification of
steroidogenic cells, and therefore also allowed all other cells to be defined as
nonsteroidogenic cells. It also indicated that luteal regression is not instigated by the
loss of 3p HSD enzyme because it was found to be present in functionally regressing
corpora lutea, and because it persisted in luteal tissue until after functional regression
was completed.
Structural luteal regression was characterised primarily by cell death. Steroidogenic
cell death occurred by two different processes; apoptosis, and a process which
resulted in vacuole formation in the cell. Vacuolisation may be due to the
accumulation of lipids in spontaneously regressing marmoset corpora lutea, but
steroidogenic cell vacuoles do not contain lipid in corpora lutea subjected to
178
induction of regression by the administration of luteolytic agents. It is possible that
steroidogenic cell vacuole formation after induced luteal regression may be a
consequence of impaired osmotic control, membrane perturbation and subsequent
cell oedema.
Nonsteroidogenic cell numbers did not appear to change during functional luteal
regression, but did appear to increase during structural luteal regression. However, it
is still not known how different populations of nonsteroidogenic cells are affected by
luteal regression. This information could be obtained by performing
immunocytochemistry with specific markers for endothelial cells, fibroblasts and
macrophages. It is also unclear whether increases in nonsteroidogenic cell numbers
during structural regression are a result of proliferative increases, or are a
consequence of the dynamics of shrinking tissue. This issue could be resolved by
determining the number and the type of cells undergoing proliferation in regressing
corpora lutea.
apoptosis occurs in regressing marmoset corpora lutea as shown by morphological
analysis, by 3' end labeling and by gel electrophoresis of extracted DNA. Apoptosis
occurs in both steroidogenic and non-steroidogenic cells after peripheral
progesterone concentrations have fallen to follicular phase values in naturally
regressing corpora lutea and in corpora lutea induced to undergo regression with
PGF2a or GnRH antagonist. Ubiquitin is expressed in the nuclei of a small number
of mid luteal phase day 10 steroidogenic cells, and in the cytoplasm of steroidogenic
cells after PGF2a induced luteal regression, but is not expressed in luteal cells after a
luteolytic dose of GnRH antagonist. Induced luteolysis with both PGF2a and GnRH
antagonist is associated with an increase in apoptosis, but ubiquitin expression is not
an indicator of apoptosis in the corpus luteum of the marmoset monkey.
3.2.12 Conclusions.
Marmoset luteal cells were identified as being either steroidogenic or
nonsteroidogenic. The number of steroidogenic cells decreased as luteal regression
proceeded. Steroidogenic cell numbers were depleted by the occurrence of two
different processes; apoptosis, and the formation of cytoplasmic vacuoles.
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Nonsteroidogenic cell numbers remained constant during the luteal phase and
functional luteal regression, but apparently increased during structural luteal
regression. It appears that changes in steroidogenic cell numbers precede changes in
nonsteroidogenic cell numbers in luteal regression. The decline in progesterone
production during functional luteal regression is not bought about by the apoptotic
deletion of steroidogenic cells. Apoptosis in primate corpora lutea occurs after
functional luteal regression is completed and is characteristic of structural luteal
regression.
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Chapter 4: The Vasculature of the Corpus Luteum.
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4.0 Introduction
Morphological analysis of H&E stained sections of marmoset corpora lutea indicated
that the number of nonsteroidogenic cells did not change during the luteal phase or
functional luteal regression, but increased during structural luteal regression (see
chapter 3). The nonsteroidogenic cells of the corpus luteum are primarily endothelial
cells, fibroblasts, and immigrant cells of the immune system. Quantification of
nonsteroidogenic cell numbers may not reflect changes in individual sub-populations
of nonsteroidogenic cells. Further examination of nonsteroidogenic cells can be
facilitated by specific identification of one or more of these types. Approximately
50% of the cells in the corpus luteum are endothelial cells (Lei et al., 1991;
Christenson and Stouffer, 1996), and an extensive capillary network penetrates the
corpus luteum, so much so that every steroidogenic cell is in contact with at least one
capillary (Redmer and Reynolds 1996). The primary function of the corpus luteum is
the production of steroid hormones, and steroidogenesis is entirely dependent upon
the delivery of cholesterol substrates and regulatory gonadotrophins through the
vasculature, and peak progesterone production does not occur until the luteal
vasculature is fully developed. Early luteal phase corpora lutea cultured in vitro and
stimulated with gonadotrophins secrete more progesterone than mid and late luteal
phase corpora lutea (Hild-Petito et al., 1989), but maximal secretory activity does
not occur in vivo until the mid luteal phase, and it is thought that this is due to
inadequate development of the luteal vasculature in the early luteal phase (McClellan
et al., 1975). It is believed that the vasculature is absolutely vital to normal
functioning of the corpus luteum, but it is not clear what role it plays in luteal
regression. It is not known whether changes in the vasculature, or changes in blood
flow, precede functional luteal regression in the primate, and neither is it clear when
or how the vasculature changes during the process of structural regression.
4.0.1 Blood Flow in the Corpus Luteum.
Blood flows through the corpus luteum at the rate of approximately 10 - 15 ml per
minute per gram of tissue (Abdul-Karim and Bruce 1973; Bruce and Moor 1976) and
this rate of flow is higher than that to any other organ of the body; flows of 0.61,
182
1.86, and 1.78 ml per minute per gram of heart, brain and kidney respectively have
been observed (Bruce and Moor, 1976). Within the ovary rates of blood flow are
2.66 and 6.68 ml per minute per gram of stroma or follicles respectively, showing
that blood flow to the follicles is of the same order as that seen to corpora lutea
(Bruce and Moor, 1976). It is not known why blood flow through the corpus luteum
is so much higher than through other tissues. Blood flow to the ovary bearing the
corpus luteum, and also through the corpus luteum, decreases as the luteal phase
advances (Niswender et al., 1976; Bruce and Moor, 1976) and studies utilising
radioactive microspheres indicate that approximately 90% of the blood flowing to
the ovary goes through the corpus luteum during the mid luteal phase (Niswender et
al., 1976; Abdul-Karim and Bruce, 1973), but that this decreases to 28% in the late
luteal phase (Bruce and Moor, 1976), which indicates that a mechanism for reducing
luteal blood flow exists, and an arteriole-venule shunting system which results in
reduced blood flow to individual steroidogenic cells has been proposed (Niswender
et al., 1976).
4.0.2 Effects of Luteolytic Agents on Luteal Blood Flow.
LH may have effects on luteal blood flow. Administration of anti-LH antibodies to
sheep causes a decrease in serum progesterone levels and a concomitant decrease in
blood flow to the ovary, and infusion of additional LH causes an increase in serum
progesterone levels and an increase in blood flow (Niswender et al., 1976) but the
temporal relationships between changes in steroid hormone production and changes
in luteal blood flow are unclear. Administration of PGF2a in vivo to rabbits does
not, however, cause a decreased blood flow to the corpora lutea until 6 hours after a
significant decrease in plasma progesterone concentration has occurred (Bruce and
Hillier, 1974), so the luteolytic action of PGF2a is unlikely to be mediated by
reduced blood flow. It does, however, appear to be mediated by endothelial cells
because steroidogenesis was not inhibited by PGF2a in pure cultures of bovine
luteal steroidogenic cells, but steroidogenesis was inhibited in mixed cultures of
endothelial and steroidogenic cells (Girsh et al., 1995). Disruption of the vasculature
also prevents the luteolytic effect of PGF2a on dispersed rat or dispersed marmoset
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luteal cells in vitro (Thomas et al., 1978; Webley et al., 1989). In addition, PGF2a
has longer term effects on luteal vasculature; 24 hours after in vivo administration of
PGF2a to sheep 28% of endothelial cells were morphologically abnormal and
capillary lumina were occluded with cellular debris (Sawyer et al., 1990; Stacey et
al., 1976). It has also been suggested that vascular occlusion during luteal regression
could result in hypoxic conditions, and that ischemia could therefore be a component
of structural luteal regression.
4.0.3 The Morphology of Luteal Vasculature.
A number of studies have quantified different cell types of the corpus luteum. In one
study, the cellular composition of sheep corpora lutea was determined by a 'hit'
technique whereby luteal components were classified as large or small luteal cells,
capillaries or connective tissue. The number of 'hits' in endothelial cells or capillary
lumina decreased by approximately 50% from the mid to late luteal phase, but the
number of 'hits' in leukocytes and in intracapillary debris increased during the same
time period, while connective tissue quantification remained constant (Niswender et
al., 1976). The decrease in the number of endothelial cell 'hits' occurred before
serum progesterone levels decreased, suggesting that changes in luteal vasculature
may instigate functional regression. The majority of workers, however, have found
that in ruminants structural changes are first seen in the vasculature concomitant
with falling serum progesterone values, and that during luteal regression there
appears to be a change in the vasculature bought about by the loss of small
capillaries and an increase in larger microvessels (Zheng et al., 1993; Redmer and
Reynolds 1996). The mid-phase bovine corpus luteum has a dense capillary network
made up of fully differentiated endothelial cells with a flattened elongated
morphotype and numerous tight junctions (Modlich et al., 1996). Early luteal
regression is characterised by the dissociation of endothelial tight junctions,
widening capillary basal lamina and disruption of osmotic regulation. Endothelial
cell nuclei condense and may fragment in a process which closely resembles the
initial stages of apoptosis, and the cells then slough off into the lumen of the blood
vessel, so forming localised blockages. This loss of endothelial cells further perturbs
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the integrity of capillary basal lamina and accelerates the loss of osmotic
equilibrium. Occlusion of the capillaries may also cause ischemia. Parenchymal
steroidogenic cells then undergo degenerative changes, either by the formation of
vacuoles, or by apoptosis. The loss of steroidogenic cells appears to be accompanied
by the loss of small capillaries and their replacement with larger microvessels, and
late structural regression is also characterised by a-smooth muscle-actin positive
myofibroblast proliferation, which results in the formation of contractile layers
around arterioles and small arteries with consequent vasoconstriction and additional
detachment of endothelial cells from the basement membrane. This results in further
protrusion of endothelial cells into the lumina of small blood vessels, and the
eventual occlusion of the vasculature in very late regressing corpora lutea so that the
resulting corpus albicans is formed predominantly of fibroblasts and endothelial cells
(Deane el al., 1966; O'Shea el al., 1977; Modlich el al., 1996).
4.0.4 Vascular Endothelial Growth Factor.
The growth and development of blood vessels is controlled by a number of
angiogenic factors, one of which, Vascular Endothelial Growth Factor (VEGF), is a
secreted heparin-binding endothelial mitogen and is also an important regulator of
luteal vascular development (Redmer and Reynolds, 1996). Endothelial cells isolated
from macaque corpora lutea respond to VEGF in vitro by proliferating (Christenson
and Stouffer, 1996) and VEGF has also been found in the corpus luteum of the pig
(Ricke et al., 1995), sheep (Doraiswamy et al., 1995a), cynomolgus monkey
(Ravindranath et al., 1992), rat (Phillips et al., 1990), mouse (Shweiki et al., 1993)
and human (Gordon et al., 1996; Kamat et al., 1995). In bovine corpora lutea, the
highest levels of VEGF mRNA are found in the early luteal phase and a gradual
reduction then occurs throughout the remainder of the luteal phase (Redmer et al.,
1996). VEGF mRNA levels are also reduced by luteolytic treatment with GnRH
antagonist, although it took three days for this response to occur (Ravindranath et al.,
1992). VEGF has been immunohistochemically located to vascular pericytes in
ovine corpora lutea but does not appear to be expressed by endothelial, small or large
luteal cells in this species (Redmer and Reynolds, 1996), however VEGF has been
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detected by immunocytochemistry in follicular cells and in granulosa-lutein and
theca-lutein in the human (Gordon et ah, 1996; Kamat et al., 1995). It would appear
that while VEGF is likely to be the principal regulator of angiogenesis in the ovary,
much has still to be learned about changes in expression and its role during follicular
development. In addition, studies on its localisation within the corpus luteum seem
to suggest species differences and variation in results between laboratories.
The VEGF receptor, Flt-1, is a tyrosine kinase cell membrane receptor, and it was
hypothesised that it might be expressed by endothelial cells in the corpus luteum
(Jakeman et al., 1992; Shweiki et al., 1993).
4.0.5 Aims
The aims of this study were to examine luteal vasculature and to characterise
relationships between vascular changes and luteolysis. Specific aims were to: (i)
quantify non-steroidogenic cell numbers throughout the luteal phase and after
spontaneous and induced luteal regression, (ii) to identify endothelial cells and
quantify endothelial cell numbers throughout the luteal phase and after spontaneous
and induced luteal regression and (iii) to examine the morphological distribution and
temporal changes in VEGF in the marmoset corpus luteum.
4.1 Results
4.1.1 Identification of Endothelial Cells using Von Willebrand
Factor VIII Antigen (vW).
Ovarian sections subjected to immunocytochemistry with antibodies against von
Willebrand Factor VIII antigen (vW) had specific immunoreactivity around lumina
containing red blood cells, and there was also vW immunoreactivity which
delineated smaller vessels which did not contain erythrocytes (Figure 4.1). There was
no vW immunoreactivity in steroidogenic cells, nor in negative control sections
(Figure 4.1), although there was some non-specific staining in the cytoplasm of
steroidogenic cells when DAB was used in the visualisation procedure. The vW
staining was quite diffuse, and masked individual cell nuclei. In addition the trypsin
186
incubation compromised cellular morphology, and both these factors made it difficult
to count individual vW positive endothelial cells, therefore measurement of area of
staining was considered to be more accurate than attempting to count individual
endothelial cells in these sections. Antigen retrieval techniques utilising microwave
irradiation destroyed the vW antigen.
The pattern of vW staining during the early and mid luteal phases was consistent
with an extensive capillary network in which every steroidogenic cell was in contact
with the vasculature (Figure 4.1a and b). Blood vessels were generally too small in
section to be able to see red blood cells. This pattern changed in late regressing
corpora lutea, and was characterised by a decrease in capillary staining and an
increase in staining of small arterioles and venules in which erythrocytes were
frequently identified (Figure 4. Id). The pattern of vW immunoreactivity after
induced regression was slightly different from that seen in spontaneously regressing
corpora lutea (Figure 4. If and g). There was a greater range of blood vessel size,
with some sections having predominantly small capillaries simular to those seen in
untreated mid luteal phase corpora lutea, and others having a combination of small
capillaries and dilated blood vessels. Corpora lutea collected 24 hours after treatment
with PGF2a or GnRH antagonist did not have the same vascular formation as
spontaneously regressing corpora lutea, although the corpora lutea treated with
luteolytic agents, and the untreated regressing corpora lutea were equivalent to each
other inasmuch as serum progesterone concentrations were at baseline levels.
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Figure 4.1: Von Willebrand Factor VIII Antigen (vW)
Immunocytochemistry in Marmoset Corpora Lutea.
Ovaries collected on (a) luteal days 2-5, (b) luteal day 10,
(c) luteal day 18 (functional luteal regression) and (d)
luteal days 22-25 (structural luteal regression). Panel (e) is
a serial section of (b) and is a representative example of
antibody negative control sections. The corpus luteum
shown in panel (f) was obtained 24 hours after in vivo
administration of the luteolytic agent PGF2a analogue,
cloprostenol, and (g) shows luteal tissue 24 hours after in
vivo administration of GnRH antagonist. Specific vW
immunostaining is either red-pink or brown-black, and is
localised between rounded steroidogenic cells. All pictures




4.1.2 Quantification of vW Immunoreactivity After Spontaneous
Luteal Regression.
Area of immunoreactive vW staining in the early luteal phase (52151371pm , n=4,
Figure 4.2) was significantly higher than at all other stages of the cycle (Luteal days
6-8, 21591465, p<0.01, Luteal day 10, 35171491, p<0.01, Luteal day 18, 34621420,
p<0.01, Luteal days 20-24, 4060+191, p<0.05) and area of staining decreased
gradually until luteal day 18. Area of vW immunoreactivity did not change as
progesterone levels fell to follicular phase values (40601191, n=3). Two animals
from which corpora lutea were collected on luteal days 25-28, however, had 2040
and 2101pm2 of vW immunoreactivity respectively, which suggests that loss of the
vasculature may be the last thing to occur in structural luteal regression (Figure 4.2).
The pattern of vW staining in the early and mid luteal phases was consistent with an
extensive capillary network in which every steroidogenic cell was in contact with the
vasculature to a pattern in structurally regressing corpora lutea characterised by a
decrease in capillary staining and an increase in staining of small arteries and veins.
This was quantified by expressing the area of vW immunoreactivity as a percentage
of the total area of luteal tissue in order to derive an approximate measure of the
luteal volume occupied by the vasculature. In the early luteal phase the vasculature
occupied 7.1310.5% of the volume of the corpus luteum. By the mid luteal phase this
had decreased to 4.8110.67%, and this was sustained during functional luteal
regression (4.7310.57%, n=3). Structural luteal regression, however, was associated
with an increase in vascular volume (5.5510.26%, n=3).
4.1.3 Quantification of vW Immunoreactivity After Induced Luteal
Regression.
Induction of luteolysis resulted in an increase in the area of vW immunoreactivity
(Figure 4.3), from 416711130pm (n=3) in mid luteal phase corpora lutea to
883511218pm2 (n=3, p<0.05) 12 hours and 840311607 (n=4, p<0.05) 24 hours after
administration of GnRH antagonist. Induction of luteolysis with PGF2a did not
result in a significant increase in vW immunoreactive staining either 12 (430711765,
n=3) or 24 (598111307, n=4) hours after luteolytic treatment.
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Figure 4.2: Area of Endothelial Cell Specific Staining
in Marmoset Corpora Lutea.
Histogram showing area of von Willebrand Factor VIII
Antigen (vW) specific immunostaining in marmoset
corpora lutea. Ovaries containing corpora lutea were
collected on luteal days 2-5 (early, n=4), luteal day 10
(mid, n=4), luteal day 18 (functional luteal regression,
n=3), luteal days 22-25 (structural luteal regression, n=3)
and luteal days 25-28 (late structural regression, n=2). The
total area of vW specific immunostaining per 31400pm
unit area of luteal tissue was determined for each corpus
luteum, and shown as mean±SEM for each stage of the
luteal phase. Data were subjected to one way analysis of
variance. The area of vW immunostaining per unit area
measured during the early luteal phase was significantly
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Figure 4.2: Endothelial Cell Specific Staining in Marmoset Corpora Lutea
Figure 4.3: Area of Endothelial Cell Specific Staining
in Marmoset Corpora Lutea After Induced Luteal
Regression.
Histogram showing area of von Willebrand Factor VIII
Antigen (vW) specific immunostaining in marmoset
corpora lutea. Ovaries containing corpora lutea were
collected on luteal day 10 (control, mid luteal, n=3), 12
hours (PG12, n=3) and 24 hours (PG24, n=4) after in vivo
administration of the PGF2a analogue, cloprostenol, and
12 hours (Gnl2, n=3) and 24 hours (Gn24, n=4) after in
vivo administration of a GnRH antagonist, anterelix.
Luteolytic agents were administered on luteal day 9, 24
hours before collection on luteal day 10. The area of vW
immunostaining per 31400pm" unit area of luteal tissue
was determined for each corpus luteum. The area
(mean+SEM) of vW immunostaining 12 and 24 hours
after induction of luteolysis with GnRH antagonist was
significantly higher than the area of vW immunostaining
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Figure 4.3: Endothelial Cell Specific Staining in Marmoset
Corpora Lutea After Induced Luteal Regression.
4.1.4 Vascular Morphology During the Luteal Phase and
Spontaneous Luteal Regression.
Luteal vascualture was further examined by determining the number of discrete areas
of vW immunostaining at each stage of the luteal phase, and using the assumption
that each discrete area of vW immunostaining represented one blood vessel (Figure
4.4). The number of blood vessels per unit area appeared to be highest during the
early luteal phase, decreased to a baseline level, then increased gradually during the
remainder of the luteal phase. However, the number of individual blood vessels then
decreased markedly as structural luteal regression progressed, as would occur if
numerous small capillaries were replaced by lower numbers of larger blood vessels.
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Figure 4.4: The Relationship Between Luteal Age and
the Number of Blood Vessels in Marmoset Corpora
Lutea.
Each data point (A) represents the number of distinct
'y
areas of von Willebrand immunostaining per 31400pm
unit area of luteal tissue from one animal. Ovaries
containing corpora lutea were collected on luteal days 2-5
(early, n=3), luteal day 10 (mid, n=4), luteal day 18
(functional luteal regression, n=4), luteal days 22-25
(structural luteal regression, n=3) and luteal days 25-28
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Figure 4.4: Relationship Between Luteal Age and the Number of Blood
Vessels in Marmoset Corpora Lutea.
4.1.5 Further Techniques for Identification of Endothelial Cells
Since vW ICC obscured endothelial cell morphology, attempts were made to
establish an alternative method of endothelial cell identification. Unfortunately these
were unsuccessful, and these negative data are reported here briefly.
An antibody against the lectin, Ulex europaeus agglutinin-1 (UEA-1), which binds a
sugar found only on primate endothelial cells (Christenson and Stouffer, 1996), was
not available for this study, so another lectin, Griffonia (Bandeiraea) simplicifolia
lectin I, isolectin B4 (Vector Laboratories, Peterborough, UK) was used instead. It is
a specific endothelial cell marker in mouse, rat and sheep. However, staining in
sections of sheep pituitary was inconsistent and not reproducible, and no staining at
all occurred in marmoset corpora lutea.
A rat anti mouse monoclonal antibody against CD31/PECAM was kindly donated by
Dr Annunciata Vecchi (Istituti di Ricerche Farmacologiche <Mario Negri>, Italy).
This antibody was found to identify mouse blood vessel endothelial cells (Vecchi et
al., 1994) and we were also informed that it had affinity to endothelial cells in
marmoset uterus (Dr Roy Bicknell, Oxford University, pers comm.). The method
used was similar to vW ICC with the exception that the hybridoma supernatant was
used at a dilution of 1:4 or less, and the secondary antibody was biotinylated goat
anti rat (DAKO, High Wycombe, UK). Both human and marmoset cryostat and
paraformaldehyde fixed sections were subjected to this ICC protocol, but no
immunoreactivity was observed in any of these. Future work could examine (a) the
efficacy of different antigen retrieval systems, (b) Apply Dr Vecchi's protocol to her
mouse sections in our laboratory, and also determine whether our marmoset sections
processed in the laboratory of Dr Vecchi or Dr Bicknell display CD 31
immunoreactivity, since the antibody may have been inactivated during
transportation to our laboratory and (c) include mouse positive control sections in
our procedure.
Periodic Acid-Schiff procedures stain epithelial mucins (Culling, 1974) and have
been used as markers for blood vessels. Accordingly marmoset, macaque and human
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paraformaldehyde fixed luteal sections were brought to water, incubated with 1%
periodic acid for 5 minutes at room temperature, washed with water for 5 minutes
before staining with Schiffs reagent for 15 minutes at room temperature. The
sections were then washed and counterstained with haematoxylin before mounting.
This procedure was repeated a number of times with minor changes to incubation
times and reagents, but the results were always identical. Some blood vessels
containing erythocytes did stain brilliant pink in each section, but intra and inter¬
section staining was very variable, and not all blood vessels stained positive. In
addition, the membranes of luteal steroidogenic cells stained pink, and small patches
of stroma also had vibrant positive staining, therefore it was concluded that the
method was not specific for luteal blood vessels.
Antibodies against the antigen CD34 are commonly used to identify endothelial
cells. Although CD34 ICC successfully identifies endothelial cells in human corpora
lutea in our laboratory, the same procedure does not immunolocalise endothelial
cells in marmoset corpora lutea (Dr. Hamish Fraser, pers. comm.).
4.1.6 Immunolocalisation of Vascular Endothelial Growth Factor
(VEGF).
Specific immunoreactivity for VEGF was found in the cytoplasm of luteal
steroidogenic cells (Figure 4.5), but not in any other luteal cell type, nor in negative
control sections (Figure 4.5 inset, and Figure 4.6b). Oocytes were immunopositive,
and theca and granulosa cells in atretic follicles were weakly immunopositive, but
theca and granulosa cells in morphologically healthy follicles were VEGF
immunonegative (Figure 4.5). The majority of steroidogenic cells in corpora lutea of
the early luteal phase had positive VEGF immunoreactivity (Figure 4.6a and c), and
intensity of staining was fairly uniform throughout each corpus luteum. Both the
number of immunopositive steroidogenic cells and the uniformity of staining
decreased as the luteal phase proceeded, so that by luteal day 18 scattered
immunopositive cells had weak to intense staining (Figure 4.6d and e). After
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progesterone values had fallen to follicular phase values, however, intensity of
staining appeared to increase, although the volume of steroidogenic cells also
decreases at this time and staining intensity appeared to increase as amount of
cytoplasm decreased (Figure 4.6f and g). The number of immunoreactive
steroidogenic cells increased 12 hours after luteolysis was induced with either
PGF2a or GnRFI antagonist (Figure 4.7c and d respectively), but decreased to levels
simular to those seen in spontaneously regressing corpora lutea 24 hours after
luteolytic treatment (Figure 4.7e and f)
4.1.6.1 A Receptor for VEGF, Flt-1.
Only two sections showed positive staining for Flt-1, the naturally regressing corpus
luteum collected on day 18 of the luteal phase, and the corpus luteum collected 12
hours after regression was induced with GnRH antagonist. Flt-1 immunoreactivity
was expressed exclusively in large blood vessels within the corpus luteum. Flt-1
immunoreactivity was not found in marmoset corpora lutea at any other stage of the
luteal phase, and neither was it found in mid luteal phase human tissue. Flt-1
immunoreactivity was also absent from negative control sections.
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Figure 4.5: Vascular Endothelial Growth Factor
(VEGF) Immunolocalisation in Mid Luteal Phase
Marmoset Corpus Luteum.
Ovary obtained on luteal day 10 and steroidogenic cell
cytoplasm shows brown VEGF immmunoreactivity. Cell
nuclei counterstained with haematoxylin. Inset is the
antibody negative control serial section for the main
picture. Scale bar represents 20pm.
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Figure 4.6: Vascular Endothelial Growth Factor
(VEGF) Immunolocalisation Throughout the Luteal
Phase of the Marmoset.
Luteal days 2-5 are shown in (a) and (c), (b) is a serial
section of (a) and is a representative example of antibody
negative control sections. Luteal day 18 demonstrating
functional luteal regression is shown in (d) and (e). (f) and
(g) were obtained on luteal days 22-25 and are examples
of structural luteal regression, (h) is the antibody negative
control serial section of (g) and shows luteal tissue
surrounded by developing follicles. Each picture is from a
different animal, unless otherwise stated. VEGF




Figure 4.7: Vascular Endothelial Growth Factor
(VEGF) Immunolocalisation During Induced Luteal
Regression.
Ovaries collected on (a) luteal day 10, (b) antibody
negative control serial section of (d). The corpus luteum
shown in panel (c) was obtained 12 hours after PGF2a
analogue and (d) shows luteal tissue 12 hours after GnRH
antagonist, (e) and (f) are corpora lutea collected 24 hours
after in vivo administration of PGF2a and GnRH
antagonist respectively. Specific VEGF immunostaining is
red-brown and is localised to the cytoplasm of luteal
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4.2 Discussion
This study has demonstrated for the first time that there are structural changes in the
vasculature during the luteal phase of the primate, and has determined the temporal
and morphological distribution of proliferating cells in the marmoset corpus luteum,
particularly during luteal regression.
4.2.1 Comparison of Nonsteroidogenic and Endothelial Cell
Numbers in Corpora Lutea.
The proportion of non-steroidogenic cells in marmoset corpora lutea is lower than in
other species. During the mid luteal phase 69±0.7% and 60±0.3% of all luteal cells
are non-steroidogenic in human and bovine corpora lutea respectively (Lei et al.,
1991), but at the equivalent time in the marmoset luteal phase non-steroidogenic
cells comprise 48±3% of the corpus luteum. Lei et al (1991) found that the
proportion of non-steroidogenic cells increases by approximately 20% as luteal
regression proceeds, and we found an increase of the same order during spontaneous
luteal regression in the marmoset. Changes in the vasculature after induced luteal
regression, however, were different from those observed in naturally regressing
corpora lutea. Administration of GnRH antagonist resulted in an initial reduction in
nonsteroidogenic cell numbers to 36±7% twelve hours after the treatment followed
by an increase to 47±10% 24 hours after the treatment, similar to the proportion of
non-steroidogenic cells which is found in untreated luteal day 10 corpora lutea.
There was no change in the proportion of non-steroidogenic cells 12 or 24 hours
after administration of PGF2a.
The percentage area of luteal section immunopositive for von Willibrand Factor
VIII, a specific endothelial cell marker, followed the same pattern as non¬
steroidogenic cell numbers in naturally regressing corpora lutea, both numbers
increased as spontaneous regression proceeded. The area of vW immunopositivity
increased significantly, however, both 12 and 24 hours after administration of GnRH
antagonist. There are two possible explanations for this situation in which the
percentage of non-steroidogenic cells remained constant but the area of endothelial
cell-specific staining increased; (1) The percentage of non-steroidogenic, non-
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endothelial cells such as macrophages or fibroblasts decreased, so that a greater
proportion of the non-steroidogenic cells counted were endothelial cells and (2) the
area occupied by individual endothelial cells increased, perhaps owing to decreased
numbers of steroidogenic cells.
4.2.2 Effects of Administration of Luteolytic Agents on Luteal
Vasculature.
The administration of luteolytic agents did not appear to have major effects on luteal
vasculature. The significant increase in the area of vW immunoreactive staining after
administration of GnRH antagonist can probably be attributed to the dynamics of
shrinking tissue. In this scenario the steroidogenic cells died as a result of GnRH
antagonist induced LH-depletion, and blood vessels were therefore able to move
closer together thus resulting in increased numbers of blood vessels in each unit area.
There was also a slight, non-significant increase in the area of vW immunostaining
after administration of PGF2a, and this was of a similar order to that seen during
spontaneous regression. Increases in endothelial cell numbers can be attributed
partially to the remaining blood vessels moving closer together as the regressing
luteal tissue decreases its size, but increases may also be due to proliferation of
endothelial cells, so it would be advantageous to study rates of cell proliferation in
order to differentiate between these two effects.
PGF2a has no effect on luteal blood flow (Bruce and Hillier, 1974), and the absence
of change to non-steroidogenic or endothelial cell numbers after administration of
PGF2a supports the hypothesis that the luteolytic effect of PGF2a is not mediated
directly by changes to the vasculature, and also leaves open the possiblility that
PGF2a acts by stimulating the production of oxygen free radicals. In fact PGF2a
may have a number of overlapping luteolytic effects. It may initially instigate
functional luteal regression by stimulating the generation of hydrogen peroxide in
the corpus luteum (Riley and Behrman, 1991) which may trigger off a cascade of
oxygen free radical reactions which inhibit steroidogenesis in a very short period of
time. Hydrogen peroxide also induces partial endothelial cell detachment (Bradley et
ah, 1995), and endothelial cell detachment has been observed during early luteal
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regression in ruminants. PGF2a also stimulates luteal endothelial cells to produce
endothelin-1, which in turn stimulates vasoconstriction. In addition, PGF2a
stimulates bovine luteal steroidogenic cells to produce oxytocin, which further
stimulates endothelial cell production of endothelin-1 in a feedback mechanism
(Girsh et al., 1996). The combination of vasoconstriction and vascular occlusion
afforded by endothelial protrusion into vascular lumina may create hypoxic
conditions which contribute to progressive degeneration of the parenchymal
steroidogenic cells. In addition to this, Modlich et al (1996) found that late luteal
regression was effected partially by proliferation of myofibroblasts cells which
could cause contraction of the microvasculature. It would therefore be interesting to
determine whether proliferation of myofibroblasts occurs during the later stages of
luteal regression in the primate.
4.2.3 Morphology of Marmoset Luteal Vasculature.
Immunocytochemistry for vW indicated that during the early and mid luteal phase
vascular morphology was consistent with an extensive network of fine capillaries
with a high surface area to volume ratio. During luteal regression, however, the area
of vW immunostaining decreased while the volume occupied by the vasculature
increased, and this apparent contradiction was probably caused by a change in the
vasculature from a capilliary network to a lower number of relatively large blood
vessels with a low surface area:volume ratio. This was further supported by data
indicating that the number of blood vessels per unit area also decreased during
structural luteal regression. This data was based on the assumption that each distinct
area of vW immunopositive staining represented one blood vessel. Clearly this
assumption is inaccurate; the same blood vessel may intersect the histological plane
of section any number of times. In addition, it is possible that some endothelial cells
may have been vW immunonegative, and this would lead to an underestimation of
the amount of vasculature present. However, these inaccuracies would probably have
been constant in all the experimental groups, and these data therefore support the
hypothesis that there is an initial period of angiogenesis during formation of the
corpus luteum, then a period of vascular regression during late functional and early
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structural regression, followed by a second period of angiogenesis during structural
luteal regression. This appears to result in the formation of larger blood vessels
which are suitable for channelling away the cellular debris of structural luteal
regression.
Luteal regression in ovine and bovine corpora lutea involves detachment of the
endothelial cells from vascular basal lamina, and the occlusion of capillaries with
cellular debris. This does not seem to occur to the same extent in marmoset corpora
lutea, although it is important to equate the precise time in the luteal phase that
capillary occlusion occurs in ruminant corpora lutea with the equivalent time-point
in the marmoset luteal phase. The average ovine reproductive cycle is 16.5±0.1 days
(Deane et al., 1966). The oestrus, or 'follicular phase' (although in ruminants
follicles develop throughout the luteal phase) when progesterone concentrations are
at basal levels, begins on Day 0, and ovulation occurs 24 hours later at the beginning
of Day 1. Functional luteal regression is therefore completed 16.5 days later.
Progesterone values start decreasing on Day 14 (O'Shea et al., 1977), and
pronounced morphological changes are also seen at this time; ovine corpora lutea
collected on days 14 and 15 of the oestrous cycle had many blood vessels containing
cellular debris. Marmoset reproductive cycles are far more variable, both between
animals and between the cycles of the same animal, but for the sake of this
comparison it can be assumed that it is a 30 day cycle with a 10 day follicular phase
and ovulation occurring on the morning of day 11, or day 1 of the luteal phase.
Progesterone concentrations begin to decrease from luteal day 14, simular to sheep,
but do not fall to follicular phase values until day 19 or 20, therefore functional
luteal regression occurs during a period of 2 days in the sheep, and during a period of
4-6 days in the marmoset. Although some structural changes have been observed in
human corpora lutea on day 14 of the luteal phase, marmoset corpora lutea have not
been subjected to morphological examination at this stage of the luteal phase,
however corpora lutea collected on day 18 do show some morphological changes
indicative of regression; lower steroidogenic cell volume compared to that seen at
luteal day 10 and a slight non-significant increase in the number of apoptotic cells
and an increased numbers of steroidogenic cell cytoplasmic lipid droplets. However,
vascular changes are not obvious, and there is certainly no widespread distribution of
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blood vessels containing large quantities of fragmented cellular debris as there is in
ovine corpora lutea. Marmoset corpora lutea collected on luteal days 22-24 after
progesterone had fallen to follicular phase values tended to have dilated or relatively
large blood vessels which did not contain cellular debris, but again there was no
evidence of large numbers of occluded capillaries.
Vascular thrombi were found slightly more frequently after induction of luteolysis
with PGF2a or GnRH antagonist, and marmoset corpora lutea collected 24 hours
after induction of luteolysis may be considered analogous to ovine corpora lutea
collected on day 16, but even these did not display vascular occlusion to the same
extent as is seen in ovine corpora lutea. Of course it is not surprising to find that
primate corpora lutea are different from ruminant corpora lutea, and these species
differences appear to be related to the length of time available to remove luteal
tissue. The ovine 'follicular phase' is a mere 24 hours, during which time structural
luteal regression has to be essentially complete in order that there be room for a
subsequent corpus luteum, whereas the regressing marmoset corpus luteum can
complete structural regression during the 10 days of the follicular phase. In sheep,
functional and structural luteal regression appear to proceed simultaneously, in cows
there is some overlap between functional and structural regression, but not as much
as in the sheep, and in the primate the two phases are essentially separated. It is
interesting that although functional regression appears to always precede structural
regression, it does not seem necessary to complete functional regression before
structural regression can proceed, and that the relationship between functional and
structural regression within each species can be quite flexible. Functional regression
appears to be largely completed before structural regression begins in spontaneously
regressing marmoset corpora lutea. Marmoset corpora lutea collected 12 hours after
induction of luteolysis, however, had falling progesterone values indicating that
functional regression was in progress, and also had regressive morphological
changes indicating that structural luteolysis was occurring at the same time.
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4.2.4 Vascular Endothelial Growth Factor in the Corpus Luteum.
Blood flow to the corpus luteum is higher than to any other organ in the body, and
this high blood flow is related to the steroidogenic capacity of luteal tissue.
Therefore it is interesting to find that VEGF is highly expressed in the early
marmoset corpus luteum, and also that gonadotrophins upregulate VEGF (Laitinen et
al., 1997; Shweiki et al., 1993; Christenson and Stouffer, 1997), suggesting that
luteal formation concomitant with upregulated VEGF is one mechanism for ensuring
a blood supply sufficient for maintenance of luteal steroidogenesis. Steroidogenic
cell VEGF immunoreactivity in marmoset corpora lutea decreases with increasing
luteal age, and LH pulsitility also slows with increasing luteal age (Soules et al.,
1984), so it would be interesting to determine the effects of LH on VEGF expression
in luteal tissue in vivo. However the finding that VEGF expression is maintained 12
hours after administration of GnRH antagonist suggests that LH does not regulate
VEGF. In addition to this, the lifespan of primate corpora lutea is not prolonged by
experimentally maintaining early luteal phase LH pulsitility throughout the late
luteal phase, so it is unlikely that reduced luteal blood flow caused by LH
downregulation of VEGF expression is a mechanism for instigating functional luteal
regression under normal conditions in vivo.
VEGF secretion is also increased by hypoxia in human granulosa cells luteinised in
vitro (Friedman et al., 1997) which suggests that expression of VEGF during
functional luteal regression in the marmoset corpus luteum may be due to
upregulation by hypoxic conditions, and that VEGF upregulation in the non-
steroidogenic corpus luteum of regression may stimulate the formation of large
blood vessels which become a means of removing the detritus of structural luteal
regression.
The majority of steroidogenic cells in the early luteal phase express VEGF, and it
was hypothesised that VEGF-expressing steroidogenic cells contribute to the
angiogenic activity which occurs during the early luteal phase and results in
extensive capilliarisation of the corpus luteum. In order for VEGF to have an
angiogenic effect, it was presumed that luteal endothelial cells would have to express
a receptor for VEGF, however a preliminary study of the VEGF receptor, Fit-1, did
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not find any expression at all in two early luteal phase corpora lutea, although
positive Fit-1 immunoreactivity was found in the large blood vessels of one late
luteal phase corpus luteum, and also in another corpus luteum collected 12 hours
after administration of GnRH antagonist. Since Fit-1 immunoreactivity was not
found in the positive control human luteal section, nor in the two early luteal phase
marmoset corpora lutea, it was assumed that technical procedures were inadequate
and the study was discontinued. However, retrospectively it was considered that
human mid phase corpora lutea might not express Flt-1, and Flt-1 might only be
expressed in large blood vessels during functional luteal regression, therefore it is
possible that further investigation of the temporal and morphological distribution of
Flt-1 would yield interesting results.
Flt-1 is one of three VEGF receptors, so although Flt-1 has not yet been
demonstrated in early luteal phase tissue, it is also possible that one of the other
receptors, most likely Flk-l/KDR, may mediate the angiogenic effects of VEGF in
the early corpus luteum (Lee et al., 1996). Flt-1 is upregulated by hypoxia (Gerber et
al., 1997; Sandner et al., 1997), so if it proves to be expressed in the late luteal
phase, its presence would support the hypothesis that hypoxic conditions exist in
regressing corpora lutea.
4.2.5 Summary
In summary, endothelial cell numbers appear to be highest in the early luteal phase.
Since endothelial cell proliferation occurs at a higher rate than cell death from the
early to the mid-luteal phase, this result may have been influenced by changes in the
volume of individual steroidogenic cells. Steroidogenic cells in newly formed
corpora lutea are in the initial stages of hypertrophy, and therefore have lower
volumes than mid luteal phase steroidogenic cells. Since the steroidogenic cells
utilise less space in the early luteal phase, the number of endothelial cells in each
unit area appears to be higher than in mature luteal tissue.
The number of endothelial cells remains constant during the mid luteal phase and
during functional luteal regression, but appears to increase during structural luteal
regression. Observed increases in endothelial cell numbers may be due to either (a)
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the dynamics of shrinking tissue during which parenchymal steroidogenic cells are
lost and blood vessels move closer together which results in a higher number of
endothelial cells in each unit area, or (b) proliferation of endothelial cells.
Examination of cell proliferation during luteal regression is therefore necessary in
order to determine the relative importance of these two effects.
The number of individual blood vessels appears to be highest during the luteal phase,
but again, this is probably an artifact of the scoring system bought about by the
dynamics of expanding tissue. The number of capillaries falls to a baseline by luteal
day 7 when the corpus luteum has reached a mature form. There is then a slight,
nonsignificant increase in the number of capillaries per unit area as the luteal phase
proceeds and also during functional regression. During structural luteal regression,
however, there is a marked decrease in the number of individual blood vessels, and
this occurs at the same time as the observed increase in individual endothelial cell
numbers.
4.2.6 Conclusions.
It is possible to draw two main conclusions about luteal vasculature in the marmoset.
(1) Morphological changes in luteal vasculature do not precede functional luteal
regression in marmoset corpora lutea and (2) the vasculature changes from an extensive
network of fine capillaries during the luteal phase to a vascular system comprised of
lower numbers of larger microvessels during structural luteal regression.
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Luteal regression is essentially a process of cell loss and tissue shrinkage, therefore it
appears counter-intuitive to examine cell proliferation in this context, since
increasing cell numbers would clearly retard the removal of luteal tissue. However,
examination of the vasculature during luteal regression indicated an increase in
endothelial cell numbers during structural luteal regression. It was not clear, whether
the increase was due to an artefact of the counting system, whereby blood vessels in
shrinking tissue moved closer together to gove an artifactual increase in endothelial
cell numbers for each unit area, or if the increase was due to endothelial cell
proliferation. In addition, the vasculature changed from a network of fine capillaries
during the luteal phase to a system of larger arterioles and venules during luteal
regression, and this vascular shift could require both cell death to remove capillaries
and cell proliferation to form larger vessels. It is therefore important to characterise
the rates of proliferation of different cell types within the corpus luteum, and to
determine proliferative rates prior to and during luteal regression.
5.0.1 Evaluation of Proliferation
Analysis of proliferation depends on assessment of the number of cells undergoing
mitosis in a given population, but mitosis is completed in approximately five
minutes, so the likelihood of observing mitotic spreads in histological sections is
very low. In electron micrographs of ovine corpora lutea, only one mitotic figure was
observed amongst 3548 nuclei examined in a mid luteal phase corpus luteum
(O'Shea et al., 1986). However, there are a number of more sensitive methods
commonly used for evaluating proliferation, and they all exploit various aspects of
the cell cycle.
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Figure 5.1: The Cell Cycle
The cell cycle has a period of intense DNA synthesis, the S phase, which can take 7
to 12 hours to complete. This is followed by a post-synthetic gap (G2) of 1 to 6 hours
in length during which the cell undergoes growth and prepares for mitosis. The next
phase, mitosis, takes a maximum of two hours to proceed through prophase,
metaphase, anaphase and telophase. During the subsequent post-mitotic gap (Gi)
cells recover from mitosis and grow to an optimal size. The Gi phase can be of
variable length, and it is also at this stage of the cycle that cells can enter a fifth
phase, (Go), during which they are not actively proliferating. This is considered to be
a resting phase in which cell status does not change. Specific proliferative stimuli can
cause some cells to re-enter the cell cycle in a state equivalent to the early part of the
post-mitotic gap phase (Gia) whereas other cells lose their proliferative competency
and never re-enter the cell cycle. Cells permanently in the Go phase are often
terminally differentiated (Boulton and Hodgson, 1995).
Quantification of the number of cells in the S or M phase does not give an accurate
picture of the overall dynamics of proliferation for a particular tissue, because the
duration of these stages may vary between cell types, and with proliferative rate. A
complete description quantifies the proportion of the total cell population that is in
the S or M-phase, and also quantifies the rate at which cells enter and leave the cell
cycle (Boulton and Hodgson, 1995: Sasaki et al., 1988). The higher the proportion of
cycling cells in the S-phase, the shorter is the cell cycle for that particular population
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of cells. The percentage of the total population of cells that is cycling is known as the
growth fraction.
5.0.2 Methods for Assessing Cell Proliferation
DNA synthesis occurs before mitosis, and some methods for assessing proliferation
utilise substances which are incorporated into DNA during synthesis in vivo, and are
then subsequently visualised ex vivo. Tritiated thymidine [3H] can be incorporated
into newly synthesised DNA in place of thymidine, and can be recognised by
autoradiography or by fluorescence-activated cell sorting (FACS) techniques
(Boulton and Hodgson, 1995). Bromodeoxyuridine, a modified pyrimidine analogue
which is a halogenated derivative of thymidine, can likewise be incorporated into
new DNA in place of thymidine. It can then be visualised using standard
immunocytochemical techniques which utilise a specific monoclonal antibody raised
against bromodeoxyuridine (Boulton and Hodgson, 1995). These two methods have
the advantage of labelling proliferating cells in vivo, and only the visualisation steps
are completed after death or removal of the tissue from the organism being studied.
The number of cells labelled using these techniques depends upon the amount of
time the DNA nucleotide replacement substance was available to be incorporated
into newly synthesised DNA and this in turn is dependent upon the initial
concentration and the clearance rate of the substance being used. The number of
labelled cells increases as the amount of time between administration of the label and
collection of the tissue increases. 'Pulse' labelling occurs when the labelling period is
shorter than the duration of the S-phase for the cell population concerned, so that
only cells which are in the synthetic phase are labelled (Boulton and Hodgson, 1995).
Additional methods for evaluating proliferation detect proteins ostensibly expressed
exclusively by proliferating cells, with detection by standard immunocytochemical
means. The Proliferating Cell Nuclear Antigen (PCNA) is a 36 kDa acidic nuclear
auxiliary protein for DNA polymerase S which has also been identified as 'cyclin'.
The PCNA-DNA polymerase 5 complex is required for cell division, hence PCNA is
a marker for proliferation. PCNA has a relatively long half life of up to 20 hours
(Diebold et al., 1994), and its expression increases during Gi, then peaks during the
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S-phase before decreasing during G2 (Boulton and Hodgson, 1995). PCNA
immunoreactivity occurs in the nuclei of proliferating cells but non-specific
cytoplasmic staining is also common (Wolf and Dittrich, 1992; Sabattini et al.,
1993). The intensity of nuclear staining can be very variable and it has been
suggested that nuclei with weak PCNA immunopositivity may have left the cell
cycle and be quiescent, but still contain residual amounts of PCNA (Sabattini et al.,
1993).
Ki67 antigen is a nuclear non-histone short lived protein which appears in a reticulate
structure surrounding the anaphase chromosomes, but which can be detected
throughout mitosis (Gerdes et al., 1984). Ki67 has a half life of less than one hour
(Bruno and Darzynkiewicz, 1992) and is expressed in all phases of the cell cycle
except the early part of Gl, and Go. Gerdes et al (1984) showed that cells moving
from Go to Gl are not Ki67 positive, but in subsequent cycles cells are Ki67 positive
during the entire Gl phase. Ki67 antigen also disappears when proliferating cells are
induced to differentiate into resting cells (Gerdes et al., 1983) and this suggests that
Ki67 is expressed by cycling cells in Gl, but not by cells in Gl which are about to
enter or which have just left the Go phase of the cell cycle.
5.0.3 Comparison of Ki67, Tritiated Thymidine,
Bromodeoxyuridine and PCNA.
The appearance of Ki67 antigen closely paralleled the uptake of tritiated thymidine
in peripheral mononuclear blood lymphocytes (PBL) stimulated to proliferate by the
addition of phytohemagglutinin A (PHA). In this study (Gerdes et al., 1983) 9.9% of
cells were Ki67 positive but negative for tritiated thymidine ([3H]) and 1.3% Ki67
negative but [3H] positive. These data were explained as indicating that 9.9% of the
cells were in the Gl or G2 phase of the cell cycle, and that 1.3% of the cells had been
labelled during the S phase but had subsequently become quiescent and no longer
expressed the Ki67 antigen. The majority of Ki67 positive cells, however, were also
[3H] positive.
PCNA immunocytochemistry (ICC) consistently labelled more cells than Ki67 ICC
did in the same tissue samples (Sabattini et al., 1993; Jones et al., 1994). It was
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suggested this may be due to PCNA having a longer half life than Ki67. Likewise,
Ki67 labelled more cells than BrdU in specimens of malignant tumours. In this study
(Sasaki et al., 1988), Ki67 immunocytochemistry was carried out on cryostat
sections of the tumours, but Brd U incorporation occurred during a 60 minute period
of in vitro culture of the same tumour specimens, and no control was included to
determine the effect of in vitro culture on rates of DNA synthesis. However, since
Ki67 is expressed during three phases of the cell cycle, and BrdU is only
incorporated during the S-phase of the cell cycle, the finding that more cells were
Ki67 positive than were BrdU positive was probably correct. In addition, this study
found that Ki67 and BrdU values paralleled each other, so that when one specimen
had a high Ki67 index, it also had a high BrdU value, indicating that although these
two methods gave different absolute proliferative indices, they also yielded the same
relative values. Ki67 labels cells at all phases in the cell cycle, so gives a measure of
the population of cycling cells, whereas pulsed BrdU only labels cells in the S-phase,
so a comparison of Ki67 and BrdU results can give an indication of the proliferative
rate of a particular tissue (Sasaki et al, 1988).
5.0.4 Proliferation in Corpora Lutea
In ewes, following administration of 5mg/kg BrdU i.v. 1 hour before obtaining the
corpora lutea, the percentage of BrdU labelled cells decreased exponentially as the
corpus luteum aged (Jablonka-Shariff et al., 1993). In this study, few BrdU positive cells
were also 3PHSD immunopositive, the majority of BrdU positive cells were also Factor
VIII positive, but a proportion of BrdU positive cells were neither steroidogenic nor
endothelial cells. In bovine corpora lutea the percentage of PCNA positive luteal cells
likewise decreased as the luteal phase progressed, and these proliferating cells were
thought to be small parenchymal, fibroblast or endothelial cells, but not steroidogenic
large luteal cells (Zheng et al., 1994). In macaque ovary, Ki67 immunocytochemistry
showed that in corpora lutea cell proliferation was also highest during the early luteal
phase and proliferation decreased significantly during the late luteal phase when
progesterone levels were falling and functional luteal regression was underway
(Christenson and Stouffer, 1996). In these macaque corpora lutea 3PHSD
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immunopositive steroidogenic cells were not Ki67 immunopositive at any stage of the
luteal phase, but 85-95% of Ki67 immunopositive cells were colabelled with the
endothelial cell marker, platelet endothelial cell adhesion molecule 1 (CD31). Another
study of proliferation in human corpora lutea used CD34 as a specific endothelial cell
marker. In this study the percentage of cells which were both CD34 and PCNA
immunopositive decreased as the luteal phase progressed, but this study did not examine
non-endothelial cell proliferation (McClure et al., 1994). Rodger et al (1997)
demonstrated that in human corpora lutea the number of Ki67 immunopositive
endothelial cells was highest during the early luteal phase, had decreased to a basal level
by the mid luteal phase and remained at this level during the initial stages of functional
luteal regression and also during a simulated early pregnancy model. Numbers of Ki67
immunopositive parenchymal cells showed a simular pattern.
5.0.5 Aims
This study aims to quantify and identify cells undergoing proliferation in the marmoset
corpus luteum, with particular emphasis on the changes associated with luteal
regression. Proliferation will be examined by (i) immunolocalisation of the Proliferating
Cell Nuclear Antigen (PCNA) (ii) immunolocalisation of Ki67 Antigen (Ki67) (iii)
determining the temporal and morphological distribution of BrdU incorporation in
spontaneously regressing corpora lutea and (iv) identifying BrdU positive cells by
colabelling with the steroidogenic cell marker 3p hydroxysteroid dehydrogenase
(3PHSD), or the endothelial cell marker von Willebrand Factor VIII Antigen (vW).
5.1 Results
5.1.1 PCNA Immunocytochemistry
The nuclei of some granulosa and theca cells in morphologically healthy follicles
were PCNA immunopositive (Figure 5.2), whereas the number of PCNA
immunopositive cells in atretic follicles was markedly lower, indicating that follicles
on the same section as luteal tissue provided good internal positive and negative
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controls. Nuclei in negative control sections were not PCNA immunopositive, but
non-specific cytoplasmic staining was common, and interfered with quantification.
There was only one immunocytochemical run examining spontaneously regressing
luteal tissue in which the optical density of non-specific cytoplasmic staining was
lower than the optical density of PCNA immunopositive nuclei, and quantitative data
are shown for that run. Unfortunately two sections, one from the early luteal phase
and one structurally regressing corpus luteum collected in the early follicular phase,
were rendered unquantifiable by the procedure, hence resulting in an incomplete data
set. The results from other PCNA ICC procedures conducted on spontaneously
regressing corpora lutea, however, were consistent with those presented here.
Both steroidogenic and non-steroidogenic cell nuclei were PCNA immunopositive
(Figure 5.2). Approximately 4% of the total number of PCNA-positive cells counted
per field of view overlapped with another PCNA-positive nucleus.
5.1.1.1 Quantification of PCNA ICC
The number of PCNA immunopositive cells did not change significantly throughout
the luteal phase nor during spontaneous luteal regression (Figure 5.3). However the
general trend was that the number of proliferating cells was highest during the early
luteal phase, lowest during the mid luteal phase, increased again during functional
luteal regression and decreased during structural regression after progesterone had
fallen to follicular phase values. The total number of PCNA positive cells likewise
did not change significantly after administration of the luteolytic agents GnRH
antagonist or PGF2a (Figure 5.4), and distinguishing between PCNA
immunopositive steroidogenic and nonsteroidogenic cells also failed to reveal any
significant changes after induced luteal regression. Interestingly, the number of
PCNA immunopositive nonsteroidogenic cells was significantly higher 24 hours
after luteolytic treatment with GnRH antagonist (82.5±2.7, n=4) than 24 hours after
administration of PGF2a (41+3.16, n=4, p<0.05).
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Figure 5.2: Proliferating Cell Nuclear Antigen (PCNA) Immunocytochemistry
in a Marmoset Mid Luteal Phase Ovary.
Ovary collected on luteal day 10. A, luteal tissue in upper half, follicle comprising
an outer layer of theca and an inner layer of granulosa cells in lower halfof picture.
B. Luteal tissue. Arrows indicate PCNA positive cells. Scale bars represent 20um.
Figure 5.3: Numbers of Proliferating Cell Nuclear
Antigen (PCNA) Immunopositive Cells in
Spontaneously Regressing Corpora Lutea.
Ovaries containing corpora lutea were collected on luteal
days 2-5 (early, n=3), luteal day 10 (mid, n=4), luteal day
18 (functional regression, n=3) and luteal days 22-25
(structural luteal regression, n=3). The total number of
PCNA immunopositive cells per 31400 pm unit area
were determined for each corpus luteum, and are shown as
mean±SEM for each stage of the luteal phase. One way
analysis of variance found no significant differences
between means.
224










Day of Luteal Phase
22-25
Figure 5.4: Numbers of Proliferating Cell Nuclear
Antigen (PCNA) Immunopositive Cells in Corpora
Lutea After Induced Luteal Regression.
Ovaries were collected on luteal day 10 (control, n=3), 12
hours (PG12, n=3) and 24 hours (PG24, n=4) after PGF2a
analogue, cloprostenol, and 12 hours (Gnl2, n=3) and 24
hours (Gn24, n=4) after GnRH antagonist, anterelix. The
number of PCNA immunopositive steroidogenic (grey
bars) or nonsteroidogenic (white bars) cells per 31400 pm
unit area were determined for each corpus luteum, and are
shown as mean+SEM for each experimental group. Data
were subjected to one way analysis of variance. The
number of PCNA-immunopositive nonsteroidogenic cells
24 hours after induction of luteolysis with PGF2a was
significantly different from the number of PCNA-
immunopositive nonsteroidogenic cells 24 hours after
administration of GnRFl antagonist (P<0.05). There were
no significant differences between any other groups
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5.1.2 Ki67 Immunocytochemistry
The nuclei of some granulosa and theca cells in morphologically healthy follicles
were intensely Ki67 immunopositive, whereas the number of Ki67
immunopositive cells in atretic follicles was markedly lower, indicating that
follicles on the same section as luteal tissue provided good internal positive and
negative controls (Figures 5.5 and 5.6). Nuclei in negative control sections were
not Ki67 immunopositive, and cytoplasmic non-specific staining was low or
entirely absent (Figure 5.5). Both steroidogenic and non-steroidogenic nuclei
were immunopositive in all sections examined. Nonsteroidogenic cell nuclei had
intense immunostaining, but the staining in steroidogenic cell nuclei was rarely
as intense as in nonsteroidogenic cells and ranged from strong to very faint
(Figures 5.5, 5.6 and 5.7). Some endothelial cells were Ki67 immunopositive in
mid luteal phase corpora lutea (Figure 5.5), but the identity of Ki67
immunopositive nonsteroidogenic cells after induced regression was not as clear
(Figure 5.6). A proportion of Ki67 immunopositive nonsteroidogenic cells in
spontaneously regressing corpora lutea were found lining blood vessels,
suggesting that they may have been endothelial cells (Figure 5.7C), but the
rounded morphology of other Ki67 positive cells combined with non-vascular
localisation (Figure 5.7D) suggests a different phenotype.
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Figure 5.5: Ki67 Immunocytochemistry in Mid Luteal
Phase Day 10 Corpus Luteum.
Marmoset ovarian section shows luteal tissue and a
follicle. Ki67 immunopositive cell nuclei are pink to dark
crimson red, and negative cell nuclei are counterstained
blue with haematoxylin. Inset shows Ki67 antibody
negative control, and scale bar represents 20pm.
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Figure 5.6: Ki67 Immunocytochemistry in Marmoset
Corpus Luteum After Induced Luteal Regression.
Panels A and B show corpora lutea 24 hours and 12 hours
respectively after in vivo administration of GnRH
antagonist. Panels C and D show luteal tissue 24 hours and
12 hours respectively after treatment with PGF2a
analogue. All ovaries were collected on luteal day 10.
Each panel shows luteal tissue and follicular layers of
theca and granulosa cells. Ki67 immunopositive cell
nuclei are pink to dark crimson red, and immunonegative
cell nuclei are counterstained blue with haematoxylin.
Scale bars represent 20pm.
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Figure 5.7: Ki67 Immunocytochemistry in
Spontaneously Regressing Marmoset Corpora Lutea.
Luteal tissue fixed in 4% paraformaldehyde and collected
on A. luteal days 2-5, B. luteal day 10, C. luteal day 18
(functional luteal regression) and D. luteal days 22-25
(structural luteal regression). Insets show the same section
at a lower magnification. Ki67 immunopositive cell nuclei
are pink to dark crimson red, but immunonegative cell
nuclei are not counterstained. Scale bars represent 20pm.
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5.1.2.1 Quantification of Ki67 ICC.
The numbers of Ki67 immunopositive cells did not change during spontaneous luteal
regression (Figure 5.8). The numbers of Ki67 immunopositive steroidogenic cells
were constant during the early (10±1.4, mean±sem, n=4) and mid (10.25±3.5, n=4)
luteal phases, but decreased markedly by luteal day 18 (4.3+0.7, n=3, Figure 5.8).
The numbers of Ki67 immunopositive steroidogenic cells increased to 11.1 +4
(mean+sem, n=3) during structural luteal regression. The number of Ki67
immunopositive nonsteroidogenic cells was highest during the early luteal phase
(13.9±8.7, n=4, Figure 5.8) and decreased as the luteal phase proceeded to a nadir
during functional luteal regression (4±0.4, n=3). This increased significantly to 6±0.6
(n=3, p<0.05) immunopositive nonsteroidogenic cells during structural regression.
Induction of regression caused the number of Ki67-positive steroidogenic cells to
decrease significantly from 18.6±3.2 cells (n=3) in mid luteal phase day 10 corpora
luteato 2.4±1.1 cells (n=3, p<0.01) and 2.4±0.7 cells (n=3, p<0.01) 24 hours after
administration of PGF2a and GnRH antagonist respectively (Figure 5.9). The
numbers of Ki67-positive nonsteroidogenic cells, however, were not significantly
changed by the administration of luteolytic agents (Figure 5.9).
The percentages of all cells which were Ki67 positive were 8.8±4% (n=3, Figure 5.17)
in the early luteal phase, 6.3±2% (n=3) in the mid luteal phase, 4.6±1.9% (n=3) during
functional regression, and 5.0±1.8% (n=3) during structural regression. The percentage
of Ki67 positive non-steroidogenic cells was 53.5±17% in the early luteal phase,
36+17% in the mid luteal phase, 49±4.7% during functional regression and 39±9%
during structural regression (Figure 5.17), indicating that more than half of the Ki67
immunopositive cells were steroidogenic cells. The percentage of Ki67-positive
nonsteroidogenic cells decreased significantly from 8.4±0.8% during the early luteal
phase, to 0.6±0.3% (p<0.01) during functional luteal regression and 2.2+0.5% (n=3,
p<0.01) during structural luteal regression.
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Figure 5.8: Numbers of Ki67 Immunopositive Cells in
Spontaneously Regressing Marmoset Corpora Lutea.
Ovaries on luteal days 2-5 (early, n=4), luteal day 10 (mid,
n=4), luteal day 18 (functional luteal regression, n=3) and
luteal days 22-25 (structural luteal regression, n=3). The
total number of Ki67 immunopositive steroidogenic (grey
bars) and nonsteroidogenic (white bars) cells per 10700
prn2 unit area were determined for each corpus luteum,
and shown as mean±SEM for each stage of the luteal
phase. There was no significant differences between
means after a one way analysis of variance.
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Figure 5.9: Numbers of Ki67 Immunopositive Cells in
Marmoset Corpora Lutea After Induced Luteal
Regression.
Ovaries were collected on luteal day 10 (control, n=3), 12
hours (PG12, n=3) and 24 hours (PG24, n=4) after PGF2a
analogue, and 12 hours (Gnl2, n=3) and 24 hours (Gn24,
n=4) after GnRH antagonist. The number of Ki67
immunopositive steroidogenic (grey bars) or
nonsteroidogenic (white bars) cells per 31400pm2 unit
area were determined for each corpus luteum, and are
shown as mean±SEM for each experimental group. Data
were subjected to one way analysis of variance. The
numbers of Ki67-immunopositive steroidogenic cells 12
and 24 hours after induction of luteolysis with either
PGF2a or GnRH antagonist were significantly lower than
the number of Ki67-immunopositive steroidogenic cells
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5.1.3 BrdU Immunocytochemistry
The nuclei of some granulosa and theca cells in morphologically healthy follicles
were intensely BrdU immunopositive, whereas the number of BrdU immunopositive
cells in atretic follicles was markedly lower, indicating that follicles on the same
section as luteal tissue provided good internal positive and negative controls (Figure
5.1 OA). Nuclei in negative control sections were not BrdU immunopositive, and
cytoplasmic non-specific staining was entirely absent (Figure 5.10A and B). BrdU
immunopositive steroidogenic cells were infrequent, but BrdU immunopositive
nonsteroidogenic cells were found in all sections examined. Intensity of staining was
also consistent and did not vary according to cell type or luteal stage (Figures 5.10
and 5.11). A proportion of BrdU immunopositive nonsteroidogenic cells in
spontaneously regressing corpora lutea were found lining blood vessels, suggesting
that they may have been endothelial cells (Figures 5.10C and 5.11 A) but the rounded
morphology of other BrdU positive nonsteroidogenic cells combined with non¬
vascular localisation (Figures 5.11A and C) suggests a different phenotype.
5.1.3.1 Quantification of BrdU ICC
BrdU immunopositive steroidogenic cell numbers were low during the early luteal
phase (4.3±2.3, mean±SEM, n=3), absent in functionally regressing corpora lutea,
and high in some structurally regressing corpora lutea (43±40, n=4, Figure 5.12). The
number of BrdU immunopositive nonsteroidogenic cells was 29±5.7 cells per unit
area (n=3) in the early luteal phase, but there was a significant decrease (2.7±0.8,
n=3, p<0.01) in BrdU positive nonsteroidogenic cell numbers during functional
luteal regression. This was followed by a significant increase (38±29, n=4, p<0.01)
in corpora lutea undergoing structural luteal regression after progesterone had fallen
to follicular phase values (Figure 5.12).
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Figure 5.10: Bromodeoxyuridine (BrdU)
Immunocytochemistry in Functionally Regressing
Corpus Luteum.
A. Primordial, developing, antral and atretic follicles, B.
Primary antibody negative control serial section of (A),
and C. Luteal tissue from the same ovary. BrdU positive
cell nuclei were immunostained blue-black,
immunonegative nuclei were counterstained blue-purple
with haematoxylin and cytoplasm was counterstained with
Light Green. Scale bars represent 20pm.
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Figure 5.11: Bromodeoxyuridine (BrdU)
Immunocytochemistry in Spontaneously Regressing
Corpora Lutea.
Ovaries collected on; A. luteal days 2-5, B. luteal day 18
(functional luteal regression) and C. luteal days 22-25
(structural luteal regression). BrdU immunopositive cell
nuclei were blue-black, immunonegative nuclei were
counterstained blue-purple with haematoxylin and




Figure 5.12: Numbers of Bromodeoxyuridine (BrdU)
Immunopositive Cells in Spontaneously Regressing
Marmoset Corpora Lutea.
Ovaries containing corpora lutea were collected on luteal
days 2-5 (early, n=3), luteal day 18 (functional luteal
regression, n=3) and luteal days 22-25 (structural luteal
regression, n=4). The number of BrdU immunopositive
steroidogenic (grey bars) and nonsteroidogenic (white
bars) cells per 10700 pm unit area were determined for
each corpus luteum, and shown as mean±SEM for each
stage of the luteal phase. Data were subjected to one way
analysis of variance. Mean numbers of BrdU positive
steroidogenic cells were not significantly different
between groups. The numbers of BrdU-immunopositive
nonsteroidogenic cells on luteal day 18 were significantly
lower than the number of BrdU-immunopositive
nonsteroidogenic cells per unit area of luteal tissue during
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5.1.4 Identification of BrdU Positive Cells
5.1.4.1 BrdU Colocalisation ICC with 3p Hydroxysteroid Dehydrogenase (3(3
HSD).
The cytoplasm of cells with the morphological appearance of steroidogenic cells had
pink 3p HSD immunostaining (Figure 5.13A). Not all steroidogenic cells were 3p
HSD immunopositive, and this was also apparent in 3p HSD ICC (see chapter 3).
Brown BrdU immunostaining was localised only to cell nuclei, and BrdU positive
cells were not 3p HSD immunopositive. Visualisation substrates can sometimes
mask the colour of a second dye used in colocalisation studies. The Vector Red used
to visualise 3p HSD immunopositivity was fluorescent, and NBT does not mask
fluorescent Vector Red. Figure 5.13B shows that BrdU immunopositive cells are not
3p HSD immunofluorescent, and also that the nuclei of steroidogenic cells are 3P
HSD immunonegative as would be expected. Negative control sections were clearly
3p HSD and BrdU immunonegative.
5.1.4.2 BrdU Colocalisation ICC with von Willebrand Factor VIII Antigen
(vW).
Pink vW immunopositivity was predominantly cytoplasmic and localised to the
edges of lumina which contained red blood cells (Figure5.14A), as well as to cells
which had the morphological appearance of nonsteroidogenic cells but which did not
clearly enclose a lumen. Positive immunostaining was also apparent in the theca, but
not the granulosa layers of follicles (Figure 5.14B). Brown BrdU immunostaining
was localised to cell nuclei (Figure 5.14A and B), and was found in granulosa, theca
and luteal cells. Figure 5.14C shows that BrdU immunopositive cells are both vW
immunofluorescent and vW immunonegative, indicating that only a proportion of the
BrdU positive cells are endothelial cells, or that a proportion of endothelial cells are
vW negative. Negative control sections were clearly vW and BrdU immunonegative
(Figure 5.14D).
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Figure 5.13: Immunocytochemistry for
Bromodeoxyuridine (BrdU) Colocalised with 3p
Hydroxysteroid Dehydrogenase (3PHSD) in
Spontaneously Regressing Marmoset Corpora Lutea.
Luteal tissue collected on luteal day 18 during functional
luteal regression. Panel A, light field photomicrograph of
luteal tissue with BrdU-positive cell nuclei brown-black,
and immunonegative nuclei purple. 3PHSD positive cells
had red-pink cytoplasmic immunostaining, and 3PHSD
immunonegative cells were counterstained with Light
Green. The inset is a antibody negative control section for
both anti-BrdU and anti-3pHSD antibodies. Panel B is a
fluorescent dark field photomicrograph of panel A, in
which 3PHSD positive immunostaining fluoresces red, but
BrdU positive and immunonegative areas appear black.
Scale bars represent 20pm.
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Figure 5.13
Figure 5.14: Immunocytochemistry for
Bromodeoxyuridine (BrdU) Colocalised with von
Willebrand Factor VIII Antigen (vW) in
Spontaneously Regressing Marmoset Corpora Lutea.
Luteal tissue collected during the early luteal phase. Panel
A; from the left hand side can be seen the granulosa cells
and then the theca cells of a follicle, then part of a corpus
luteum. BrdU-positive cell nuclei are immunostained
brown, and endothelial cells display pink-red vW positive
immunostaining. Panel B is a primary antibody negative
control section for both anti-BrdU and anti-vW antibodies.
Panel C shows a corpus luteum of another animal and
Panel D is a fluorescent dark field photomicrograph of
panel C, in which vW-positive immunostaining fluoresces
red, but BrdU positive and immunonegative areas appear
black. Scale bar represents 20pm.
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Figure 5.14: Bromodeoxyuiidine co-localised with von Willebrand
Factor VIII Antigen in marmoset corpora lutea
5.1.4.3Quantification of BrdU Colocalisation ICC with von Willebrand Factor
VIII Antigen (vW).
BrdU quantification in corpora lutea collected in the early luteal phase or on luteal
day 18 was the same after sections were subjected to BrdU Procedure II, and to the
vW/BrdU Colocalisation procedure (Figure 5.15). The numbers of BrdU positive
cells were different in structurally regressing corpora lutea. This data was also
excluded from statistical analysis because there were only two animals in the group,
but is presented here as an indication of relative trends.
In the early luteal phase, 64.6% of BrdU positive cells are vW positive endothelial
cells (17±3.5, mean±SEM, n=3, Figure 5.16). The percentage of BrdU positive cells
which are endothelial cells increases to 80.76% during functional luteal regression,
but the number of proliferating endothelial cells per 40x field of view decreases
significantly (0.42±0.2, n=3, p<0.001) at this time. There is then an indication that
numbers of BrdU positive endothelial cells may return to levels similar to those seen
in the early luteal phase (15.712.5, n=2, Figure 5.16). The numbers of BrdU positive
cells which are not endothelial cells follow a similar pattern and are highest during
the early luteal phase (9.313.2),they then show a significant decrease during
functional luteal regression on luteal day 18 (0.1+0.09, n=3, p<0.001) followed by a
rebound during structural luteal regression.
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Figure 5.15: Numbers of Bromodeoxyuridine (BrdU)
Immunopositive Cells in Spontaneously Regressing
Marmoset Corpora Lutea After Two Separate
Immunocytochemical Procedures.
Ovaries on luteal days 2-5 (early, n=3), luteal day 18
(functional luteal regression, n=3) and luteal days 22-25
(structural luteal regression, n=2). Ovarian sections were
subjected to BrdU immunocytochemical Procedure II
(white bars) or to a procedure in which BrdU positive cells
were colocalised with von Willebrand Factor VIII Antigen
(vW, black bars). The number of BrdU immunopositive
cells per x40 field of view were determined for each
corpus luteum, and shown as mean±SEM for each stage of
the luteal phase. Data were subjected to one way analysis
of variance and the mean numbers of BrdU positive cells
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Figure 5.16: Numbers of Proliferating Cells after
Colocalisation Immunocytochemistry with
Bromodeoxyuridine (BrdU) and von Willebrand
Factor VIII Antigen (vW).
Ovaries on luteal days 2-5 (early, n=3), luteal day 18
(functional luteal regression, n=3) and luteal days 22-25
(structural luteal regression, n=2). Cells displayed either
dual immunopositivity for both BrdU and vW (black bars)
or were immunopositive for BrdU only (white bars). The
number of BrdU immunopositive cells per x40 field of
view shown as mean±SEM for each stage of the luteal
phase. Mean numbers of BrdU-immunopositive cells on
luteal day 18 were significantly lower than the number of
BrdU-immunopositive cells per x40 field of view during
luteal days 2-5 or 22-25 (**, p<0.01).
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5.1.5 Comparison of Ki67 and BrdU ICC
In order to compare assessments of proliferation by Ki67 and BrdU ICC, data were
expressed as percentages (Figure 5.17). The percentage of BrdU positive cells was
always lower than the percentage of Ki67 positive cells, except in structurally
regressing corpora lutea in which the mean percentage of BrdU positive
nonsteroidogenic cells was higher than the mean percentage of Ki67
nonsteroidogenic cells. In this case the median number of BrdU positive cells was
2.16 and the median of the equivalent Ki67 positive cells was 5.45, so if the variation
was compensated for, BrdU measurement in this case was also lower than Ki67, as
would be expected. Ki67 and BrdU measurements of nonsteroidogenic cells
paralleled each other reasonably well, but percentages of Ki67 positive steroidogenic
cells tended to be significantly higher than percentages of BrdU positive
steroidogenic cells. The percentage of proliferating nonsteroidogenic cells was high
during the early luteal phase (BrdU, 8.36±0.8, n=3; Ki67, 9.9±5.6, n=3, Figure 5.17)
but decreased significantly by luteal day 18 when functional luteal regression was
occurring (BrdU, 0.55±0.3, n=3, p<0.001 and Ki67, 4.3+2, n=3, p<0.01). Percent
proliferation did not change significantly (Ki67, 4±0.4, n=3 and BrdU, 2.2±0.5, n=3,
Figure 5.17) as luteal regression proceeded, and remained low during stuctural luteal
regression.
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Figure 5.17: Percentages of Ki67 and BrdU
Immunopositive Cells in Spontaneously Regressing
Marmoset Corpora Lutea.
Ovaries collected on luteal days 2-5 (early, n=3), luteal
day 18 (functional luteal regression, n=3) and luteal days
22-25 (structural luteal regression, n=3). The total number
of Ki67 immunopositive nonsteroidogenic (dark grey
bars), BrdU nonsteroidogenic (white bars), Ki67
steroidogenic (light grey bars) and BrdU steroidogenic
(hatched bars) cells per 10700 pm unit area expressed as
a percentage of the total number of nonsteroidogenic or
steroidogenic cells for that unit area. Data are shown as
the mean percentage±SEM for each stage of the luteal
phase. The mean percentages of nonsteroidogenic cells on
luteal day 18 and on luteal days 22-25 were significantly
lower than the mean percentages of nonsteroidogenic cells
per x40 field of view during luteal days 2-5 (BrdU **,
pO.OOl; Ki67 *, p<0.05).
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5.2 DISCUSSION
5.2.1 The Automated Quantification System.
The use of an automated cell counting system allowed relatively large areas of luteal
tissue to be assessed in a short period of time, and it also incorporated rigorous
objectivity: nuclei were deemed to be immunopositive on the basis of an optical
density threshold which was consistent throughout the entire assessment. Humans
had to make decisions about whether to include a cell in the count, and in addition
the criteria for making those decisions could change as the analysis proceeded. The
automated system could not distinguish overlapping cells, but these errors were
compensated for by counting large numbers of cells, and by only using the system to
analyse tissue sections in which the number of overlapping cells was less than 5% of
the total cell number.
Determination of the ratio between the ellipse long axis and the ellipse short axis of
each nucleus was an acceptable means of immunopositive cell identification, as long
as the frequency of overlapping immunopositive nuclei remained low and therefore
this method became increasingly inaccurate as the number of immunopositive nuclei
increased. The area of nuclear immunopositivity and the length of the perimeter of
PCNA immunopositivity were not good indicators of cell type because they varied
according to the plane of sectioning for that particular cell. A steroidogenic nucleus
sectioned at its tip could have a similar area and perimeter to an endothelial cell
nucleus cut in perfect cross-section. The ratio of nuclear axis, however, was a
measure of shape in which a perfect circle would have a ratio of 1. Of 203
steroidogenic cell nuclei measured in three different corpora lutea, none had a ratio
higher than 1.8, indicating that since steroidogenic cell nuclei are regularly shaped
spheres, sectioning in different planes did not greatly alter the basic circular ratio.
Variation was greatest in the untreated mid luteal phase day 10 sample (Figure 6.2),
and this was probably because steroidogenic cells were easily identifiable by the
mass of cytoplasm, and every steroidogenic cell in measured fields of view was
scored. Tuteolytic treatment with either GnRH antagonist or PGF2a, however, made
some cells unidentifiable on morphological grounds alone, and these cells were not
included in the analysis, so introducing a bias towards clearly identifiable cell types
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which more closely approached morphological norms in these samples.
Nonsteroidogenic cell ellipse ratios showed greater variation than steroidogenic cell
nuclear ratios, and this reflected the greater number of shapes which can be obtained
by sectioning an elongated oval. Misidentification was possible if endothelial cell
nuclei were sectioned in transverse cross section which would give a circular shape
with a similar ratio to steroidogenic cell nuclei. However nuclei with ratios < 1.7 and
with an area corresponding to endothelial cell nuclei area were very rare, and did not
adversely affect results, so this was not a significant problem. There was
subpopulation of nonsteroidogenic cells which had ratios <1.7, but which also had
areas in the same range as steroidogenic cells. These had the morphological
appearance of immune system cells, and macrophage numbers increase in luteal
tissue as regression proceeds (Lei et al., 1991), therefore this misidentification may
have significantly affected results, and requires further characterisation. Overall,
variation within experimental groups was 27.7+15% (mean±SD, n=8, PCNA, Fig. 5)
and 32.88±15% (meaniSD, n=8, Ki67, Fig. 10), and inaccuracy due to the
automated counting system was 7.7±3.72% (Fig. 3). Reducing the variation by 7.7%
might have made a statistical difference in the PCNA study when comparing the
results obtained 24 hours after administration of GnRH antagonist with mid luteal
phase controls, but compensating for variation due to the automated counting system
does not change results obtained from any other examination of the effects of
induced regression upon cell proliferation.
5.2.2 Suitability of Experimental Design.
High variability within experimental groups may be attributable to the lack of
differentiation between younger (ovulated more recently) and older corpora lutea. In
marmosets, ovulations can occur as much as 24 hours apart in the same cycle,
therefore the figure derived from one ovary encompassed variability in luteal age.
The cycle tracking regime was accurate ± 24hours, therefore an ovary collected on
day 4 of the luteal phase may in fact have been 3 or 5 days post-LH/ovulation. The
Ki67 figure derived from each experimental group therefore encompassed variability
attributable to cycle tracking. In addition, the large SEM in the early luteal phase
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group probably reflected the degree of differentiation/luteinisation in individual cells,
and variable maturation of the corpora lutea. The large SEM in 20-25 day old CL
probably reflected variability in the length of the luteal phase. Marmosets had a
luteal phase of 20+10 days (mean ± S.D, n=87, range 6-63 days). Median length of
luteal phase was 18 days, but functional regression could start from day 12 onwards,
and progression of functional and structural regression was highly variable. Ovaries
collected on luteal day 22 might be starting structural regression in one animal,
whilst another animal might have completed structural regression by luteal day 22.
Therefore, the interpretation of these results is confounded by large inter-animal
variation as well difficulty in determining the exact stage of the luteal phase. These
two sources of variation were sufficient to obscure significant changes in rates of
proliferation in the experimental design used. These studies attempted to relate
changes in rate of proliferation with stage of luteal regression, but it would have been
more accurate to determine relative changes in proliferation within the cycles of
individual animals, however considerations of animal welfare precluded this.
Alternatively, different quantification systems may have yielded results which were
more sensitive to changes in proliferative rates.
5.2.3 Interpretation of Data from PCNA Study.
The 18 hour long half-life of PCNA rendered this method of analysing proliferation
too insensitive for use in the corpus luteum, where noticeable changes occur within
six to twelve hours during luteal regression. The long half -life of PCNA may also be
the reason why so many more cells were identified as being proliferative than were
identified using Ki67 or BrdU.
5.2.4 Steroidogenic Cell Proliferation in Marmoset Corpora Lutea.
Steroidogenic cells were immunopositive with three different markers for
proliferation, PCNA, Ki67 and BrdU. This was unexpected, since a number of
studies have demonstrated that steroidogenic cell numbers do not increase as the
luteal phase progresses in ovine (O'Shea et al., 1986), bovine (O'Shea et al., 1989)
human (Lei et al.t 1991) or marmoset (see chapter 3) corpora lutea. If the number of
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steroidogenic cells labelled by the above techniques were actually proliferating, then
equal or slightly higher rates of cell death would be required to maintain constant
steroidogenic cell numbers, but there is no evidence for such high levels of cell death
during the early or mid luteal phases (Corner, 1956; Zheng et al., 1994, and see
chapter 3). This suggests that luteal steroidogenic cells may be in the cell cycle, and
thus expressing the cell cycle antigens PCNA and Ki67, but that they may be arrested
in one part of the cell cycle and do not proceed to synthesis or mitosis. It is
noticeable that extremely low numbers of steroidogenic cells label with BrdU in the
early luteal phase, when granulosa or theca-lutein might conceivably be proliferating
during the process of transformation from follicle to corpus luteum, but that there
were no BrdU labelled steroidogenic cells in late luteal phase corpora lutea,
indicating that steroidogenic cells were not synthesising DNA at this time. The
number of BrdU labelled steroidogenic and nonsteroidogenic cells increased during
structural luteal regression, but numbers of Ki67 immunopositive steroidogenic cells
remained constant. One of the first stages of apoptosis can be activation of
endogenous endonucleases and fragmentation of DNA, and it is possible that the
very early stages of DNA fragmentation might also be accompanied by futile DNA
repair processes. It has been shown that apoptotic glandular prostate cells incorporate
BrdU during futile DNA repair when the cells are in the GO phase (Berges et al.,
1993), therefore high numbers of BrdU labelled non-proliferating cells might be
observed in tissues in which there are also high rates of apoptosis. It is possible that
the high numbers of BrdU labelled steroidogenic and nonsteroidogenic cells
observed in structurally regressing corpora lutea are not actually proliferating, but are
in the initial stages of cell death. This could be determined by measuring the amount
of DNA in these subpopulations of BrdU-labelled cells, and differentiating between
normal, non-proliferating diploid DNA content and the increased DNA content
normally found in proliferating cells.
It was considered that the immunostaining of steroidogenic cells with Ki67 and
PCNA might be an artefact of the antigen retrieval system, since some workers have
not specifically reported immunopositive steroidogenic cells using these antibodies
(McClure et al., 1994) however others have reported that parenchymal luteal cells
are immunopositive in the bovine (Zheng et al., 1994), ovine (Jablonka-Shariff et al.,
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1993), macaque (Christenson and Stouffer, 1996) and human (Rodger et al., 1997)
corpora lutea, but that these proliferation-labelled parenchymal cells did not colabel
with the steroidogenic cell marker 3PHSD, indicating that one of the conditions
under which cells with the morphological appearance of steroidogenic luteal cells
may express cell cycle antigens is that they are not actually steroidogenic and they do
not produce steroid hormones and express cell cycle antigens simultaneously. Our
data support this hypothesis; BrdU immunopositive parenchymal cells in regressing
corpora lutea were all 3pHSD immunonegative. Additionally, the same antigen
retrieval system was used by Rodger et al (1997) to examine proliferation in human
corpora lutea. The majority of parenchymal luteal cells which were Ki67
immunopositive and which had the morphological appearance of steroidogenic cells
did not colabel with 3PHSD.
In addition to this, the number of Ki67 immunopositive steroidogenic cells was
significantly decreased after induction of luteolysis with either GnRH antagonist or
PGF2a, whereas numbers of Ki67 immunopositive nonsteroidogenic cells remained
unchanged. This differential regulation of cell types by luteolytic agents requires
further investigation.
5.2.5 Nonsteroidogenic Cell Proliferation in Marmoset Corpora
Lutea.
The number of Ki67 immunopositive nonsteroidogenic cells was highest during the
early luteal phase, but decreased to a lower level by the mid luteal phase, then stayed
at this level during structural and functional luteal regression. Numbers of Ki67
immunopositive nonsteroidogenic cells were also the same after induction of
luteolysis with either GnRH antagonist or PGF2a, so the numbers of Ki67
immunopositive nonsteroidogenic cells remain at mid luteal phase levels throughout
both induced and spontaneous luteal regression. However, it is possible than the two
sources of variation mentioned, inter-animal variation and inaccuracy in determining
the exact stage of the luteal phase, may be responsible for obscuring a significant
decrease in nonsteroidogenic cell proliferation during functional luteal regression.
Figure 5.18 details the data concerned, and shows that only one of four mid luteal
264
phase corpora lutea had lower numbers of proliferating cells than luteal day 18
corpora lutea. It could be speculated that this particular animal might have had a
proliferation rate approaching zero had it been possible to sample the same corpus
luteum at a later time in the same cycle. Ki67 nonsteroidogenic cell data does not
contradict the hypothesis that a significant decrease in the number of
nonsteroidogenic cells undergoing proliferation occurs during functional luteal
regression. This was followed by a slight, nonsignificant increase in Ki67 positive
nonsteroidogenic cell numbers during structural regression, coincident with a slight,
nonsignificant increase in area of vW immunostaining at the same time.
Nonsteroidogenic cell numbers doubled between functional and structural regression
(see chapter 3), but numbers of proliferating nonsteroidogenic cells barely changed,
indicating that the increase in nonsteroidogenic cell numbers observed during
structural luteal regression is primarily due to the dynamics of shrinking tissue in
which remaining cells move closer together and therefore increase the number of
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Figure 5.18: Interanimal Variation in Ki67 Immunocytochemistry
Quantification.
The total number of Ki67 immunopositive cells in each unit area was determined for
one corpus luteum per animal. Data points also indicate which day of the luteal phase
individual corpora lutea were collected.
The number of BrdU immunopositive nonsteroidogenic cells was highest during the
early luteal phase, lowest during functional luteal regression and increased during
structural luteal regression. As previously stated, the increase during structural luteal
regression can probably be attributed to BrdU incorporation by dying cells rather
than being a true indication of proliferation. With this modification, BrdU and Ki67
data show good agreement with each other.
A proportion of BrdU positive cells were neither steroidogenic nor vW positive
endothelial cells. There are two possible explanations for this, that some endothelial
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cells are not positive for the vW antigen, or that the proliferating cells were another
cell type, such as macrophages, or fibroblasts.
5.2.6 Summary
High levels of nonsteroidogenic cell proliferation during the early luteal phase are
commensurate with the initial formation of the luteal vasculature (Rodger et al.,
1997), and decreased nonsteroidogenic cell proliferation during the mid luteal phase
is consistent with a moderate turnover rate during which normal wear and tear of the
vasculature is counteracted by low levels of proliferation which maintain constant
cell numbers. Labelling with BrdU indicates that there is then a significant decrease
in nonsteroidogenic cell proliferation at the end of the luteal phase when
progesterone levels are falling and functional luteal regression is underway. The
percentage of nonsteroidogenic cells which were proliferating at this time was
0.5±0.3% (meaniSEM, n=3), and the percentage of all cell types undergoing
apoptosis at this time was 0.85±0.94% (mean+SEM, n=3, see chapter 4). These
figures are not significantly different, but since luteal regression is probably
characterised by a combination of decreasing rates of proliferation and increasing
rates of apoptosis, these data may indicate that functional luteal regression is the
period of time during which these factors first become apparent. Certainly the rate of
apoptosis is significantly higher (3.46±1.45%, mean±SEM, n=3, see chapter 4) than
the rate of proliferation (2.19±0.5%, mean±SEM, n=3, Fig. 20) after progesterone
has fallen to follicular phase values and structural luteal regression is underway.
In short, the number of proliferating endothelial cells is highest during the early
luteal phase, then when the corpus luteum is fully formed, endothelial cell
proliferation falls to a basal level sufficient for maintenance of the luteal vasculature.
Endothelial cell proliferation then decreases markedly during functional luteal
regression, and stays low during structural regression.
5.2.7 Conclusions
It is therefore possible to draw two main conclusions: 1. One component of
functional luteal regression is a dramatic reduction in luteal cell rates of proliferation
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and 2. the observed increase in nonsteroidogenic cell numbers during structural luteal
regression is primarily due to the dynamics of shrinking tissue in which remaining






This project examined luteal regression in the marmoset monkey (Callithrix
jacchus). Endocrinological and cellular changes that occurred during luteal
regression were described, and three candidate mechanisms for the initiation and
regulation of luteal regression were examined: apoptotic cell death, vascular changes,
and the effects of PGF2a.
6.1 Cell Death and Luteal Regression
Apoptosis is a form of programmed cell death displaying specific biochemical and
morphological criteria (Kerr et al., 1972; Arends et al., 1990). Macrophage numbers
in human corpora lutea increase as the luteal phase advances (Lei et al., 1991),
coincident with decreasing progesterone production and functional luteal regression.
Macrophages secrete TNFa (Zhao et al., 1998), which has been shown to induce
apoptosis (Witty et al., 1996; Jo et al., 1995). It was hypothesised, therefore, that
luteal cell apoptosis was stimulated by TNFa secreted by macrophages. The
resulting reduction in the number of steroidogenic cells would result in a decrease in
the amount of progesterone produced by the corpus luteum as a whole, and therefore
initiate functional luteal regression.
Results described in this thesis have shown that apoptosis does indeed occur in
primate corpora lutea, and that there is a low basal rate of approximately 0.3% of all
cells undergoing apoptosis throughout the luteal phase. However there is not a
significant increase in the number of cells undergoing apoptosis until after functional
luteal regression is completed. Recent work has demonstrated that progesterone
inhibits apoptosis in rat granulosa cells (Peluso and Pappalardo, 1998) and this
supports our finding that luteal apoptosis did not occur until after serum progesterone
concentrations had fallen to follicular phase values. Therefore, apoptotic cell death
does not instigate functional luteal regression in primates.
Apoptotic cell death is, however, a component of structural luteal regression in
primates, and there may be an association between PGF2a concentration and the
occurrence of apoptosis. It is possible that the endogenous production of PGF2a
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stimulates the production of oxygen free radicals (Sawada et al. 1991) which may
stimulate apoptotic pathways (Haeker and Vaux, 1994, Murdoch 1998). Expression
of the PGF2a receptor corresponds with apoptosis in rat (Orlicky et al., 1992) and
mouse (Hasumoto et al., 1997) corpora lutea.
A second possibility is that steroid hormones inhibit apoptosis (Peluso and
Pappalardo, 1998), and the cessation of steroidogenesis therefore removes that
inhibition and apoptosis occurs. Since progesterone (Sugino et al., 1996) and estogen
(Murdoch 1998) have antioxidant properties, the production of highly reactive
oxygen species might be delayed until steroidogenic hormone levels decrease below
a threshold concentration.
The combination of these two possibilities suggests that the exogenous
administration of PGF2a would first cause a decrease in progesterone levels by
production of the mildly reactive H2O2 (Behrman and Aten, 1991; Behrman and
Preston, 1989). The lowering of progesterone below a particular threshold would
result in loss of antioxidant protection and the consequent generation of highly
reactive oxygen free radicals with the ability to stimulate apoptotic pathways. The
administration of GnRH antagonist removes the trophic support for steroidogenesis,
similarly resulting in decreased progesterone levels and increased apoptosis. If
apoptosis is associated with decreased progesterone concentrations, the exogenous
administration of both PGF2a and GnRH antagonist would result in similar levels of
apoptosis. This was supported by observed results; there was no significant
difference in the incidence of apoptosis in H&E stained sections or in situ 3' end
labeled sections or in P labeled oligonucleosomes.
The endogenous production of PGF2a might begin on luteal day 12-14 in
marmosets, and gradually inhibit LH-stimulated progesterone production (Michael et
al., 1994). Apoptosis would be delayed until the total luteal production of
progesterone fell below a specific threshold - these studies suggest that threshold
would be approximately 32nmol/L - at which point apoptosis could occur.
During non-apoptotic cell death damaged proteins may be hydrolysed by ubiquitin
(Majno and Joris, 1995). Ubiquitin expression was only found in PGF2a, but not in
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GnRH antagonist treated luteal tissue. The ubiquitin-mediated degradation of
proteins is an energy-dependent system that requires ATP, and therefore ubiquitin
expression can only occur in live cells (Majno and Joris, 1995). The finding that
GnRH antagonist treated cells did not express ubiquitin could be interpreted to mean
that all the cells were already dead, or that the cells were not in a cell death pathway,
or that cell death was occurring via different mechanisms in PGF2a and GnRH
antagonist treated animals.
The initial observations of steroidogenic cell vacuolation in H&E stained sections
were interpreted as being indicative of cell death because of the morphological
similarity to cells undergoing oncosis after an ischemic event. This was further
supported by observing randomly fragmented DNA characteristic of necrosis (in the
oligonucleosome study), and so the assumption was made that the fragmented DNA
originated from the vacuolated cells. However, vacuolated cells were not 3' end
labeled, which suggested that random DNA fragmentation did not occur in
vacuolated cells, and that the DNA was intact. It is possible that the randomly
fragmented DNA originated from only a small proportion of the vacuolated cells, and
that a higher proportion of vacuolated cells were either in the very early stages of a
death pathway, or were not undergoing cell death at all. The presence of ubiquitin
suggested that the early stages of a non-apoptotic cell death pathway occurred 24
hours after PGF2a administration, but that the later stages of DNA fragmentation
had not taken place. In contrast, the lack of ubiquitin, combined with the lack of 3'
end labeled vacuolated cells, 24 hours after administration of GnRH antagonist,
suggested that these cells had not progressed as far down a death pathway as had
PGF2a treated cells. Therefore the lack of ubiquitin expression in vacuolated cells in
GnRH antagonist treated animals and the presence of ubiquitin in PGF2a treated
animals, suggested that GnRH antagonist treatment did not stimulate non-apoptotic
cell death pathways, whereas PGF2a administration did.
Progesterone levels were significantly decreased 4 hours after the administration of
GnRH antagonist to marmosets (Webley et al., 1991), and macaques (Fraser et al.,
1986). The administration of hCG to marmosets 24 hours after administration of
GnRH antagonist did not restore steroidogenesis (Webley et al., 1991), and
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macaques also failed to resume progesterone production after the administration of
GnRH antagonist in the mid to late luteal phase (Fraser et al., 1986). A recent study
however, found that administration of the GnRH antagonist antide on luteal day 6 did
not ablate progesterone production, which recovered to control levels 48 hours later
(Duffy et al., 1999). Administration of daily GnRH antagonist on luteal days 6, 7 and
8 caused steroidogenic cells to be vacuolated (Duffy et al., 1999). Cell vacuolation,
but not apoptosis was increased 12 hours after the administration of either PGF2a or
GnRH antagonist to marmosets in these studies. This suggests that the primate
corpus luteum can be subjected to decreased progesterone concentrations for 8-12
hours before apoptotic pathways are activated, but it is not known when vacuolation
occurs in relation to decreased progesterone levels, nor the cause of vacuolation. Oil—
Red-0 staining, however, indicated that vacuolation was not due to an accumulation
of intracellular lipid.
In summary, marmoset functional regression is not caused by apoptosis, but
apoptotic cell death does occur during structural luteal regression. Another, non-
apoptotic form of cell death in which ubiquitin plays a role appears to be stimulated
by PGF2a, but not by GnRH antagonist. Lastly, decreased steroidogenesis may
cause cytoplasmic vacuolation in luteal steroidogenic cells.
6.2 Vascular Changes and Luteal Regression
The induction of regression with luteolytic agents did not cause a decrease in
endothelial cell numbers, indicating that the inhibition of steroidogenesis could occur
independently of changes to the vasculature. This was supported by the examination
of corpora lutea undergoing spontaneous functional regression in vivo, vascular
changes were not observed. Therefore, functional luteal regression is not initiated by
structural changes in the vasculature in primates.
The number of endothelial cells per unit area increased after the administration of
luteolytic agents, but the number of Ki67 positive proliferating endothelial cells per
unit area remained constant, indicating that the number of endothelial cells in each
corpus luteum did not increase. Therefore the increase in the number of endothelial
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cells per unit area was probably an artifact attributable to the dynamics of shrinking
tissue. In this scenario steroidogenic cells died and the remaining non-steroidogenic
cells occupied spaces left by deleted steroidogenic cells. Since the same unit area
was scored before and after administration of luteolytic agents, there would appear to
be increased numbers of endothelial cells per unit area.
The number of endothelial cells per unit area was significantly increased after
administration of GnRH antagonist, but not after administration of PGF2a.
Conversely, the incidence of apoptosis was slightly higher in PGF2a treated animals.
It is likely that more endothelial cells underwent apoptosis after administration of
PGF2a than after GnRH antagonist, resulting in fewer endothelial cells in PGF2a
than in GnRH antagonist treated corpora lutea.
Endothelial cells do not express PGF2a receptors (Orlicky et al., 1992) therefore
endothelial cell apoptosis was probably mediated by PGF2a action on steroidogenic
cells. The steroidogenic cell response to PGF2a which resulted in endothelial cell
apoptosis was probably not a consequence of inhibition of LH-stimulated
steroidogenesis, since the same effect was not observed after GnRH antagonist
treatment. Endothelin 1 (ET-1) has been demonstrated in porcine (Flores et al., 1995)
and human (Apa et al., 1998) corpora lutea and levels in bovine corpora lutea were
highest during regression (Girsh et al., 1996). ET-1 inhibited steroidogenic enzymes
and progesterone production in rat granulosa cells (Tedeschi et al., 1992) and
inhibited progesterone production by human luteal cells in vitro (Apa et al., 1998).
ET-1 expression in bovine corpora lutea was significantly elevated 2 hours after
administration of PGF2a but before a significant decrease in progesterone levels
(Girsh et al., 1996). Vasopressin and oxytocin also stimulated endothelial cell
production of ET-1 (Girsh et al., 1996), and PGF2a stimulated steroidogenic cell
oxytocin production (Heath et al., 1983).
Oxytocin and oxytocin receptors have been demonstrated in primate corpora lutea
(Einspanier et al., 1994; Dawood and Khan-Dawood 1986; Khan-Dawood and
Dawood 1998), and receptor numbers peak during the mid luteal phase in baboons
(Khan-Dawood et al., 1993). Therefore it is possible that in primates, the endogenous
production of PGF2a stimulates steroidogenic cell secretion of oxytocin, which
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stimulates endothelial cell ET-1 production during the mid-luteal phase. Mid luteal
phase endothelial cell production of ET-1 might inhibit steroidogenic cell
progesterone production, and augment the direct inhibitory effects of PGF2a upon
steroidogenesis. It is possible that a period of oxytocin stimulation is required to
prime endothelial cells for apoptosis during structural luteal regression, and hence
PGF2a, but not GnRH antagonist treatment would result in endothelial cell apoptosis
at the end of functional luteal regression.
Endothelial cell numbers did not change during spontaneous functional or structural
regression, although endothelial cell proliferation decreased significantly during
functional regression, then increased during structural regression. Endothelial cells
did not undergo apoptosis during functional regression, but probably did die by
apoptosis during structural regression, suggesting that the increase in endothelial cell
proliferation during structural regression served to maintain endothelial cell numbers.
There was, however, a change from a pervasive network of capillaries during the mid
luteal phase to a less extensive vascular bed comprised of larger arterioles and
venules during structural luteal regression. It is possible that the combination of
endothelial cell apoptosis and proliferation were required to effect this change. The
extensive network of small blood vessels observed during the mid-luteal phase and
functional regression was associated with steroidogenesis. The replacement of this
vascular bed with a lower number of larger blood vessels during structural regression
may have reflected a functional requirement to transport the debris of luteal
regression away from the ovary.
6.3 The Role of PGF2a in Luteal Regression
Although primate luteal regression is not caused by PGF2a from the uterus (Beling
et al., 1970), primate corpora lutea produce prostaglandins (Challis et al., 1976;
Swanston et al., 1977; Valenzuela et al., 1983; Kauma et al., 1990), and ovarian vein
prostaglandin metabolite concentrations increase as luteolysis proceeds (Auletta et
al., 1984), therefore it is possible that endogenous PGF2a might be luteolytic in
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primates. Administration of exogenous PGF2a to corpora lutea might mimic a
spontaneous, in vivo mechanism.
Steroidogenic cells express PGF2a receptors, and PGF2a has been shown to inhibit
LH receptor secondary messenger transduction (Behrman and Preston, 1989;
Behrman and Aten, 1991), prior to and distal from LH-stimulated cAMP
accumulation (Michael and Webley 1993), therefore PGF2a could inhibit LH-
stimulated progesterone production and bring about functional luteal regression. The
in vivo administration of PGF2a did not inhibit hCG stimulated steroidogenesis in
pregnant marmosets (Hearn and Webley 1987), but it is possible that receptor
transduction might be modulated by ligand binding, and LH might elicit a different
response than hCG. The in vivo administration of PGF2a to marmosets in the mid
luteal phase halved serum progesterone concentrations within an hour, and
coadministration of hCG did not prevent inhibition of steroidogenesis (Webley et al.,
1991) supporting the premise that PGF2a inhibits LH receptor secondary messenger
pathways.
The insertion of implants containing PGF2a into pig corpora lutea in the mid luteal
phase resulted in significantly increased macrophage numbers 6 hours later, and
significantly decreased progesterone levels 12 hours later (Hehnke et al., 1994).
Implants containing vehicle resulted in an increase in macrophage numbers but no
change in progesterone concentration, indicating that the presence of macrophages
alone did not induce luteolysis, but that the combination of macrophages and PGF2a
was necessary for induction of functional luteolysis (Hehnke et al., 1994). This
supports the idea that the changing responsiveness of the corpus luteum to PGF2a
might be related to the immigration of leukocytes, or accumulation of specific
cytokines or growth factors, with increasing luteal age.
A number of leukocytes secrete factors which either inhibit gonadotrophin-
stimulated steroidogenesis, or stimulate the production of oxygen free radicals, or
stimulate steroidogenic cell production of PGF2a, and these interactions are
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Figure6.1: Mechanisms of Functional Luteal Regression
Data in this thesis support the hypothesis that endogenous steroidogenic cell
production of PGF2a causes functional luteal regression by:
1. Stimulating steroidogenic cell hydrogen peroxide production with a consequent
inhibition of cAMP-stimulated cholesterol transport and decreased
steroidogenesis. Formation of LH-dependent cAMP was inhibited 15 minutes
after administration of PGF2a in rats (Thomas et al., 1978, Dorflinger et al.,
1983) and this was due to uncoupling of the G(s) protein from adenyl cyclase
(Abayasekara et al., 1993).
2. Inhibition of LH-R secondary messenger pathways, with a subsequent reduction
in steroidogenic cell ability to respond to LH.
3. Stimulation of steroidogenic cell oxytocin production, which stimulates
endothelial cell endothelin-1 production, which inhibits basal steroidogenic cell
progesterone production.
4. Decreased steroidogenesis results in the generation of highly reactive oxygen free
radicals. The combination of superoxide and hydrogen peroxide radicals
produces the highly reactive hydroxyl ion, which causes lipid peroxidation,
disruption of osmotic control and possible cytoplasmic vacuolation. May also
disrupt receptor transduction pathways, by preventing the binding or dissociation
of G-proteins.
5. Reduction of steroid hormone levels below a specific threshold results in the
further generation of reactive oxygen free radicals which cause both random and
apoptotic DNA fragmentation, with consequent apoptotic and non-apoptotic cell
death.
6.4 The Relationship Between Functional and Structural Luteal
Regression.
The original question about the initiating mechanism of luteal regression remains
unanswered, although the temporal relationship between functional and structural
regression has been clarified. In the marmoset monkey plasma progesterone
concentrations were greatly reduced before the first signs of structural regression
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were observed. These morphological changes were subtle; a slight decrease in
parenchymal steroidogenic cell volume and a slight, nonsignificant increase in the
number of vacuolated and apoptotic cells, but there was no change in the number of
endothelial cells. The only major change was that the number of 3PHSD
immunopositive cells decreased at this time. Major morphological changes only
occurred after progesterone had fallen to follicular phase values and functional luteal
regression was completed. The main morphological change during structural luteal
regression was steroidogenic cells apoptosis or vacuolation.
It is therefore proposed that functional luteal regression largely precedes structural
luteal regression in primates. This is clearly not the case in ruminants, in which
functional and structural regression seem to occur simultaneously. These species
differences appear to be related to the length of time available to remove luteal
tissue. The ovine 'follicular phase' is a mere 24 hours, during which time structural
luteal regression has to be essentially completed in order that there be room for a
subsequent corpus luteum, whereas the regressing marmoset corpus luteum can
complete structural regression during the 10 days of the follicular phase. In sheep,
functional and structural luteal regression appear to proceed simultaneously. In cows
there is some overlap between functional and structural regression, but not as much
as in the sheep, and in the primate the two phases are essentially separated.
The use of luteolytic agents in marmosets suggested that the two components of
luteolysis are partially independent of each other. Marmoset corpora lutea collected
12 hours after induction of luteolysis had falling progesterone values indicating that
functional regression was in progress, and regressive morphological changes
indicating that structural luteolysis was occurring at the same time. In spontaneously
regressing corpora lutea functional and structural luteal regression occured one after
the other, but after the administration of luteolytic agents functional and structural
regression overlapped, suggesting that the temporal relationship between the two is




This thesis seems to have raised more questions than it has answered. The key
questions, and some experiments to determine the answers, are summarised here.
1. Does hysterectomy fail to prevent luteolysis in marmosets as it does in other
primates?
2. Does PGF2a production by the corpus luteum occur from luteal day 12 until
regression is completed?
Measure PGF2a and PGE luteal content and luteal secretion by corpora lutea
collected on luteal days 10, 12, 15, 16, 18 and 20.
3. Do progesterone and/or estrogen protect against apoptosis?
Induce luteal regression with either GnRFI antagonist or PGF2a, but administer
exogenous steroid hormones to maintain serum concentrations. Collect corpora
lutea 24 hours after the administration of luteolytic agents and determine
apoptotic index.
4. Which free radical species are generated in vivo during functional and luteal
regression? Is apoptosis during luteolysis caused by oxygen free radicals?
5. Does exogenous PGF2a stimulate luteal ET-1 and/or oxytocin production in
marmosets? Does the administration of GnRFI antagonist fail to stimulate luteal
ET-1 and or oxytocin production?
Do ET-1 levels correlate with progesterone concentrations for individual
animals?
Immunocytochemistry for ET-1 and oxytocin on existing ovarian sections.
6.6 Summary
There were six key findings in this thesis: (1) Induction of luteal regression with
either PGF2a or GnRH antagonist resulted in two morphological changes to
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steroidogenic cells. One change had the morphological and biochemical features of
apoptosis, and the other change resulted in the formation of cytoplasmic vacuoles
which were not filled with lipid. (2) Steroidogenic cells in naturally regressing
corpora lutea also developed cytoplasmic vacuoles, but these were qualitatively
different from those formed after induced luteal regression. (3) Apoptosis in
naturally regressing corpora lutea did not occur until after progesterone had
decreased to follicular phase values, therefore apoptosis is unlikely to be an
instigating mechanism in functional luteal regression. (4) Endothelial cell numbers
remained constant after administration of luteolytic agents, indicating that induced
luteal regression was not effected by vascular changes. (5) Similarly, the vascualture
did not change during functional regression in untreated animals, but vascular
remodelling occured during structural luteal regression. The vasculature changed
from an extensive network of small capillaries to a system comprised of a lower
number of larger blood vessels. (6) Luteal cell proliferation decreased during
functional luteal regression.
6.7 Conclusion
Luteal regression in primates can be divided into two separate processes, functional
luteal regression and structural luteal regression. Functional luteal regression is
characterised by decreased steroidogenesis, and its completion can be delineated by
the presence of follicular phase concentrations of serum progesterone. Decreased
rates of cellular proliferation are concomitant with functional luteal regression, but
the relationship between decreased proliferation and decreased steroidogenesis is
unclear and requires further work. Functional regression is not caused by the
apoptotic deletion of steroidogenic cells, nor by a decrease in endothelial cell
numbers, nor by structural changes to the vasculature. It is suggested that the
endogenous production of PGF2a commences on luteal day 12, and this inhibits LH-
stimulated progesterone production. In addition, PGF2a may stimulate an oxytocin-
ET-1 feedback loop that inhibits basal progesterone production. Decreased
progesterone production may cause cytoplasmic vacuolation. Reduction in steroid
hormone levels below a specific threshold results in the generation of highly reactive
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oxygen free radicals that cause apoptotic cell death. Structural luteal regression is
therefore characterised by decreased numbers of luteal cells, and by vascular
remodelling to replace the extensive network of small blood vessels with a lower
number of larger blood vessels suitable for transporting the debris of structural
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(Key at foot of table)
Early Luteal Phase
543 1218 406 183 1 78 0 3 vW, flt-1, PCNA
581 1293 75 1 102 2 3 PCNA
619 905 410 163 171 4 PCNA
622 722 399 90 146 4 PCNA
679 1271 466 88 0 168 3 3 BrdU, Ki67, vW, VEGF
728 745 390 152 1 46 0 2 BrdU, Ki67, vW, VEGF
730 700 383 120 1 148 2 3 BrdU, Ki67, vW
Mid Luteal Phase
447 2308 422 136 1 200 2 10 DNA, vW, VEGF, PCNA
480 1306 1 1 8 vW, flt-1
530 1 1 8 H&E, Apo, vW
533 1637 505 221 1 200 2 10 H&E, Apo, vW, DNA, Flt-1, PCNA,
Ki67
546 401 246 2 134 2 8 H&E, DNA, vW, PCNA
552 1531 400 1 1 10 DNA
644 1018 512 118 1 273 3 10 H&E, Ki67, vW, PCNA, Apo, VEGF,
3b, Ub
683 1004 98 1 93 1 10 Ki67, Ub, VEGF, Apo, 3b, vW, PCNA
705 1585 123 61 10 Ki67, Ub, VEGF, vW, 3b, PCNA
Functional Lulteal Regression
473 370 90 1 118 1 18 H&E, vW, PCNA
539 1698 410 121 1 56 0 18 H&E, PCNA
579 1415 391 60 0 99 2 18 H&E, vW, PCNA, Ki67, Apo
701 938 419 107 1 135 2 18 BrdU, Ki67, vW, VEGF, 3b, Flt-1
712 832 157 2 58 0 18 BrdU, vW, VEGF, 3 b
719 860 395 95 1 172 1 18 BrdU, Ki67, VEGF, 3b
Structural Luteal Regression
655 1857 84 84 22 BrdU, Flt-1
662 1307 82 65 23 H&E, Ki67, vW, VEGF, PCNA, 3b,
Apo
641 553 233 181 22 H&E, PCNA, 3b, Apo
700 1032 387 103 1 107 0 23 BrdU, Ki67, vW, VEGF
716 772 79 147 23 BrdU, VEGF, Ki67, vW
545 116 1 115 2 24 H&E, PCNA, 3b, Apo
554 1600 2 26 H&E, vW
567 204 235 27 H&E
640 687 76 113 26 vW
















Prostaglandin nduced Luteal Regression
681 762 394 120 1 121 2 12hr H&E, vW, VEGF, PCNA, Ki67
693 1673 109 2 96 2 12hr H&E, vW, VEGF, PCNA, Ki67
708 1517 307 161 1 127 1 12hr H&E, vW, VEGF, PCNA, Ki67
532 378 67 0 133 1 24hr DNA
542 1738 464 135 2 133 2 24hr H&E, DNA, Apo, PCNA
549 117 1 147 2 24hr DNA
569 1201 186 2 100 2 24hr DNA
572 1263 38 0 120 3 24hr DNA
573 1438 475 64 0 106 1 24hr H&E, vW, apo
582 1254 445 44 0 138 3 24hr H&E, Ub, vW, PCNA, Ki67
611 1175 518 186 1 143 1 24hr H&E, DNA, Ki67, Apo, PCNA, VEGF,
3b, Ub
676 1135 50 0 144 2 24hr Ki67, vW, VEGF, 3b, Ub
690 971 161 45 24hr Ki67, vW, VEGF, 3b, Apo, PCNA
576 1208 68 80 48hr H&E
GnRH Antagonist Induced Luteal Regression
665 858 340 64 0 153 2 12hr H&E, vW, VEGF, PCNA, Ki67
689 716 390 88 0 143 2 12hr H&E, vW, VEGF, PCNA, Ki67
709 1517 331 74 0 158 2 12hr H&E, vW, VEGF, PCNA, Ki67
507 1700 400 86 1 127 2 24hr DNA
528 1697 440 133 1 120 1 24hr H&E, Ub, vW, VEGF, PCNA, Ki67
612 1336 108 2 44 0 24hr H&E, Ki67, vW, Apo, PCNA, VEGF, 3b.
624 916 442 36 155 3 24hr DNA
627 1141 330 105 2 29 0 24hr H&E, Ub, Apo
686 742 393 69 0 162 3 24hr DNA, H&E, vW, Apo, PCNA, VEGF, 3b.
704 1582 110 2 64 0 24hr Ki67, vW, Apo, PCNA, VEGF, 3b.
714 1642 122 141 24hr DNA, Ub, Fit-1, Ki67
525 1648 401 94 1 80 1 48hr DNA
478 ? 323 77 1 72 1 48hr H&E
505 48hr DNA













DNA extracted and examined for oligonucleosome formation
Morphological examination of H&E stained sections
In situ 3' End Labelling
von Willebrand Factor VIII Antigen
Proliferating Cell Nuclear Antigen
3b Hydroxysteroid Dehydrogenase Isomerase
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